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Abstract 
 
Alzheimer’s disease (AD) is the most common form of neurodegenerative disease that is currently 
affecting over 28 million people worldwide. Even after more than a century of research, there still is no 
cure or even effective, long-term therapeutics for AD. As a result, AD continues to increase in prevalence 
and presents a major socioeconomic burden for today’s society. The absence of a cure is most certainly a 
result of our limited understanding of the cause(s) of AD. For example, due to the involvement of many 
pathological factors, such as misfolded and aggregated proteins, dysregulated metal ions, and 
overproduced reactive oxygen species, it is very difficult to unravel and identify the most up-stream 
causative factors of AD to which a drug can be designed to correct. Therefore, it is clear that in order to 
begin to determine the underlying cause of AD, we first must develop tools that can be used to probe and 
investigate the interconnections between these pathological facets. The work presented in this dissertation 
highlights our efforts toward this goal. Following a detailed introduction given in Chapter 1, a structure-
reactivity study is presented in Chapter 2 to determine key pharmacophores that have potential 
applications for the development of multifunctional chemical tools for AD. In Chapter 3, a small, compact 
redox-active molecule is identified as a potential anti-amyloidogenic agent for AD that relies on the 
formation of intramolecular ligand–peptide crosslinks and represents a novel strategy for amyloid 
management. The applicability of transition metal complexes to control the self-assembly of amyloid-β 
(Aβ) peptides is further probed in Chapter 4 with the use of tetramethylcyclam metal complexes which 
are shown to hydrolytically cleave amide bonds of Aβ peptides. Finally, Appendix A proposes a novel 
method to synthetically generate specific diastereomers of our tetramethylcyclam metal complexes based 
on a newly identified anion effect. Overall, our findings presented herein offer significant contributions 
toward advancing the development of chemical tools and therapeutics for AD, and our particular 
emphasis on establishing reaction mechanisms and biological applicability gives us further directions to 
improve our next-generation reagents.  
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by SOFAST-HMQC NMR. (a-e) SOFAST-HMQC NMR spectra (top) and chemical shift perturbations 
(CSPs) (bottom) of Aβ40 upon treatment with (a) AQDA2, (b) AQP2, (c) AQ2, (d) AQP4, and (e) 
AQDA3. Two horizontal lines represent the average chemical shift (dashed line) plus one standard 
deviation (dotted line). Residues which show no CSP are the result of unresolved peaks in the spectra. 

Figure 2.10. Docking studies of AQ derivatives with Aβ40 monomer. Top: The two lowest energy 
cartoon conformations of (a) AQ1, (b) AQ2, (c) AQP1, (d) AQP2, (e) AQP4, (f) AQDA1, (g) AQDA2, 
and (h) AQDA3 with Aβ40 (PDB 2LFM) by AutoDock Vina. Hydrogen bonding is indicated with dashed 
lines (2.0–2.7 Å). Bottom: Summary of calculated binding energies of the AQ series to each Aβ 
conformation. 

Figure 2.11. Mass spectrometric and ion mobility–mass spectrometric analyses of AQ1, AQ4, AQP1, 
AQP4, AQDA1-3, and ML upon addition of CuCl2. MS spectra of (a) AQ1, (b) AQ4, (c) AQDA1, (d) 
AQDA2, (e) AQDA3, (f) ML, (g) AQP1, and (h) AQP4. (i) IM–MS drift time analysis. Collision cross 
section data for all ion mobility data sets are presented in Table 2.3. L = ligand (i.e., AQ1, AQ4, 
AQDA1-3, ML, AQP1, AQP4). *Indicates a contaminant refractory to our purification methods. 

Figure 2.12. Analysis of the amount of copper-bound Aβ40 as a function of ligand concentration. 
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Compared to baseline levels of metal-bound Aβ40, AQDA1, AQDA2, ML, and AQP1 are all shown to be 
capable of reducing the concentration of Cu(II)-associated peptide species.  

Figure 2.13. Cu(II) binding studies of AQ1-3, AQP1-4, and AQDA1-3. (a-j) UV-vis spectra of ligands 
[(a) AQ1, (b) AQ2, (c) AQ3, (d) AQP1, (e) AQP2, (f) AQP3, (g) AQP4, (h) AQDA1, (i) AQDA2, and 
(j) AQDA3; black lines] with the addition of increasing amounts of CuCl2 (colored lines; 30 min 
incubation; room temperature). Experimental conditions: for AQ1 and AQ3, [M(II)]:[L] = 1:2, 20 mM 
HEPES, pH 7.4, 150 mM NaCl; for AQ2, [M(II)]:[L] = 1:2, CH3CN;  for AQP1-2, [M(II)]:[L] = 1:1, 20 
mM HEPES, pH 7.4, 150 mM NaCl; for AQP3, [M(II)]:[L] = 1:2, CH3CN; for AQP4, [M(II)]:[L] = 1:2, 
20 mM HEPES, pH 7.4, 150 mM NaCl; for AQDA1-3, [M(II)]:[L] = 1:1, 20 mM HEPES, pH 7.4, 150 
mM NaCl.  

Figure 2.14. Zn(II) binding experiments. (a-j) UV-vis spectra of [(a) AQ1, (b) AQ2, (c) AQ3, (d) AQP1, 
(e) AQP2, (f) AQP3, (g) AQP4, (h) AQDA1, (i) AQDA2, and (j) AQDA3; black lines] with the addition 
of increasing amounts of ZnCl2 (colored lines; 30 min incubation; room temperature). Experimental 
conditions: for AQ1, [M(II)]:[L] = 1:2, 20 mM HEPES, pH 7.4, 150 mM NaCl; for AQ2, [M(II)]:[L] = 
1:2, CH3CN; for AQ3, [M(II)]:[L] = 1:2, EtOH; for AQP1-2, [M(II)]:[L] = 1:1, 20 mM HEPES, pH 7.4, 
150 mM NaCl; for AQP3, [M(II)]:[L] = 1:2, EtOH; for AQP4, [M(II)]:[L] = 1:2, 20 mM HEPES, pH 7.4, 
150 mM NaCl; for AQDA1-3, [M(II)]:[L] = 1:1, 20 mM HEPES, pH 7.4, 150 mM NaCl. 

Figure 2.15. Zn(II) binding studies, measured by 1H NMR. 1H NMR spectra of AQ3 (red) with 3.5 equiv 
of ZnCl2 (black) were obtained at room temperature. Experimental conditions: CD3CN; [AQ3] = 5 mM; 
[ZnCl2] = 17.5 mM; 10 min incubation. Note that Zn(II) binding to AQP3 could not be determined due to 
limited solubility under experimental conditions. 

Figure 2.16. Solution speciation studies of AQP1, AQP4, and AQDA1-3. UV-vis variable-pH titration 
spectra (left) and solution speciation diagrams (right) of (a) AQP1 (pH 2–11), (b) AQP4 (pH 2–11), (c) 
AQDA1 (pH 2–10), (d) AQDA2 (pH 2–10), and (e) AQDA3 (pH 2–10) (FL = fraction of species at given 
pH). Acidity constants (pKa) of L (L = AQP1, AQP4, and AQDA1-3) are summarized in the table. 
Experimental conditions: [L] = 50 μM (L = AQP4 or AQDA1) or 25 μM (L = AQP1, AQDA2, and 
AQDA3); I = 0.10 M NaCl; room temperature. Charges are omitted for clarity. a The error in the last digit 
is shown in the parentheses. 

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Figure 2.17. Solution speciation studies of AQP1, AQP4, and AQDA1-3 in the presence of Cu(II). UV-
vis variable-pH titration spectra (left) and solution speciation diagrams (right) of (a) AQP1, (b) AQP4, 
(c) AQDA1, (d) AQDA2, and (e) AQDA3 upon incubation with Cu(II) (FCu = fraction of species at given 
pH). Stability constants (logβ) of Cu(II)−L complexes (L = AQP1, AQP4, and AQDA1-3) are 
summarized in the table. Charges are omitted for clarity. a The error in the last digit is shown in 
parentheses. Experimental conditions: [AQP1] = 25 μM, [CuCl2] = 12.5 μM, pH 2–11 (titrated from 
basic to acidic); [AQP4] = 100 μM, [CuCl2] = 50 μM, pH 2–9 (titrated from basic to acidic); [AQDA1] = 
25 μM, [CuCl2] = 12.5 μM, pH 2–8 (titrated from basic to acidic); [AQDA2] = 25 μM, [CuCl2] = 12.5 
μM, pH 2–8 (titrated from acidic to basic); [AQDA3] = 25 μM, [CuCl2] = 12.5 μM, pH 2–8 (titrated from 
acidic to basic); incubated for 1 h; I = 0.10 M NaCl; room temperature.  

Figure 2.18. Metal selectivity of AQP4 and AQDA1-3 for Cu(II) over other biologically relevant 
divalent metal ions. Gray bars represent the subsequent addition of CuCl2 (50 μM) to solutions containing 
ligand (50 μM) with (a) 1 equiv or (b) 20 equiv of the other divalent metal ions (MgCl2, CaCl2, MnCl2, 
FeCl2, CoCl2, NiCl2, and ZnCl2). The absorbance wavelengths of AQP4, AQDA1, AQDA2, and AQDA3 
used to calculate AM/ACu are listed as follows: 290 nm, 449 nm, 449 nm, and 338 nm, respectively. *Due 
to similar optical bands of the ligand upon binding to Cu(II) and the other metal ions, accurate metal ion 
selectivity cannot be obtained. 

Figure 2.19. Biological activities of small molecules. (a) Inhibitory activity of AQ1, AQ3, AQ4, 
AQDA1, and AQDA3 toward Cu-mediated ROS formation as determined by the 2-deoxyribose assay. 
The absorbance values are normalized to the ligand-free condition ([CuCl2] = 10 μM; [ligand] = 125 μM). 
(b) Antioxidant activity of AQ1-3, AQP1, AQP2, AQP4, and AQDA1-3, identified by the TEAC assay 
using cell lysates. The TEAC values are relative to that of the vitamin E analogue, Trolox (6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid).  

Figure 2.20. Cell viability of AQ1-4, AQP1-4, AQDA1-3, and ML in N2a cells in the absence and 
presence of Cu(II) and Zn(II). (a) Cu(II):ligand (1:1) (5 μM), (b) Zn(II):ligand (1:1) (5 μM), (c) 
Cu(II):ligand (1:1) (10 μM), and (d) Zn(II):ligand (1:1) (10 μM). Cell viability (%) was determined by the 
MTT assay compared to cells treated with DMSO only (1% v/v) [MTT = 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide]. Black, blue, and green bars indicate cell viability upon incubation 
with ligand only and ligand with CuCl2 or ZnCl2, respectively.  
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Figure 3.1. Solution and metabolic stability of DMPD. (a) FAME calculation of DMPD. aPredicts the 
sites of metabolism, the atom where a metabolic reaction is initiated. The number reported is the 
probability of each atom being a site of metabolism. Therefore, the closer the number is to one, the more 
likely that atom is a site of metabolism [see Kirchmair, J. et al. J. Chem. Inf. Model. 2013, 53, 2896–
2907]. (b) Stability of DMPD in DMSO and PBS. DMPD is shown to be degraded by ca. 20% in PBS for 
12 h. (c) Oxidation of DMPD by hydrogen peroxide (H2O2) in PBS (t1/2 = 55 min). Conditions: DMPD 
(0.5 mM); H2O2 (5 mM); pseudo-first order kinetics. (d) Metabolic stability of DMPD using liver 
microsomes. Based on Lineweaver–Burk analysis, the values of Vmax and KM (ca. 22.9 nM/min and ca. 
2.07 mM, respectively) are obtained. 

Figure 3.2. Effects of DMPD toward metal-free/metal-induced Aβ40 aggregation in vitro. (a) Chemical 
structure of DMPD (N,N-dimethyl-p-phenylenediamine) and amino acid sequence of Aβ (the self 
recognition site is underlined and highlighed in red). (b) Scheme of the (I) inhibition or (II) 
disaggregation experiments. The metal-free samples were prepared in both the absence (left) and presence 
(right) of O2. (c) Analyses of the resultant Aβ species from (I) and (II) by gel electrophoresis with 
Western blotting (gel/Western blot) using an anti-Aβ antibody (6E10). For the experiment (I), the samples 
containing metal-free Aβ40 were prepared under anaerobic (left, white background) and aerobic (right, 
gray background) conditions. Conditions: Aβ (25 μM); CuCl2 or ZnCl2 (25 μM); DMPD (50 μM); 24 h; 
pH 6.6 (for Cu(II) experiments) or pH 7.4 (for metal-free and Zn(II) experiments); 37 °C; constant 
agitation. (d) TEM images of the Aβ40 samples prepared under aerobic conditions (from (c)). Inset: Minor 
species from TEM measurements. White and black scale bars indicate 200 and 500 nm, respectively. 
 
Figure 3.3. Effects of DMPD on metal-free and metal-induced Aβ42 aggregation. (a) Scheme of (I) 
inhibition and (II) disaggregation experiments. (b) Analyses of the resultant Aβ species from I and II by 
gel/Western blot using an anti-Aβ antibody (6E10). Conditions: Aβ (25 μM); CuCl2 or ZnCl2 (25 μM); 
DMPD (50 μM); 24 h; pH 6.6 (for Cu(II) experiments) or pH 7.4 (for metal-free and Zn(II) experiments); 
37 °C; constant agitation. (c) TEM images of the Aβ42 samples from (b). White scale bars indicate 500 
nm. 
 
Figure 3.4. Effect of DMPD toward metal-free and metal-induced Aβ40 aggregation in a cell culture 
medium. Gel/Western blot analyses of the resultant Aβ40 species upon treatment with DMPD in a cell 
culture medium containing 1:1 Minimum Essential Media (MEM) and Ham’s F12K Kaighn’s 
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Modification Media (F12K), 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL 
streptomycin. Conditions: Aβ (25 μM); CuCl2 or ZnCl2 (25 μM); DMPD (50 μM); 24 h; 37 °C; constant 
agitation. The experimental scheme is depicted in Figure 3.2b. 
 
Figure 3.5. Interactions of DMPD with monomeric Aβ and fibrillar Cu(II)–Aβ, observed by 2D NMR 
spectroscopy and Cu K-edge X-ray absorption spectroscopy, respectively. (a) 2D 1H–15N SOFAST-
HMQC NMR investigation of DMPD with 15N-labeled Aβ40. (b) Chemical shift perturbations (CSPs) of 
Aβ40 were determined upon addition of DMPD (Aβ : DMPD = 1 : 10). On the chemical shift plot, the 
dashed and dotted lines represent the average CSP and one standard deviation above the average, 
respectively. Relatively noticeable CSPs were observed around the hydrophobic residues of the peptide. 
*Residues could not be resolved for analysis. (c) Molecular dynamics (MD) simulations of the Aβ40–
DMPD complex. DMPD and Aβ40 are shown to interact directly with the hydrophobic region of the Aβ40 
monomer in its lowest energy conformation (see Figure 3.6). The chemical structure of DMPD is colored 
as follows: Carbon, orange; hydrogen, white; nitrogen, blue. The self-recognition site of Aβ40 is 
highlighted in light violet. (d) Left: X-ray absorption near edge structure (XANES) region of the Cu K-
edge X-ray absorption spectrum of DMPD-incubated Cu(I)- (red) and Cu(II)-loaded (blue) Aβ42 fibrils. 
Top right (blue): Magnitude FT and FF (inset) extended X-ray absorption fine structure (EXAFS) of 
DMPD-incubated Cu(II)-loaded Aβ42 fibrils showing the experimental data (solid line), simulated 
spectrum (dashed line), and difference spectrum (dotted line). Shell #1 (N scatterer): n = 2.3(2); r = 
1.889(3) Å; σ2 = 0.0041(4) Å2; ε2 = 0.93. Bottom right (red): Magnitude FT and FF (inset) EXAFS of 
DMPD-incubated Cu(I)-loaded Aβ42 fibrils showing the experimental data (solid line), simulated 
spectrum (dashed line), and difference spectrum (dotted line). Shell #1 (N scatterer): n = 2.2(2); r = 
1.882(4) Å; σ2 = 0.0033(1) Å2; ε2 = 0.85.   
 
Figure 3.6. Conformations of the Aβ40–DMPD complexes as determined by molecular dynamics (MD) 
simulations. (a-c) Complexes of DMPD with Aβ40 (PDB 1BA4). DMPD is shown to interact with Aβ40. 
Atoms of DMPD are colored as follows: Carbon, orange; hydrogen, white; nitrogen, blue. The self-
recognition site of Aβ40 is also highlighted in light violet. Gibb’s binding energies (ΔGbinding) for each 
conformation are summarized in the table (bottom). 
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Figure 3.7. XANES region of the XAS spectrum for DMPD-incubated Cu(II)-loaded Aβ42 fibrils 
following one (solid), two (dashed), and three (dotted) scans on the same spot. Total exposure time for 
each scan is ca. 45 min. 
 
Figure 3.8. Transformation of DMPD with or without Cu(II) and/or Aβ40, monitored by UV-vis. (a and 
b) UV-vis spectra of DMPD with or without CuCl2 in the absence and presence of Aβ under aerobic 
conditions. (c) UV-vis spectra of DMPD with or without Aβ under anaerobic conditions. Blue, red, and 
green lines correspond to incubation for 0, 4, and 24 h, respectively. Conditions: Aβ (25 μM); CuCl2 (25 
μM); DMPD (50 μM); pH 6.6 (for Cu(II) experiments) or pH 7.4 (for metal-free experiments); room 
temperature; no agitation. (a and c) DMPD +/– Aβ40; (b) [DMPD + CuCl2] +/– Aβ40.  
 
Figure 3.9. UV-vis spectra of DMPD with or without Aβ40 and/or metal ions. (a) DMPD ± Aβ40; (b) 
DMPD ± [CuCl2 + Aβ40]; (c) DMPD ± [ZnCl2 + Aβ40]. Black and red lines represent the absence and 
presence of Aβ40, respectively. Conditions: Aβ40 (25 μM); CuCl2 or ZnCl2 (25 μM); DMPD (50 μM); pH 
6.6 (for Cu(II) experiment) or pH 7.4 (for metal-free and Zn(II) experiments); room temperature; no 
agitation. The spectra were obtained right after addition of metal ions and/or Aβ40. 
 
Figure 3.10. Transformation of benzoquinone (BQ) in the presence of Aβ40. (a) UV-vis spectrum of BQ 
under aerobic conditions. (b) UV-vis spectrum of BQ with Aβ40 under aerobic conditions. Blue, red, and 
green lines correspond to incubation periods of 0, 4, 24 h, respectively. Conditions: Aβ40 (25 μM); BQ 
(50 μM); HEPES buffer (1 mM, pH 7.4); room temperature, no agitation.  
 
Figure 3.11. Effects of BQ on metal-free and metal-induced Aβ40 and Aβ42 aggregation. (a) Scheme of 
(I) inhibition and (II) disaggregation experiments. (b & c) Analyses of the resultant Aβ species [(b) Aβ40 
and (c) Aβ42] from I and II by gel/Western blot using an anti-Aβ antibody (6E10). Conditions: Aβ (25 
μM); CuCl2 or ZnCl2 (25 μM); BQ (50 μM); 24 h; pH 6.6 (for Cu(II) experiments) or pH 7.4 (for metal-
free and Zn(II) experiments); 37 °C; constant agitation.  
 
Figure 3.12. Analysis of the resulting species upon interaction of Aβ40 with DMPD or BQ by mass 
spectrometry (MS) and ion mobility–mass spectrometry (IM–MS), as well as a proposed mechanism. (a) 
MS analysis showing the complex formation of Aβ40 (25 μM) with DMPDtransformed (50 μM) (red lines) in 
the 4+ and 5+ charge states ([Aβ + DMPDtransformed]4+ and [Aβ + DMPDtransformed]5+) (i). IM–MS was 
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applied to the 4+ charge state to resolve the conformational rearrangement of Aβ40 upon addition and 
conversion of DMPD to DMPDtransformed (ii). Extracted arrival time distributions support the existence of 
two resolvable structural populations [collision cross section (CCS) data, inset tables]. The interaction 
with DMPDtransformed trapped the peptide in a more packed conformation (dominant peak = 1) when 
compared to the apo form (dominant peak = 2). (b) MS analysis showing the complex formation of Aβ40 
(25 μM) with BQ (50 μM) supports that BQ binds readily to the peptide (red) (i). In line with the DMPD 
data presented above, BQ-containing samples support a mass gain of 104 Da attributed to covalent 
binding with K16 (Figure 3.11). IM–MS was applied to the 4+ charge state to resolve the conformational 
rearrangement of Aβ40 upon binding BQ. Extracted arrival time distributions indicate the existence of 
three resolvable structural populations (CCS data, inset table) (ii). The first two of these conformations 
support, within least square error analysis, CCS values consistent with the DMPD-bound data (Figure 
3.12a). (c) Comparison of tandem MS/MS sequencing using the quadrupole isolated 5+ charge state (trap 
collision energy 90 V) of Aβ405+ (top) and [Aβ + DMPDtransformed]5+ (bottom). Analysis of these data in 
addition to the MS and IM–MS support the attachment of DMPDtransformed to Aβ40 through a covalent 
modification of the peptide via K16 resulting in an observed mass shift of 103.93 ± 0.04 Da calculated 
from internal monoisotopic calibration data sets. (d) Proposed mechanistic pathways between DMPD and 
Aβ. DMPD may undergo an oxidative transformation under aerobic conditions to generate a cationic 
imine (CI)–Aβ complex (1). CI could then generate BQI (shown in 2) through hydrolysis. Once 
hydrolyzed, BQI is proposed to undergo further hydrolytic conversion to generate BQ (shown in 3). Our 
MS studies support that BQ forms covalently bound protein-ligand adducts (4) that are capable of 
forming intramolecular crosslinks (5) that trap Aβ in an altered conformational geometry compatible with 
our IM–MS dataset. 
 
Figure 3.13. MS/MS sequencing of the samples containing BQ and Aβ40. Complimenting DMPD 
analysis (Figure 3.12), studies were performed on incubated samples of Aβ40 with BQ. Consistent with 
[Aβ40 + DMPD] analyses, an adduct of 104.1 ± 0.1 Da was identified to be covalently linked to K16.  
 
Figure 3.14. MS studies of the BQ-bound Aβ dimer. (a) MS/MS analysis used to identify if BQ was 
capable of forming intermolecular crosslinks in Aβ dimers (M: Aβ monomer; D: Aβ dimer). Upon 
quadrupole isolation of the BQ-bound 5+ Aβ40 dimer ion (b), it was subjected to collisional activation and 
subsequent fragmentation (c). These results support that BQ forms intramolecular crosslinks, with masses 
corresponding to intact monomeric apo and BQ-bound peptides suggesting these conclusions. 
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Figure 3.15. Cytotoxicity of DMPD in the absence and presence of metal ions, and its effect toward 
metal-free/metal-treated Aβ40-triggered cytotoxicity. The cytotoxicity of (a) DMPD only (2.5-100 μM; 
1% v/v DMSO); DMPD (2.5–50 μM) with (b) CuCl2 or (c) ZnCl2 in a ratio of 1:1 using the human 
neuroblastoma SK-N-BE(2)-M17 (M17) cells. (d) Viability (%) of M17 cells incubated with Aβ40 (10 
μM), CuCl2 or ZnCl2 (10 μM), and/or DMPD (20 μM) for 24 h. Cell viability, determined in M17 cells 
by the MTT assay, was calculated in comparison to that treated with DMSO only (1% v/v). Error bars 
represent standard error from three independent experiments.  
 
Figure 3.16. Monitoring changes in body weight. No significant difference in body weight was observed 
between the vehicle- and DMPD-treated 5×FAD mice. Body weights of male (squares; n = 6 for each 
treatment) or female (circles; n = 5 for each treatment) 5×FAD mice were measured for 30 days 
immediately before the daily injection of vehicle (black) or DMPD (1 mg/kg/day, i.p.; gray), starting 
from 3 months of age. All values represent mean + SEM. 
 
Figure 3.17. Reduction of cerebral amyloid pathology by DMPD in the 5×FAD mice. After the total 30 
daily i.p. injections of vehicle or DMPD (1 mg/kg/day), the brain tissues were collected from the 5×FAD 
mice at 4 months of age. (a) Bars denote the amounts of SDS-soluble, FA-soluble, or total (PBS plus SDS 
plus FA) Aβ40/Aβ42 peptides in the whole brains, which were calculated from three independent sandwich 
Aβ ELISA assays (n = 14–17). (b) Representative microscopic images of 4G8-immuno 
stained (brown) or Congo red stained (red) brain sections of 5×FAD mice show that DMPD significantly 
reduced the burden of amyloid deposits in the brain. Ctx, cortex; Hip, hippocampus. Scale bar = 100 μm. 
(c) The load of 4G8-immunoreactive amyloid deposits and the total number of congophilic amyloid 
plaques in the microscopic photographs of the identical cortical areas (b) were measured in five brain 
sections taken from each animal. All values represent mean ± SEM (n = 7). *P < 0.05, **P < 0.01, or 
***P < 0.001 by unpaired two-tail t-test. 
 
Figure 3.18. Cognitive enhancement by DMPD in the 5×FAD AD mouse model. Using the Morris water 
maze task, spatial learning and memory activities were compared in the 5×FAD and their littermate wild-
type mice after thirty consecutive vehicle or DMPD (1 mg/kg/day, i.p.) treatments. (a) The escape latency 
time was daily measured for the final five days of the drug treatment. (b) The probe trials were performed 
on the day of the final treatment to assess the time when the mice spent to reach the escape platform. (c) 
Upper circular images display the representative swimming paths for the mice to locate the escape 
platform in the water maze for 60 sec. Lower graphs show the time how long they spent in the target 
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quadrant (NW, highlighted in gray). The statistical comparisons were performed between 5×FAD and 
their wild-type littermate mice with vehicle (pound), or between consecutive vehicle and DMPD 
treatments in 5×FAD mice (asterisk), according to the one-way ANOVA followed by a Student-Neuman-
Keuls post hoc test. *P < 0.05, **,##P < 0.01 or **,###P < 0.001 (n = 17 for wild-type mice or n =14 for 
vehicle- or DMPD-treated 5xFAD mice). 

Figure 4.1. Chemical structures of macrocyclic polyamines and their metal complexes. (a) Chemical 
structures of cyclen, cyclam, and M(II)(TMC) (trans-I and trans-III isomers). Cyclen = 1,4,7,10-
tetraazacyclododecane; cyclam = 1,4,8,11-tetraazacyclotetradecane; TMC = 1,4,8,11-tetramethyl-
1,4,8,11-tetraazacyclotetradecane. ORTEP diagrams of (b) [Co(TMC)(NO3)](NO3) and (c) 
[Ni(TMC)(CH3CN)](NO3)2 with ellipsoids drawn at the 30% probability level. Noncoordinated nitrate 
anions and hydrogen atoms are omitted for clarity. Selected distances (Å) and angles are summarized in 
Table 4.1. 

Figure 4.2. Capability of M(II)(TMC) (M = Co, Ni, Cu, and Zn) to control the aggregation pathways of 
Aβ40 and Aβ42. (a) Scheme of the inhibition experiment. (b) Analysis of the resultant Aβ40 (top) and Aβ42 
(bottom) species from the inhibition experiment visualized by gel electrophoresis with Western blotting 
(gel/Western blot) using an anti-Aβ antibody (6E10). Conditions: Aβ (25 μM); M(II)(TMC) (50 μM); 
incubated for 4, 8, or 24 h; pH 7.4; 37 °C; constant agitation. Lanes: “C” denotes the control lane (without 
compound treatment); (1) Aβ + TMC; (2) Aβ + Co(II)(TMC); (3) Aβ + Ni(II)(TMC); (4) Aβ + 
Cu(II)(TMC); (5) Aβ + Zn(II)(TMC). (c) TEM images for the Aβ42 samples (24 h incubation) from (b). 
Insets represent the minor species. 

Figure 4.3. Ability of M(II)(TMC) (M = Co, Ni, Cu, and Zn) to disaggregate preformed Aβ40 and Aβ42 
aggregates. (a) Scheme of the disaggregation experiment. (b) Analysis of the resultant Aβ40 (top) and 
Aβ42 (bottom) species from the disaggregation experiment visualized by gel electrophoresis with Western 
blotting (gel/Western blot) using an anti-Aβ antibody (6E10). Conditions: Aβ (25 μM); M(II)(TMC) (50 
μM); incubated for 4, 8, or 24 h; pH 7.4; 37 °C; constant agitation. Lanes: “C” denotes the control lane 
(without compound treatment); (1) Aβ + TMC; (2) Aβ + Co(II)(TMC); (3) Aβ + Ni(II)(TMC); (4) Aβ + 
Cu(II)(TMC); (5) Aβ + Zn(II)(TMC). (c) TEM images for the Aβ40 and Aβ42 samples (24 h incubation) 
from (b). Insets represent the minor species. 

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Figure 4.4. Ability of M(II)(TMC) (M = Ni, Cu, and Zn) to alter the morphology of preformed Aβ40 and 
Aβ42 aggregates. (a) Scheme of the disaggregation experiment. (b) TEM images for the Aβ40 and Aβ42 
samples (24 h incubation). Insets represent the minor species.  

Figure 4.5. Competition experiments. (a) Reaction scheme. (b) Visualization of the Aβ40 species upon 
addition of sodium azide (NaN3; 0–200 equiv; blue) or sodium cyanate (NaOCN; 0–200 equiv; green) by 
gel/Western blot utilizing an anti-Aβ antibody (6E10). Conditions: Aβ40 (25 μM); NaN3 or NaOCN (0–5 
mM); Co(II)(TMC) (50 μM); incubated for 24 h; pH 7.4; 37 °C; constant agitation. (c) Scheme and 
chemical equation of the complexation reaction of Co(II)(TMC) with the experimentally reported 
equilibrium constants obtained from spectrophotometric titrations.33 *Indicates that the stability constant 
for the pentacoordinate imidazole complex was not obtained for Co(II)(TMC) and the reported value (< 
0.30) is from Ni(II)(TMC).32  

Figure 4.6. MALDI–MS analysis of the Aβ40 samples incubated with M(II)(TMC) (M = Co, Ni, 
Cu, and Zn). (a) Mass spectra of singly-charged Aβ40. The peak intensities are normalized to Aβ40 
in the absence of M(II)(TMC). (b) The magnified low m/z range of the mass spectra. Aβ(1-12) 
[m/z = 1424], Aβ(1-18) [m/z = 2167], and Aβ(14-38) [m/z = 2587] are indicated in light green, 
cyan, and red, respectively. All measurements were conducted with the addition of an internal 
standard, melittin (5 μM), and calibrated based on the linear correlation between the concentration 
and the signal intensity (Figure 4.7). (c) MALDI–MS spectra for Aβ40 incubated with 
Co(II)(TMC) at different pH values. The peak intensity is normalized to that of Aβ40 without 
M(II)(TMC) (a, top spectrum). (d) Magnified spectrum (x 40) for each sample. All samples were 
measured with the addition of an internal standard of melittin (5 μM). (e) The amount of 
remaining singly-charged Aβ40 after M(II)(TMC) treatment is estimated and summarized in the 
table. 

Figure 4.7. Calibration plot of the internal standard, melittin. Internal standards were prepared at different 
concentrations (100 nM–20 μM). The signal intensity for each sample was measured using MALDI–MS. 
The y-axis indicates the ratio of the signal intensity for the standards to the sum of intensities for the 30 
most dominant peaks. The linear regression of the data is given by the red line (y = 0.0205x – 0.0015; R2 
= 0.9976). 

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Figure 4.8. ESI–MS spectra of Aβ40 incubated with M(II)(TMC) (M = Co, Ni, Cu, and Zn). Inset spectra 
indicate the magnification between 1500 and 1750 m/z. Colored peaks are assigned above the spectra. 

Figure 4.9. The low m/z regions of the ESI–MS spectra for (a) Aβ40, (b) [Aβ40 + Co(II)(TMC)], (c) [Aβ40 
+ Ni(II)(TMC)], (d) [Aβ40 + Cu(II)(TMC)], and (e) [Aβ40 + Zn(II)(TMC)]. The newly generated Aβ40 
fragments formed upon M(II)(TMC) treatment are labeled in blue. Ions only detected in the samples 
treated with Co(II)(TMC) or Cu(II)(TMC) are labeled in red and green, respectively. All fragments are 
listed in Table A.3. 

Figure 4.10. ESI–IM–MS spectra of Aβ403+ or complex ions of Aβ40 with M(II)(TMC) (M = Co, Ni, Cu, 
and Zn). The drift time values with the maximum intensity are indicated in the spectra. 

Figure 4.11. Analysis of the potential isomerization of trans-I-M(II)(TMC) (M = Co, Ni, and Cu) 
complexes by UV-vis. Conditions: Co(II)(TMC) (20 mM), Ni(II)(TMC) (10 mM), or Cu(II)(TMC) (2.5 
mM); pH 7.4; 37 °C; no agitation. 

Figure 4.12. EPR measurements of Co(II)(TMC). (a) (i) X-band CW-EPR spectrum of Co(II)(TMC) 
(solid black) and its simulated spectrum (dashed black); (ii) W-band Electron Spin Echo-detected EPR 
spectrum (solid blue) of Co(II)(TMC) and its simulated spectrum (dashed blue). The following 
parameters were used in the simulation: g = [2.42, 2.42, 2.21], ACo = [0, 60,0] G, D ≥ 13 cm-1, E/D = 0.3 
(b) 1H Davies ENDOR spectra of Co(II)(TMC) in H2O (black) and in D2O (blue).The subtracted 1H 
ENDOR spectrum is shown in red. 2H Mims ENDOR in D2O (black). (c) Q-band three pulse time-domain 
(left) and the frequency domain (right) ESEEM spectra of Co(II)(TMC). The blue dashed line in the 
frequency domain indicates the 17O Larmor frequency at each field.  
 
Figure 4.13. 1H-ENDOR spectra of CoCl26H2O at different magnetic fields. 

Figure 4.14. Q-band ESEEM time-domain (left) and Fourier transformed frequency domain spectra 
(right) of CoCl26H2O. The red dashed line indicates the 17O Larmor frequency at each field. 

Figure 4.15. Computational examination of M(II)(TMC) complexes. (a) Experimental UV-vis spectrum 
of (i) Co(II)(TMC) in aqueous solutions (red) and the TDDFT-predicted spectra of [Co(TMC)(H2O)]2+ (S 
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= 3/2) (solid black), [Co(TMC)(OH)]+ (S = 3/2) (dashed black), [Co(TMC)(H2O)]2+ (S = 1/2) (solid gray), 
and [Co(TMC)(OH)]+ (S = 1/2) (dashed gray); (ii) experimental UV-vis spectrum of Ni(II)(TMC) in 
aqueous solutions (red) and the TDDFT-predicted spectra of [Ni(TMC)]2+ (S = 0) (solid black), 
[Ni(TMC)(OH)]+ (S = 0) (dashed black), [Ni(TMC)(H2O)]2+ (S = 1) (solid gray), and [Ni(TMC)(OH)]+ (S 
= 1) (dashed gray); (iii) experimental UV-vis spectrum of Cu(II)(TMC) in aqueous solutions (red) and the 
TDDFT-predicted spectra of [Cu(TMC)(H2O)]2+ (solid black) and [Cu(14-TMC)(OH)]+ (dashed black). 
(b-d) Calculated structures of (a) [Co(TMC)(H2O)]2+, (b) [Ni(TMC)]2+, (c) [Cu(TMC)(H2O)]2+, and (d) 
[Zn(TMC)(H2O)]2+. (e-f) The overlay of the ground-state M(II)(TMC) structures presented from the side 
and top. 

Figure 4.16. Solution speciation studies of Co(II)(TMC) and Ni(II)(TMC). UV-vis variable-pH titration 
spectra (left) and the solution speciation diagrams (right) of (a) Co(II)(TMC) (pH 4.5–11.5); (b) 
Ni(II)(TMC) (pH 7–11.5) (FL = fraction of species at given pH). Acidity constants (pKa) of 
[M(L)(H2O)]2+ (L = TMC) are summarized in the table. Experimental conditions: Co(II)(TMC) = 6 mM; 
Ni(II)(TMC) = 4 mM; I = 0.10 M NaCl; room temperature. Charges are omitted for clarity. aThe error in 
the last digit is shown in the parentheses.  

Figure 4.17. Schemes of the potential modes of action of M(II)(TMC) to modulate Aβ aggregation. (a) 
The conformation of Aβ is altered leading to the generation of off-pathway aggregates through (i) 
coordination to the metal center of M(II)(TMC) [e.g., Aβ–M(II)(TMC)]; (ii) intermolecular coordination 
of Aβ to two equivalents of M(II)(TMC); (iii) isomerization to the trans-III stereoisomer and subsequent 
formation of an octahedral complex. (b) Metal complexes facilitate the hydrolysis of amide bonds to 
generate Aβ fragments. Amide bond hydrolysis can be catalyzed by: (i) the activation of water by 
M(II)(TMC) to generate metal hydroxo nucleophiles; (ii) Lewis acid activation of the amide bonds; (iii) a 
mononuclear combined mechanisms where both substrates (i.e., water and amide) are coordinated to the 
metal complex; (iv) a binuclear combined mechanism where two equivalents of M(II)(TMC) are used to 
produce the hydroxide source and activate the amide bond.  

Figure 4.18. Cell viability measurements of Co(II)(TMC) using human neuroblastoma SH-SY5Y cells. 
Cell viability (%) was determined by the MTT assay compared to cells treated with ddH2O [MTT = 3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide].  

Figure 4.19. MALDI–MS analysis of ubiquitin incubated with Co(II)(TMC). The peak intensities are 
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normalized to ubiquitin in the absence of Co(II)(TMC). All measurements were conducted with the 
addition of an internal standard, melittin (5 μM), and calibrated based on the linear correlation between 
the concentration and the signal intensity. 

Figure A.1. Chemical structures of [M(TMC)]2+ (TMC = 1,4,8,11-tetramethyl-1,4,8,11-
tetraazacyclotetradecane). The two most common diastereomers are presented (trans-I and trans-III). The 
trans-I conformation forms pentacoordinate complexes by binding one ligand on the syn face. The trans-
III isomer generates octahedral complexes by binding two ligands in the open axial sites. 

Figure A.2. UV-vis spectra of [Cu(TMC)](NO3)2 and [Cu(TMC)](ClO4)2. The optical spectrum of 
[Cu(TMC)](NO3)2 (red line) is blue shifted in comparison to [Cu(TMC)](ClO4)2 (blue line) which is 
consistent with an octahedral trans-III-[Cu(TMC)](NO3)2 complex.  

Figure A.3. Chemical structures of [Cu(TMC)](NO3)2 and [Cu(TMC)(H2O)](ClO4)2. Hydrogen atoms are 
omitted for clarity. a) ORTEP diagram of the cationic part of [Cu(TMC)](NO3)2 with thermal ellipsoids 
drawn at the 30% probability level. b) Ball-and-stick representation of the cationic part of 
[Cu(TMC)(H2O)](ClO4)2 (gray C, blue N, red O, brown Cu). Selected bond distances (Å) and angles (°) 
are summarized in Table 1. The crystal structure of [Cu(TMC)(H2O)](ClO4)2 is adapted from reference 29 
for comparison. 

Figure B.1. 1H NMR spectrum of AQP2 [400 MHz, (CD3)2SO]. 
 
Figure B.2. 13C NMR spectrum of AQP2 [100 MHz, (CD3)2SO]. 

Figure B.3. 1H NMR spectrum of AQP3 [400 MHz, (CD3)2SO]. 
 
Figure B.4. 13C NMR spectrum of AQP3 [100 MHz, (CD3)2SO]. 

Figure B.5. 1H NMR spectrum of AQP4 [400 MHz, (CD3)2SO]. 

Figure B.6. 13C NMR spectrum of AQP4 [100 MHz, (CD3)2SO]. 

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Figure B.7. 1H NMR spectrum of AQDA1 [400 MHz, (CD3)2SO]. 

Figure B.8. 13C NMR spectrum of AQDA1 [100 MHz, (CD3)2SO]. 

Figure B.9. 1H NMR spectrum of AQDA2 [400 MHz, (CD3)2SO]. 

Figure B.10. 13C NMR spectrum of AQDA2 [100 MHz, (CD3)2SO]. 

Figure B.11. 1H NMR spectrum of AQDA3 [400 MHz, (CD3)2SO]. 

Figure B.12. 13C NMR spectrum of AQDA3 [100 MHz, (CD3)2SO]. 

Figure B.13. Q-band ESE-EPR spectra of Co(II)(TMC) complex in H2O (black), D2O (blue) and H217O 
(red). *indicates the background from the resonator. 

Figure B.14. 1H-ENDOR spectra of Co(II)(TMC) complex at different magnetic fields. 

Figure B.15. Q-band ESE-EPR spectrum of CoCl26H2O in aqueous solution. 
 
Figure B.16. Electronic absorption spectra of (a) trans-I-Cu(II)(TMC) experimentally obtained in 
aqueous solution; (b) TDDFT-predicted trans-I-[Cu(TMC)(OH)]+ (dotted gray) and trans-I-
[Cu(TMC)(H2O)]2+ (solid gray) models obtained using the BP functional; (c) TDDFT-predicted trans-I-
[Cu(TMC)(OH)]+ (dotted black) and trans-I-[Cu(TMC)(H2O)]2+ (solid black) models obtained using the 
B3LYP functional; (d) trans-III-Cu(II)(TMC) experimentally obtained in aqueous solution; (e) TDDFT-
predicted trans-III-[Cu(TMC)(OH)]+ (dotted gray) and trans-III-[Cu(TMC)(H2O)]2+ (solid gray) models 
obtained using the BP functional; and (f) TDDFT-predicted trans-III-[Cu(TMC)(OH)]+ (dotted black) and 
trans-III-[Cu(TMC)(H2O)]2+ (solid black) models obtained using the B3LYP functional. 
 
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Chapter 1. 
Tools of the Trade: Investigations into Design Strategies  
of Small Molecules to Target Components in Alzheimer’s Disease  
 
 
 
 
 
 
 
 
 
This chapter was adapted from the publication Derrick, J. S.; Lim, M. H. ChemBioChem 2015, 16, 887–
898. I thank Professor Lim for her assistance and guidance throughout the writing of this manuscript.  
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1.1. Introduction  
Preservation may be one of the most fundamental human instincts. As a population, we seek to live as 
long as possible and according to current life expectancies we have been achieving this goal. The rise in 
longevity is no doubt a direct result of the enormous advancements that have been made within the 
medical and scientific domains. Unfortunately, escalations in life span are also met with new challenges; 
in particular, the prevalence of degenerative diseases [i.e., Alzheimer’s disease (AD), Parkinson’s disease 
(PD), Huntington’s disease (HD), diabetes mellitus (DM)] has increased to the point where millions of 
people around the world are presently affected by these insidious disorders.1 Degenerative diseases are 
currently costing caregivers billions of dollars annually to supply the long-term aid required for those 
suffering from these illnesses.1 Without a cure or even an effective treatment for any degenerative 
disorder alongside a demographic shift toward an increasingly aged population, it is unclear how the 
resources necessary to manage such a large scale epidemic would be provided.  
The development of therapeutic interventions has been limited by a lack of information on the 
etiologies of degenerative diseases, mostly due to their complicated and multifactorial nature.2-6 While 
each degenerative disease is inherently unique, they do share some characteristics (e.g., accumulated 
misfolded/aggregated proteins, metal ion dyshomeostasis, and oxidative stress conditions).2-6 All of these 
common factors that are believed to contribute to toxicity to different extents also offer promise as 
potential therapeutic targets. Furthermore, if the similarities between these disorders would prove to be 
effective targets, multiple disorders could be treated utilizing a fundamental, guiding principle. The 
number of tactics proposed to address these disorders in the literature is vast and therefore cannot be 
completely summarized. Instead, some of the key design concepts for small molecule intervention in AD 
are described in this chapter. In addition, these design approaches can be and are currently being 
translated to other degenerative disorders.7-11 
 
1.2. Alzheimer’s Disease 
AD is the most common neurodegenerative disease; currently affecting about 24 million people 
worldwide.1-6,12-16 Unlike the other major causes of death in the United States, such as heart disease and 
cancer, the numbers affected by AD are projected to increase with extrapolated values reaching around 
100 million by 2050.1-6,12-16 This can be attributed to the absence of therapeutic agents with current FDA-
approved drugs only offering symptomatic relief through control of the level and activity of 
neurotransmitters (e.g., donepezil and memantine related to acetylcholine and glutamate, respectively).1,2,6 
Unfortunately, these treatments are only beneficial for short periods of time (6 to 12 months), thus 
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stressing the urgent need for the new discovery of effective treatment options.1,2,6 In order to achieve these 
future breakthroughs in drug discovery, an advance in the current understanding of the complex disease 
etiology is critical.  
 
 
Figure 1.1. A schematic representation of the amyloid cascade hypothesis and the metal ion hypothesis. 
The processing of the amyloid precursor protein (APP) by β- and γ-secretases [green segment: the 
respective soluble N-terminal cleavage products, sAPPα and sAPPβ; red segment: amyloidogenic 
isoforms, Aβ40 and Aβ42; blue segment: the APP intracellular domain (AICD)] leads to the production of 
Aβ40 and Aβ42 monomers that can go through a slow nucleation stage followed by a fast elongation phase 
resulting in the formation of mature aggregated fibrils. The overproduction of Aβ aggregates and the 
ineffective clearance cause Aβ plaque deposition. Metal interaction with Aβ species can facilitate peptide 
aggregation pathways, stabilize toxic conformations, and generate the production of reactive oxygen 
species (ROS) through Fenton-like reactions. 
 
Histopathologically, the AD-afflicted brain is characterized by the presence of senile plaques and 
neurofibrillary tangles (NFTs) composed of misfolded, aggregated amyloid-β (Aβ) peptides and 
hyperphosphorylated tau protein (ptau), respectively, both being considered hallmarks of the disease 
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(Figure 1.1).2-6,12-21 The distinct nature of Aβ plaques and NFTs has initially made them prime suspects as 
the toxic, causative agents of AD leading to the broad acceptance of their respective hypotheses (i.e., 
amyloid cascade and tau hypotheses).2-6,12-16 The amyloid cascade hypothesis claims that the 
overproduction and/or ineffective clearance of Aβ, the proteolytic cleavage product of the amyloid 
precursor protein (APP) by β- and γ-secretases, result in the accumulation of Aβ, which tends to 
aggregate into toxic oligomeric species (Figure 1.1).2-6,12-17 Initial evidence supporting the amyloid 
cascade hypothesis has been largely supplied from the less common, familial form of the disease (i.e., ca. 
5% of all AD cases are considered to be familial) that often occurs earlier in life (45 years of age or 
younger) where genetic mutations in the APP, presenilin 1 (PS1) and presenilin 2 (PS2), parts of the 
excision machinery that composes γ-secretase, have been identified.2-6,12-16,18-21 Mutations in these genes 
can lead to various phenotypes, such as the enhanced production of APP and Aβ, and the generation of 
the more aggregation-prone isoform, Aβ42.2-6 Carriers of these specific alleles are almost certain to be 
affected by the disease. How the genetic component translates to the more common sporadic form of the 
disease as well as a mechanistic understanding of how altered APP processing or Aβ production 
engenders toxicity, has not been fully elucidated. Although multiple hypotheses, such as inducing lipid 
peroxidation, impairing synapse plasticity, and disrupting membrane potentials, through the formation of 
pores have been proposed.5,6,12-17  
The aggregation and accumulation of Aβ may not be the only factor contributing to neuronal toxicity. 
The unfortunate lack of clinically successful compounds targeted at either preventing or reversing the 
aggregation pathways of Aβ, as well as the poor correlation between plaque load and neuronal function 
(i.e., 20–40% of cognitively normal individuals have plaque loads consistent with AD) have spurred 
researchers to consider additional parameters and look in different locations for new, potential 
contributors to AD pathogenesis.5,6 The involvement of metal ions in AD has been evident upon the closer 
analysis of senile plaques where elevated levels of metals [i.e., Cu(I/II), Zn(II), Fe(II/III)] are found to be 
co-localized.3,5,13-16,17,22,23 Aβ has been shown mainly through in vitro investigations to coordinate to these 
metal ions.2,5,13,16,17,23 The dyshomeostasis and miscompartmentalization of metals in the AD-affected 
brain consummated the metal ion hypothesis that attributes misregulated metals as a causative feature in 
the initiation and progression of the disease.2-6,13,15-17,23 Metal ions are indicated to facilitate Aβ 
aggregation and stabilize specific, toxic conformations of the peptides (Figure 1.1).5,13,23,24 Furthermore, 
redox active metal ions can induce the overproduction of reactive oxygen species (ROS) through Fenton-
like reactions with and without Aβ, which can cause detrimental damage of biological molecules 
eventually leading to neuronal death (i.e., oxidative stress hypothesis; Figure 1.2).5,13,16,17,23 
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Figure 1.2. The oxidative stress hypothesis. The ROS generated from labile metal pools and redox active 
metal bound to Aβ can engender damage of DNA, lipids, and proteins, as well as induce mitochondrial 
dysfunction, all of which can contribute to neuronal death.  
 
Different from Aβ which forms aggregates early in the disease pathway and whose plaques are poorly 
correlated with neuronal impairment, the generation of NFTs composed of tau aggregates occurs much 
closer to the appearance of clinical symptoms with a more significant connection to neuronal loss.6,13 Tau, 
along with other microtubule-associated proteins (MAPs), are essential for the structural stability and 
integrity of the intrinsically dynamic microtubules (MTs).4,6,12,13,18,19 The stabilization of MTs by tau is 
associated with normal anterograde and retrograde shuttling of essential nutrients, neurotransmitters, and 
organelles.6,12,13 Therefore, when hyperphosphorylation of tau catalyzes its release from MTs, toxicity 
arises via either the creation of aggregates affording paired helical filaments (PHFs) and eventually NFTs, 
or impaired synaptic plasticity and axonal transport processes that could be disturbed upon loss and 
aggregation of tau and other MAPs (Figure 1.3).6,12,13 Overall, Aβ, tau, metal ions, and oxidative stress are 
only a part of other possible factors that could lead to AD; however, the interconnection between these 
facets has suggested potential avenues and mechanisms toward neuronal death and AD, thus highlighting 
the extremely complex nature of the disease.13,25 
 
1.3. Anti-Amyloidogenic Compounds 
The identification and overaccumulation of misfolded Aβ aggregates, along with the growth in 
acceptance of the amyloid cascade hypothesis, have spurred the development of methods to control Aβ 
aggregation. The quantity of literature regarding the design of these methods to restrain the self-
association of Aβ is immense; therefore, instead of focusing on all design strategies, the theoretical basis 
for such a development of these methods will be provided with recent literature examples to highlight 
their applications. The production and processing of Aβ from APP and its subsequent aggregation 
pathways have been well studied through the use of various techniques, such as circular dichroism (CD)  
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Figure 1.3. The tau hypothesis. Alternative splicing of exons 2, 3, and 10 produces six different isoforms 
of tau ranging from 352 to 441 amino acids in length. The isoforms can have 0-2 acid repeats (0N-2N) 
(orange) and 3 or 4 microtubule binding domains (3R or 4R) (blue). Tau is a highly charged protein with 
an acidic N-terminus (pI 3.8) and extremely basic central, proline-rich domain (pI 11.4) and C-terminus 
(pI 10.8). Tau, along with other microtubule-associated proteins (MAPs), stabilizes microtubules (MTs). 
The hyperphosphorylation of tau catalyzes its dissociation from the MTs leading to MT destabilization, 
which may cause impairment in axonal transport and synaptic plasticity. 
 
and thioflavin-T (ThT) fluorescence.26-31 The results from reported studies, while highly dependent upon 
experimental conditions, have indicated that Aβ undergoes a sigmoidal shaped aggregation route.26-28,30 
During the slow lag phase, natively unfolded Aβ goes through a slow nucleation process that leads to the 
generation of oligomers and protofibrils.13,15,26-28 A fast elongation process then quickly follows, where 
oligomeric and protofibrillar Aβ quickly grow into mature fibrils.13,15,26-28 Once mature fibrils are 
produced, a plateau stage occurs where further growth of fibrils is slow.13,15,26-28 Recent computational 
analysis of kinetic data obtained from several amyloidogenic systems, however, suggests that fibrils may 
not be static, innocent bystanders.16,35 Instead, the findings support the occurrence of a fibril 
fragmentation step that ultimately magnifies the number of nuclei and overall augments the rate of the 
elongation period.16,35 A fundamental understanding of APP processing by α-, β-, and γ-secretases and Aβ 
production is critical because it allows for the identification of targets and techniques for extraneous 
intervention of Aβ aggregation. Modification of Aβ deposition can be envisioned through two avenues: 
(i) a pre-production management approach where the goal is to reduce or stop the generation of Aβ; (ii) a 
method for post-production management pathways where the formation and distribution of specific 
aggregates are controlled (Figure 1.4). 
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Figure 1.4. A diagram of design rationales toward control of Aβ aggregation. Anti-amyloidogenic 
compounds can be divided into pre-/post-Aβ production management. Pre-Aβ production pathways are 
directed at controlling the activity of the secretases that excise APP. Inhibition of β- and γ-secretases 
leads to a reduction in the amyloidogenic forms of Aβ while stimulation of α-secretase increases the 
production of the shorter, non-amyloidogenic forms and sAPPα, the neuroprotective N-terminal cleavage 
product. 
 
The most direct way to manage Aβ aggregation would be to regulate its generation from APP.26,29,30 
Reduction in the assembly of amyloidogenic Aβ isoforms, Aβ40 and Aβ42, could be accomplished through 
the inhibition of β- or γ-secretase. Similarly, the stimulation of α-secretase would also lead to the 
increased production of smaller non-amyloidogenic, nontoxic forms of the peptide.26,29,30 The 
development of inhibitors for β- and γ-secretases, however, might have limited therapeutic value because 
each proteolytic enzyme has other substrates, in addition to Aβ.26,29 Suppression of these proteins may 
interfere with biologically important metabolisms of other substrates, leading to severe consequences.26,29 
This in fact appears to be the case for nonselective inhibition of γ-secretase, the Aβ transmembrane 
protease consisting of at least four protein subunits (PS1, anterior pharynx, nicastrin, and presenilin 
enhancer 2).26,29 Knockout of PS1 results in a lethal phenotype, thought to be linked to notch receptor 1 
(NOTCH1) whose proteolytic cleavage products form an essential receptor that is important in the release 
of the notch intracellular domain (NICD), an indispensible component needed for normal transcription 
processes.26,29,36 Therefore, efforts have been made to discover specific inhibitors that only prevent APP 
processing while leaving the proteolysis of other substrates, such as NOTCH1, unaffected.26,29,36,37 This 
property has been observed in non-steroidal anti-inflammatory drugs; however, an approach to provide 
such specificity may also come from the utilization of foldamers.26,37 Helical β-peptide foldamers that 
mimic the transmembrane domain of C99, a substrate of γ-secretase, may be useful for the generation of 
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NOTCH-sparing inhibitors for γ-secretase.37 Imamura et al. identified the (S,S)-2-
aminocyclopentanecarboxylic acid (ACPC) dodecamer as a potential foldamer framework, in addition to 
discerning its target site.38 Through derivation and optimization of the foldamer scaffolds, some substrate 
recognition properties of γ-secretase were revealed, which may supply helpful information for further 
construction of selective γ-secretase inhibitors.38 
Unlike γ-secretase, abolition of the BACE1 gene in mice was not met with any gross abnormalities, 
suggesting that it might be a better inhibitory target.26,29 Unfortunately, recognizing small molecules that 
exhibit BACE1 inhibitory activity while also possessing necessary properties (e.g., blood-brain barrier 
(BBB) permeability) for applications in the brain has been a challenge.26,29 Two examples of potent 
BACE1 inhibitors are KMI-420 and KMI-490 (Scheme 1.1).36,39,40 Their parent compounds, KMI-358 
and KMI-370, contain a β-N-oxalyl-DAP group that is important for enhancing inhibitory effects toward 
BACE1; however, the functionality in solution isomerizes to α-N-oxalyl-DAP, which is much less stable 
and potent (Scheme 1.1).39-40 Interestingly, replacement of the oxalyl moiety with a tretrazole significantly 
enhanced not only its stability but also its inhibitory activity.39-40 Until now, the BBB permeability of 
these compounds was not addressed, and those results could occlude these molecules from further 
applications as β-secretase-directed therapeutic interventions.39-40 
 
 
Scheme 1.1. Chemical structures of β-secretase (BACE1) inhibitors. The parent compounds, KMI-358 
and KMI-370, were replaced with a tetrazole to afford KMI-420 and KMI-429 with improved BACE1 
inhibition. KMI-358, (5S,8S,11S,14S,15R)-5-amino-14-benzyl-16-((3-carboxyphenyl)amino)-15-
hydroxy-11-isobutyl-8-isopropyl-2,6,9,12,16-pentaoxo-3,7,10,13-tetraazahex-adecanoic acid; KMI-370, 
5-((4S,7S,10S,13S,14R)-4-amino-13-benzyl-1-carboxy-14-hydroxy-10-isobutyl-7-isopropyl-1,5,8,11-tetra 
oxo-2,6,9,12-tetra-azapentadecan-15-amido)isophthalic acid; KMI-420, 3-((4S,7S,10S,13S,14R)-4-
amino-13-benzyl-14-hydroxy-10-isobutyl-7-isopropyl-1,5,8,11-tetraoxo-1-(1H-tetrazol-5-yl)-2,6,9,12-tetr 
aazapentadecan-15-amido)benzoic acid; KMI-429, 5-((4S,7S,10S,13S,14R)-4-amino-13-benzyl-14-
hydroxy-10-isobutyl-7-isopropyl-1,5,8,11-tetraoxo-1-(1H-tetrazol-5-yl)-2,6,9,12-tetraazapentadecan-15-a 
mido)isophthalic acid. 
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An alternative to the suppression of γ- and β-secretases would be the stimulation of α-secretase; 
however, this has proven to be more difficult to achieve than inhibition.26,29 The activation of α-secretase 
might also possess an additional advantage over the obstruction of γ- and β-secretases. The N-terminal 
fragment generated from cleavage by α-secretase, sAPPα, has potent and neuroprotective, 
memory-enhancing effects; therefore, stimulation of α-secretase can enhance neuroprotection, in addition 
to diminishing the promotion of toxic, aggregation-prone Aβ isoforms.29 Although the identity of α-
secretase has not been completely elucidated, current evidence has pointed to members of the A 
disintegrin and metalloprotease (ADAM) family (i.e., specifically, ADAM9 and ADAM10).29 Particularly, 
overexpression of ADAM10 in transgenic animal models leads to a decrease in amyloid pathology, 
suggesting upregulation of ADAM10 as a possible strategy to reduce the generation of amyloidogenic 
Aβ.29 Another approach might be the application of statins, a class of drugs used to lower cholesterol 
levels, which have been shown to have positive effects on AD patients.29,41 One hypothesis for the 
beneficial effects of statins is related to their ability to enhance sAPPα levels through activation of α-
secretase; however, this is still controversial and the benefits and mode of  action are still debated.29,41 The 
mobilization of protein kinase C (PKC) or the activation of receptors that work through PKC might be an 
alternative avenue to enhance α-secretase’s activity.29 Finally, selective muscarinic M1 receptor 
antagonists, such as talsaclidine and AF102B, which have been shown to reduce Aβ concentrations in the 
cerebrospinal fluid (CSF) of AD patients, could be utilized.26,29 Most of the currently available activators 
for α-sectrease were designed for other intended purposes; thus, they exhibit poor selectivity and have 
limited applicability. Nonetheless, the emergence of novel routes and molecules to promote the activation 
of α-secretase, such as γ-aminobutyric acid-A (GABA-A) receptor regulator, EHT-0202, offers promise 
for this approach in future AD research.26,29  
The development of anti-amyloidogenic compounds targeted at post-production of Aβ could be 
theoretically directed at any specific species (i.e., monomers, oligomers, protofribils, fibrils) along the 
aggregation pathway. For example, monomer blockers that are able to stabilize monomeric Aβ in a native, 
nontoxic state could prevent any toxicity associated with the aggregation process (i.e., generation of Aβ 
oligomers), as well as inhibit the formation of plaques.30 Similarly, stabilization or conformational 
alteration of oligomers toward nontoxic states through the use of oligomer blockers could be envisioned.30 
The rational design of these types of low molecular weight (LMW) targeting compounds is not simplistic. 
The natively unstructured properties of LMW Aβ and, in the case of oligomers, a lack of high-resolution, 
structural information makes achieving specificity over larger, aggregated species extremely difficult.30 
The utilization of foldamers offers a recent approach toward achieving this type of LMW selectivity. 
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Fülöp et al. developed foldamer-dendrimer conjugates constructed with helical foldamer segments 
(Figure 1.5).37 The foldamer segments were designed to mimic the hydrophobic core of the self-
recognition sequence of Aβ (KLVFF) with neighboring zwitterionic residues, similar to K16 and E22 of 
Aβ, which they hypothesized to be critical chemical properties for interaction with LMW Aβ species.37 
Preliminary nuclear magnetic resonance (NMR) investigations validated the principle of the idea and 
Fülöp et al. then further optimized the foldamers affinity for LMW Aβ oligomers by creating a tetravalent 
foldamer-dendrimer conjugate that was able to capture oligomers at sub-micromolar concentrations as 
well as rescue long-term potentiation effects in ex-vivo tissues (Figure 1.5).37 The BBB permeability of 
these compounds was not determined, but due to their large size, structural modifications would be 
necessary to impart acceptable permeation for utilization in AD.  
 
 
Figure 1.5. A representation of the tetravalent foldamer-dendrimer conjugates developed to target low 
molecular weight (LMW) Aβ species (i.e., oligomers, black sphere). Attached to a dendrimer scaffold 
(dark grey rectangle) were foldamer segments (light grey rectangles) that were designed to mimic the 
hydrophobic core and surrounding zwitterionic residues of Aβ. Binding affinity for LMW Aβ was 
increased through tetravalent structural modifications. 
 
Another example of achieving some sort of specificity toward LMW Aβ oligomers is the use of metal 
complexes (e.g., L-PtCl2 complexes).28,42 These metal complexes interact with the histidine residues of the 
metal binding region of Aβ where ligand exchange of the chloro ligands can occur.28,42 Studies with 
cisplatin [cis-Pt(NH3)2(Cl)2] do not show appreciable ability to inhibit fibril formation, identifying the 
importance of having an aromatic auxiliary ligand, such as phenanthrolene, for pivotal π-π stacking with 
F4, Y10, and H13; however, cisplatin has been shown to inhibit hydrogen peroxide (H2O2) formation by 
copper-catalyzed oxidation of Aβ, in vitro.28-34 These aromatic Pt complexes were able to inhibit metal-
induced Aβ aggregation, as well as regulate Aβ-induced synaptotoxicity in mouse hippocampal slices.28,42 
In addition to the positive results of this study, it also serves as a proof of concept that organometallic 
complexes can be utilized against Aβ/metal–Aβ. Furthermore, the selective Aβ inhibitory activity of 
these compounds suggests that targeting the metal binding site in Aβ could also prove to be a potential 
approach to gain specificity over higher MW Aβ species.28,42 The use of metal complexes, however, still 
Dendrimer scaffold 
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needs to be subjected to more intensive in vivo testing, especially because of the potential toxicity 
associated with the introduction of exogenous redox active metals into an environment already affected 
by oxidative stress. In the case of Pt complexes, Pt(II) is most likely redox inactive within the cell; 
however, its toxicity in biological systems presents additional challenges.32,33 The use of Pt(IV) 
complexes that can then be reduced by natural reductants (e.g., glutathione) back to labile Pt(II) upon 
entering the cell may offer one solution to this obstacle.32,33 
 Finally, the development of β-sheet breakers is a strategy to manage post-Aβ production. These 
molecules are able to specifically interact with high MW Aβ fibrils to prevent or disrupt β-sheet 
formation, which has been shown to be neurotoxic by in vitro studies.26,43,44 A key innovation for the 
generation of design strategies of these compounds has been the determination of the central hydrophobic 
region (i.e., self-recognition motif) and the hydrophobic C-terminal residues in the aggregation process 
and formation of β-sheet structure.30 Most of this class of inhibitors have employed short fragments, 
generally 5 to 11 amino acid residues in length, that are similar to or mimic the nonpolar core of Aβ to 
disrupt the hydrophobic interactions pivotal for fibril elongation.26,30,44 These motifs are often modified by 
the addition of more charged or hydrophilic substituents to help with the intrinsically poor solubility in 
aqueous environments.30 Additionally, proline residues are often incorporated to decrease the hydrogen 
bonding networks with neighboring residues.30 Small molecule approaches have also been devised, many 
taking advantage of aggregation-dependent dyes, such as ThT and Congo red derivatives.30,44 Within the 
past decade a myriad of molecular scaffolds have proven to be effective at targeting fibrils some of which 
include flavonoids, polyphenols, and benzofuran derivatives.26,30 The extensive development of such 
compounds has been the subject of vast literature reports; therefore, it will not be described in this 
chapter.30 
 
1.4. Metal Chelators and Ionophores 
The dyshomeostasis of metal ions, as previously discussed, is a linking characteristic among many 
degenerative disorders, such as PD and DM, and is believed to be a contributing factor toward the onset 
of AD.2,4,5,13,15,17,20 The therapeutic use of metal chelating compounds began in the 1900’s and since then 
has been beneficial in the treatment of metal overload diseases (e.g., Wilson’s disease, Friedriche’s 
Ataxia).20,45 Neurodegenerative diseases, however, pose a more challenging setting for the application of 
classical metal chelating compounds. As a result, the concepts behind metal chelator design strategy are 
much more complex than creating molecules that indiscriminately chelate immense amounts of 
metals.9,45,46  
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In order for metal chelators to be applicable tools to AD and other neurodegenerative disorders, they 
should possess the ability to permeate the BBB.9,45-51 This critical property alone excludes numerous 
potential chelators because of the intrinsic hydrophilic nature of the molecules generated by the 
installation of donor atoms onto a structural framework to achieve metal chelation capabilities.9,45,46 
Although an increase in structural hydrophobicity could improve BBB penetration, lipophilic metal 
chelators alone are also not suitable as effective compounds for AD because they reduce water solubility 
and expands intracellular access where interference with important metalloproteins can occur.9,45,46,52 
Therefore, the polarity of these molecules needs to be carefully balanced to fashion water soluble, 
BBB-permeable chelators. Predictive methods, including Lipinski’s rules for drug likeness and calculated 
BBB partition coefficients (logBB) that can help to guide the design of potentially effective 
BBB-permeable chelators are available.2,25,50,51,53 The installation of secondary functionalities (e.g., 
glucose) can also aid in promoting the passage of potential metal chelators through active transport 
pathways.2,50 The ability of the BBB to block the passive diffusion of most small molecules has led 
researches to come up with new, innovative ways to permit passage. An example of this is the use of 
nanoparticles tethered to metal chelators that can act as small molecule chaperones across the BBB 
through low density lipoprotein (LDL) receptor-mediated avenues.48,49 This approach could offer 
promising results because it might expand new metal chelating frameworks that would otherwise not be 
applicable toward neurodegenerative diseases. Further in vivo testing is still required to fully elucidate the 
utility of this method.48,49  
A common misconception that is often affiliated with the use of metal chelating agents in 
degenerative diseases is that the goal is to chelate out or completely remove metal ions from protein 
targets.9,45-51 At first glance, the sequestration of metals may seem appealing because of their 
aforementioned ability to promote the aggregation of misfolded proteins, stabilize toxic species, and 
generate oxidative stress environments, all of which have been suggested to contribute to 
neurotoxicity.5,23,24 This erroneous assumption is, in fact, one of the biggest challenges when developing 
metal chelators. The entrapping of essential biometals required for biological processes can lead to 
serious detrimental effects, including cell death.9,45-51 In order to prevent this undesirable outcome, metal 
chelating compounds should be designed to be selective for the desired metal ion and protein target, as 
well as have carefully tuned binding affinities in order to minimize disturbance to beneficial 
metalloproteins.9,45,46 Ideal Kd values for Cu(II) and Zn(II) chelators would be generally in the nM and 
mM range, respectively; however, ligands capable of forming 1:1 and 1:2 complexes make the matter less 
trivial, with conditional dissociation constants being concentration dependent. Some degree of metal ion 
specificity can be achieved through the consideration of basic inorganic principles, such as the hard-soft 
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acid-base principal and the Irving-Williams series.25,46 Furthermore, the geometry on the metal binding 
center, as well as the stoichiometries of the generated complexes, can be considered as additional 
parameters to impart metal specificity.25,46,54  
Designing ligands directed toward the correct location (e.g., the brain) and protein target is 
conceptually as important as metal ion considerations for limiting unintended side effects, such as 
hypocalcemia and renal failure.9,45,46 Unfortunately, there are no guidelines to develop protein-specific 
chelators. Instead, the characteristics of the peptide must be considered in order to optimize one of its 
features to impart selectivity. The identity and source of these attributes obviously vary between proteins. 
The capitalization of the self-recognition (KLVFF) sequence of Aβ’s central hydrophobic core provides 
one example used by Wu and coworkers.55 They attached the Aβ recognition sequence known to be 
important in the aggregation pathway and design of β-sheet breaking compounds (vide supra) onto an 
apo-cyclen framework (Scheme 1.2).26,30,44,55 The apo-cyclen compound, cyc-KLVFF, was able to 
interact with metal–Aβ, abstract the Cu(II) bound to the peptide, thus generating a proteolytically active 
complex that was shown to inhibit Aβ aggregation and disaggregate preformed Aβ aggregates, as well as 
reduce the formation of H2O2 (ca. 75% inhibition)  generated by Cu(II)–Aβ42, and ameliorates metal–
Aβ (Cu(II)–Aβ42) induced toxicity in living cells.55 Although cyc-KLVFF was only evaluated in an AD 
model system,55 mimicking the incorporation of amino acid residues important for self-association could 
be broadly applicable to any disease in which misfolded proteins and metal ions are suspected players (i.e., 
degenerative diseases, in general).  
 
 
Scheme 1.2. The chemical structure of an apo-cyclen framework with the Aβ self-recognition sequence 
(KLVFF) installed for protein specificity. The amino acid sequence of Aβ42 is provided with the self-
recognition sequence highlighted and underlined in blue. The apo-compound abstracts Cu(II) from 
Cu(II)–Aβ, forming a proteolytically active complex capable of degrading monomeric and oligomeric Aβ 
forms. 
 
The use of prochelators, a class of ligands containing a protecting group that masks the metal binding 
site of the molecules, could provide another approach to incorporate location and protein specificity 
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(Scheme 1.3). The Franz group reported an example of such compounds.56 8-Hydroxyquinoline (8-HQ), a 
prominent bioactive metal chelator that has been extensively utilized in the AD field, was protected with a 
boronic ester group to generate the ligand, QBP, [8-((3aR,4R,6R,7R)-3a,5,5-trimethylhexahydro-4,6-
methanobenzo[d][1,3,2]dioxabor-ol-2-yl)quinoline] that is only active when H2O2 is present.56 In the 
presence of H2O2, the boronic ester group is oxidatively cleaved releasing the active chelator, 8-HQ, 
which is able to diminish Cu-catalyzed production of ROS and control the generation of Aβ aggregates.56 
The design strategy for this compound is especially innovative since it could allow for the control of 
metals and metal-mediated ROS without causing redistribution of metal ions, because QBP is only active 
in an oxidative-stress-like environment.56 Another 8-HQ-based prochelator, 1, reported by Zheng et. al., 
was designed to employ a carbamyl moiety as a protecting group for the hydroxyl O donor atom and 
incorporate a propargylamine functionality for enhancement of neuroprotective properties.47 These 
proligands were capable of gaining improved target specificity through the carbamyl mask that was found 
to be a selective and potent inhibitor of acetylcholinesterase (AChE), an enzyme responsible for the 
hydrolysis of the neurotransmitter, acetylcholine.47 Upon interaction and inhibition of AChE, the 
carbamyl functionality was cleaved, releasing the active bidentate chelator (2).47 The ability to generate 
effective metal chelating compounds from an inert prochelator could allow for the precise reactivity 
toward numerous pathogenic features of AD (e.g., chelators stimulated by β-secretase metabolism), in 
addition to AChE-activated molecules.  
 
 
Scheme 1.3. The chemical structures of 8-hydroxyquinoline (8-HQ)-based prochelators (protecting group 
highlighted in grey) and their respective active forms. The carbamyl protecting group from the 
dimethylcarbamate (1) is cleaved upon inhibition of acetylcholinesterase (AChE) to give 5-((4-(prop-2-
yn-1-yl)piperazin-1-yl)methyl)quinolin-8-ol (2). QBP [8-((3aR,4R,6R,7R)-3a,5,5-trimethylhexahydro-
4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)quino-line] is converted into its active form, 8-HQ, upon 
oxidation of its boronic ester-mask. 
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One of the most prominent metal chelators within the AD field is, clioquinol (CQ).9-11,57-62 CQ was 
initially marketed as an antifungal, antiprotozoal drug; however, its use has been restricted since treatment 
with CQ in Japan might have been linked to subactue myelo-optic neuropathy (SMON), a neuronal 
disease that causes blindness, paralysis, and death.9-11,57-62 A casual correlation between CQ and SMON 
has yet to be established, and its role in the onset of the disease is a matter of debate.9-11,57-62 CQ has 
shown promise as a therapeutic agent for multiple neurodegenerative diseases.9-11,57-60,62 Encouraging 
results were reported for its use in AD clinical trials.9,57,59 Furthermore, it was also able to improve the 
behavioral and pathogenic phenotypes in mouse models of PD and HD.9-11 Unfortunately, assessment of 
CQ was halted in AD clinical trials because of a toxic diiodo impurity during the large-scale synthesis of 
the compound.63 The contamination associated with CQ lead Bush and coworkers to design the second 
generation compound, PBT2, through a more facile synthetic approach that can avoid the impurity issues 
indicated in the production of CQ.63,64 Surprisingly, PBT2 possessed superior BBB permeability while 
still maintaining affinity for copper and zinc ions.63,64 Most importantly, in in vivo and clinical settings, 
PBT2 decreased interstitial Aβ within hours of treatment and improved cognitive functions within several 
days, overall exceeding CQ’s performance.63,64 Treatment with CQ and PBT2 in living cells was found to 
increase intracellular levels of copper and zinc.9,58,60,62,63 Investigations into the mode of action of PBT2 
and CQ revealed that they do not sequester metals like conventional chelators but instead behave more 
like ionophores, redistributing metal ions to regions where they can be beneficial (i.e., intracellular 
locations).9,58,60,62,63 A proposed mechanism for this activity in AD is that CQ can complex with copper 
localized within Aβ plaques, possibly forming ternary complexes, and then deliver the metal into the 
cell.9,64 Once in the cell, the copper complexes with CQ can activate the phosphorylation of glycogen 
synthase kinase-3 (GSK-3), which can then potentiate the activation of Jun N-terminal kinase (JNK) and, 
along with activation of phosphoinositol 3-kinase enhance the activity of matrix metalloprotease-2/3 
(MMP2 and MMP3).64 MMPs can then facilitate the breakdown and clearance of Aβ plaques (Figure 
1.6).9,64 These investigations not only report promising compounds for the intervention of degenerative 
disorders but also suggest that an ionophore mode of action might be the desired activity for future metal 
chelators.  
 
1.5. Multifunctionality  
Recently, there has been a paradigm shift in the literature for the construction of chemical tools and 
therapeutics to treat neurodegenerative diseases. The shortcomings from targeting a single feature of 
degenerative disorders, such as AChE or glutamate in AD [i.e., AChE inhibitors and N-methyl-D-
aspartate (NMDA) receptor antagonists] and monoamine oxidase (MAO) for PD [i.e., MAO inhibitors  
 16
 
Figure 1.6. A proposed mode of action of clioquinol (CQ) and other similar ionophores. CQ diffuses into 
the brain where it interacts with extracellular Aβ plaques and metals. CQ binds copper and enters 
adjacent cells. Once in the cell, the complex dissociates and the metal ions can activate the 
phosphorylation of glycogen synthase kinase-3 (GSK3) which along with activation of Jun N-terminal 
kinase (JNK) promotes the activation of matrix metalloproteinase 2 and 3 (MMP2/MMP3). 
MMP2/MMP3 then can aid in the breakdown and clearance of extracellular, metal-free and metal-bound 
Aβ plaques. 
 
(e.g., rasagiline)] have led to the advancement of multimodal approaches aiming at multiple factors (e.g., 
misfolded, aggregated proteins, enzyme inhibitors, metal ion homeostasis, and miscompartmentalization) 
of these complex diseases.25,52,65-67 Addressing multiple facets of AD simultaneously can be achieved 
through two tactics: (i) a multiple-molecule-multiple-target strategy (i.e., polypharmaceutical) and (ii) a 
single-molecule-multiple-target strategy (i.e., an integrated approach; Figure 1.7).65,66 In the 
polypharmaceutical method, two or more molecules are utilized in a cocktail solution to address different 
aspects of a disorder. As the name implies, the single-molecule-multiple-target strategy integrates 
multifunctionality within a single structural entity. The polypharmaceutical approach is not ideal for the 
generation of chemical tools or therapeutics because it makes identification of structure-reactivity 
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relationships almost impossible. Furthermore, the simultaneous utilization of multiple compounds to treat 
different parameters of the disease also greatly enhances the probability of generating unfavorable side 
effects.65  
 
 
Figure 1.7. A schematic model of the single-molecule-multiple target strategy (i.e., integration approach). 
A chemical linker can be used to connect two or more independent structural portions to gain multimodal 
action (right) (i.e., linkage approach). An incorporation approach (left) can install multiple moieties for 
the desired reactivities into a single structural entity.   
 
Integrated multifunctional molecules can be fashioned through two routes (Figure 1.7). The first tactic, 
referred to as the linkage approach, takes two or more intact and relatively unmodified molecules and 
connects them through various organic linkers (Figure 1.7).66 The advantage of this method is that it 
allows for minimal modifications to the individual structural frameworks and therefore improves the 
probability of maintaining the individual, desired reactivity of the tethered molecules.66 These molecules 
are, however, often structurally complex and highly functionalized, making them synthetically 
challenging to produce. The other strategy, which is one that our group commonly employs, is the 
incorporation approach, in which multimodality can be generated in a single molecular framework 
through the rational installation of specific functionalities (Figure 1.7).25,66 The advantage here is that size 
and complexity can be minimized, which is critical for BBB permeability and similar characteristics 
essential for applications in AD. The design principles supply the general concepts through which the 
construction of multi-directed compounds can be envisioned but it does not offer much instruction for 
specific functionalities that should be present in successful compounds. Instead, because of the extensive 
versatility of this method, the development and progress of these types of molecules will be propelled by 
structure-reactivity investigations that can be used to identify beneficial chemical moieties that can be 
incorporated into pre-existing frameworks and biological and biochemical discoveries of new pathways 
and targets.  
Our group has applied the incorporation approach toward the fabrication of small chemical tools for 
elucidating the complex AD pathology.25 In order to ascertain the role of metal–Aβ [i.e., Cu(II)–Aβ, 
Zn(II)–Aβ] in AD pathogenesis, a bifunctional ligand, L2-b, was developed through installation of two N 
donor atoms onto an Aβ imaging framework (p-I-stilbene; Scheme 1.4).25,68,69 In addition to its favorable 
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BBB permeability, (examined both in vitro and in vivo) and its competitive affinity for metal ions 
(apparent Kd, ca. 10-10 and 10-6 for Cu(II) and Zn(II), respectively), L2-b exhibited an ability to 
selectively target metal–Aβ species and modulate their reactivity (i.e., metal–Aβ aggregation, metal–
Aβ-mediated ROS generation).25,68,69 The overall metal–Aβ specific property of L2-b not only validates 
the application of the incorporation approach for constructing bimodal molecules, but also provides us 
with a tool to directly probe the involvement of metal–Aβ in AD pathology in vivo.70 In a recent study, 
the selectivity of L2-b for metal–Aβ was further evaluated through ion mobility–mass spectrometry (IM–
MS).70 IM–MS investigations showed the formation of a more compact Aβ conformation when Cu(II) 
was present; this might offer clues to explain the reactivity of L2-b.70 Most importantly, metal–Aβ 
complexes were targeted and modulated within the brain upon treatment of 5XFAD mice with L2-b; 
cognitive impairment, determined by the Morris water maze task, was improved, thus demonstrating in 
vivo experimental evidence that metal–Aβ contributes to AD pathology.70 A similar design strategy was 
applied to produce a multifunctional ligand, ML, to further evaluate the role and interconnections of 
multiple pathological factors of AD (e.g., Aβ, metal–Aβ, metal ions, ROS) (Scheme 1.4).25,54 ML was 
able to inhibit metal-free and metal-induced Aβ aggregation, disaggregate preformed fibrils into 
off-pathway nontoxic species, improve cell viability in the presence of metal-free and metal–Aβ, as well 
as control the formation of Cu(II)-triggered hydroxyl radicals.25,54 The individual structural components 
of ML were also evaluated independently and in a cocktail solution. ML presented noticeable reactivity, 
validating the design concept and accentuating the versatility available with the rational incorporation 
design principle.25,54 
 
 
Scheme 1.4. The chemical structures of the multifunctional molecules. L2-b, N1,N1-dimethyl-N4-
(pyridine-2-ylmethyl)benzene-1,4-diamine; ML,  4-(dimethylamino)-2-(((2-(hydroxymethyl)-quinolin-8-
yl)amino)methyl)phenol; 41,  5,6-dihydroxy-2-(4-(methyl(propyl)amino)benzylidene)-2,3-dihydro-1H-
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inden-1-one 4-methylbenzenesulfonate; GL3, 2-methyl-1-(4-(methylamino)phenyl)-3-(((2S,3R,4S,5S,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)pyridin-4(1H)-one; GL4, 1-(4-
aminophenyl)-2-methyl-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)pyridin-4(1H)-one. 
 
The inclusion of inhibitory activity for MAOs is an additional property that is often sought after in 
multi-directed compounds. MAOs (MAO-A and MAO-B) are flavin adenine dinucleotide (FAD)-
dependent enzymes responsible for the metabolism of neurotransmitters (e.g., dopamine, serotonin, 
norepinephrine) whose levels are decreased in AD and other degenerative disorders.71-73 One of the more 
prominent compounds of this type is M30, an 8-HQ derivative that incorporates a propargyl moiety into 
its basic framework (Scheme 1.4).72,73 The propargyl moiety was introduced into the backbone, because 
previous investigations suggested it was crucial for the neuroprotective and MAO inhibitory effects of the 
FDA-approved PD-drug, rasagiline.72 Studies by Zheng et al. indicated that, in addition to being a potent 
inhibitor of MAO, M30 was capable of preventing iron-induced lipid peroxidation through its free radical 
scavenging and metal chelating properties.72 In double transgenic (APP/PS1) AD mouse models, 
treatment with M30 improved cognitive defects and attenuated Aβ accumulation and tau 
phosphorylation.71 Li and coworkers have also reported an antioxidant benzylideneindanone derivative, 
41, that ThT and TEM investigations identified as an effective inhibitor of Aβ42 aggregation (i.e., 80%).71 
Unlike, M30, compound 41 was a potent and selective MAO-B inhibitor (IC50 7.50 μM).71 Selectivity 
when designing enzyme inhibitors, as previously discussed, is critically important in order to minimally 
disrupt the processing of additional substrates. 
The final example of the versatility that can be accomplished with a rational multi-targeted design 
strategy was presented by Orvig and coworkers who produced a multifunctional 3-hydroxy-4-(1H)-
pyridinone prochelator.74,75 The proligand utilized a masking glucose functionality, not only to protect the 
O donor atom of the bidentate framework, but also to impart improved BBB penetration (Scheme 1.4).74,75 
Furthermore, a degree of location specificity was also secured, because the active form of the molecule 
was only created upon the loss of the carbohydrate mask by the glycosidic bond hydrolysis from β-
glucosidase enzymes upon transport across the BBB.74,75 This allows for minimalized complexation of 
essential metal ions before passage into the brain, where they are able to react with Aβ by installation of 
pendant functionalities, trap and control the formation of free radicals, and exhibit adequate brain 
uptake.74,75 Overall, these five examples of multi-target-directed compounds only give a brief glimpse into 
the power of this rational design approach. The recent recognition and growing acceptance of the 
multifactorial nature of AD and other neurodegenerative disorders have led to the rapid growth in the 
development of these types of molecules, and as a result, full reviews could be dedicated to this topic 
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alone. Innovation and progress in the design of future multifaceted compounds will only be limited by the 
identification and ingenuity of researchers to target new factors contributing to the disease pathogenesis 
and the fundamental structural investigations that discern useful structural features for attaining the 
desired reactivities. 
 
1.6. Tau-Related Strategies 
Direct and indirect connections between Aβ and tau in AD pathogenesis have been discovered; 
however, the details and mechanistic understandings of these relationships have yet to be elucidated.76-79 
Western blotting and enzyme-linked immunosorbent assay (ELISA) experiments have been able to detect 
the formation of Aβ-tau complexes in vitro and in AD tissue samples.80 The complexes were more 
susceptible to glycogen synthase kinase 3β (GSK3β)-mediated phosphorylation.80 Surface plasmon 
resonance (SPR) spectroscopy determined the binding affinity of Aβ for tau to be in the low nanomolar 
range suggesting that a critical step in AD pathogenesis may be the intracellular binding of soluble Aβ to 
nonphosphorylated tau.80 Furthermore, Aβ and familial AD linked allele, apolipoprotein E4 (ApoE4), 
have been found to upregulate other kinases in addition to GSK3β, and treatment with Aβ oligomers has 
been met with disruption of MT structure and function.13,79,80 Tau has also been found to coordinate metal 
ions in vitro.13,81-83 Circular dichroism (CD), mass spectrometry (MS), and NMR investigations on full 
length and fragmented tau have determined Cu(II) binding sites, many of which have been located 
proximal to the microtubule binding domains (MTBDs).13,81-83 Compared to Aβ, tau binds Cu(II) less 
strongly, with reported Kd values for full length tau (Htau40) in the μM range (i.e., 0.5 μM).84 Given the 
low abundance of labile Cu(II) and the relatively low binding affinities of tau for Cu(II) the possibility of 
coordination in vivo is still uncertain. Coordination of metal ions was met with slight structural alterations 
in the fragmented tau, but very little modifications were observed for full-length tau.13,81,82 Trivalent metal 
ions, Fe(III) and Al(III), have been shown to induce ptau aggregation and upon ascorbate-triggered 
reduction to the divalent form reverse the self assembly process.13,85 Tau’s aptitude for mediating the 
production of ROS in the presence of metal ions is still a focus of further study, but preliminary reports 
describe that incubation of the R2 repeat domain with Cu(II) could lead to the generation of H2O2.86  
Therapeutic strategies to address the role(s) of tau in AD have been developed, but like Aβ-related 
preventative methods, have produced little success. The advancement of kinase inhibitors engineered to 
alter the phosphorylation state of tau and reduce its dissociation from MTs and growth into PHFs has 
been inadequate.87,88 An incomplete understanding of the enzymes responsible for the 
hyperphosphorylation of tau, in addition to their essential functions in the posttranslational modifications 
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of other substrates, makes kinase inhibitor design challenging.86 Point mutations in tau causing 
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), a autosomal dominant 
neurodegenerative disorder, expand the aggregation propensity of tau both in vivo and in cell studies.87 
Small molecules capable of controlling the aggregation pathway of tau, similar to anti-amyloidogenic 
compounds (vide supra), have been tested with the most noteworthy molecule, methylene blue, making it 
to phase II clinical trials for AD.77,87 A new approach to exogenously stabilize MTs in a manner similar to 
tau and other MAPs has emerged. The rationale has been utilized within the cancer field for the 
generation of antiproliferative chemotherapeutics and has just recently been applied to AD.89,90  
The formation of MT stabilizing agents began with the use of paclitaxel, a natural product isolated 
from the bark of the Western yew (Taxus brevifolia).89,91 Michaelis et al. first made apparent the utility of 
MT stabilizers for AD when they showed that treatment with paclitaxel protected neurons against 
Aβ42-induced toxicity (Scheme 1.5).92 The neuroprotective effect of paclitaxel and other MT stabilizers, 
however, appears to be concentration-dependent.89 Lower doses of MT stabilizers have been shown to be 
neuroprotective in transgenic tau models, whereas higher amounts might produce unwanted side effects, 
including neutropenia and peripheral neuropathy.89 This could be a result of the careful equilibrium 
between the growth and degeneration stages of MTs. Overstabilization of MTs leads to mitotic 
dysfunction and cell death, which is desirable for tumor suppression, while unstable MTs can lead to 
impaired axonal transport issues that can eventually contribute to neuronal toxicity and death (vide supra). 
 
 
Scheme 1.5. The chemical structures of the naturally occurring, MT stabilizers, paclitaxel and epothilone 
D. 
 
Since the effectiveness of MT stabilizers was demonstrated with paclitaxel, more MT stabilizing 
compounds have been discovered, most of which have been natural products; however, a few synthetic 
derivatives have been recognized.89,91 The biggest challenge associated with paclitaxel and many other 
natural MT stabilizers is their inability to permeate the BBB and, therefore, their applications are limited 
for AD.89,91 Recently, Ballatore and coworkers have shown that some compound classes, such as 
epothilones (in particular, epothilone D), were able to pass the BBB and, when injected into mice, 
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normalize MT density and restore fast axonal transport (Scheme 1.5).89,91 Epothilone D is currently in 
clinical AD trials.89 Paclitaxel is believed to stabilize MTs by binding to the lumen of the β-tubulin 
subunit of the MT in a location referred to as the taxane binding site.89,93 This is the same location 
targeted by tau’s microtubule binding domains.89 In fact, paclitaxel is able to displace tau from the MTs.89 
Once bound to the inside of the MT, paclitaxel is presumed to incite a conformational change within the 
M-loop of the β-tubulin subunit which causes the stabilization of adjacent protofilaments.89,93 In this sense, 
paclitaxel and other taxane binding compounds can be thought of as a figurative adhesive that connects 
and stabilizes neighboring tubulin subunits. Overall, the MT stabilizing molecules have mostly been 
restricted toward the analysis and testing of natural products; however, very little progress has been made 
for the fabrication of synthetic analogs. Furthermore, structure-reactivity studies have been limited to 
determine the key chemical characteristics of such compounds. Detailed structure-based examination 
similar to those performed for transthyretin stabilizing compounds could direct the evolution of more 
potentially BBB-permeable scaffolds that could direct new discovery of AD therapeutics.94 
 
1.7. Conclusions  
It has been almost one hundred and ten years from Alois Alzheimer’s observation of the first plaques 
and tangles in the brain of Auguste Deter. Our knowledge of AD has grown substantially since 1906. For 
example, the major protein constituents of the senile plaques and neurofibrillary tangles, Aβ and tau, 
respectively, have been discerned, and their processing and aggregation pathways have been investigated. 
The contribution of additional pathological factors, such as metal ions, to affect the self-assembly of Aβ, 
generate or stabilize toxic conformations, and produce ROS has been evaluated. These findings only 
begin to exemplify some of the numerous pivotal findings that have been paramount in not only 
furthering our understanding of the complex etiology of AD, but also for the development of therapeutics 
that are able to offer some minimal, temporary degree of relief. The demand for new treatment options, 
however, is unrelenting and has catapulted research into methods to correct for the misfolding of proteins, 
oxidative stress environments, metal ion dyshomeostasis, and altered neurotransmitter levels in AD. 
While none of these strategies have currently been proven effective, the advancement of new methods, 
such as multifunctional approaches, and the continued efforts to further elucidate the causative 
mechanisms of AD will be instrumental in providing insight into designing the next generation of 
therapeutics. 
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Chapter 2. 
Importance of the Dimethylamino Functionality on a Multifunctional  
Framework for Regulating Metals, Amyloid-β , and Oxidative Stress  
in Alzheimer’s Disease 
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2.1. Introduction 
The discovery of effective therapeutic strategies to combat Alzheimer’s disease (AD), the most 
common form of dementia, have yet to be identified, which is most likely a result of the disease’s 
complex and multifaceted pathology.1-10 For example, some pathological features being actively 
investigated include: misfolded and aggregated proteins (i.e., amyloid-β (Aβ) and tau), metal ion 
dyshomeostasis and miscompartmentalization, oxidative stress, excitotoxicity, neuroinflammation, and 
mitochondrial damage.1-6,11,12 Furthermore, the interconnections between many of these pathological 
factors, such as Aβ, metal ions, and reactive oxygen species (ROS), make the elucidation of a 
comprehensive molecular-level understanding of AD etiology extremely challenging.1-4,6-9,13,14 One 
approach to address the inherently complex multifaceted nature of AD is to utilize multifunctional 
compounds able to preferentially modulate the activities of multiple targets simultaneously. This strategy 
has been increasing in prevalence within the literature with common targets, including Aβ, tau, various 
neuroreceptors (e.g., cholinergic, glutamatergic, and dopaminergic receptors), and enzymes (e.g., 
acetylcholinesterase, monoamine oxidase).1,15-22 Unfortunately, a majority of the current multifunctional 
molecules are developed by slightly modifying existing drugs or known molecular scaffolds (e.g., tacrine, 
coumarin, curcumin).1,15-22 Such a tactic is often costly and time consuming since it frequently involves 
the high-throughput screening of many structural derivatives, most of which fail to be selected for further 
analysis.  
Rather than modifying familiar frameworks, we have recently reported that novel multifunctional AD 
agents can be generated through the use of an incorporation approach to rational ligand design.23,24 Initial 
studies with a multifunctional ligand (ML) identified the feasibility of designing a single molecular entity 
that can control metal-free and metal-induced Aβ aggregation, toxicity engendered by metal-free Aβ and 
metal–Aβ, and metal-mediated ROS generation, as well as scavenge free radicals, overall validating 
ML’s structure-based design strategy.12,23,24 Further progress toward the production of more diverse and 
improved multifunctional reagents is dependent on the recognition of critical pharmacophores that can be 
employed as figurative ‘building blocks’ to engineer next-generation ligands through such a rational 
design approach. Structure-reactivity studies, using individual components within a complex molecule 
and structurally modified molecules, can provide the information to determine the chemical 
functionalities that may impart the desired reactivities.  
Toward this goal, we have prepared a series of aminoquinoline (AQ) derivatives (i.e., AQ1-4, AQP1-
4, AQDA1-3; Figure 2.1) based on the framework of ML in order to discern a structure-reactivity 
understanding of ML’s multifunctionality. Our in vitro investigations have proposed the dimethylamino 
functionality of ML to be critical toward its ability to modulate the aggregation pathways of metal-free 
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Aβ and metal–Aβ. Two-dimensional (2D) NMR studies have shown that functionalization of the 
aminoquinoline moiety is capable of shifting the preferred region of interaction along the sequence of Aβ. 
In addition, the slight modifications to ML’s metal binding site are also indicated to direct the 
derivatives’ ability to bind Cu(II) and Zn(II), control reactive oxygen species (ROS) formation, and alter 
Cu(II)–/Zn(II)–Aβ aggregation. The overall structural variation of ML also tuned its capability to 
scavenge free radicals. Mass spectrometric studies further illustrate the importance of the metal binding 
affinity of this series of small molecules in regulating metal–Aβ aggregation and potentially suggest 
larger, higher-order oligomers as the interacting species. Similar to ML, our structural derivatives are also 
observed to be potentially suitable in biological systems since they are moderately water soluble and 
potentially possess the ability to penetrate the blood-brain barrier (BBB). Overall, our studies highlight 
the importance of the dimethylamino moiety for imparting reactivity toward AD-relevant targets (e.g., 
metals, Aβ, metal–Aβ) yet further studies are still warranted to assess its transferability to other molecular 
scaffolds.  
 
2.2. Results and Discussion  
 
 
Figure 2.1. Structural variations on a multifunctional ligand (ML) framework. Modifications were 
performed on the multimodal scaffold to identify a structure-reactivity understanding of ML’s 
multifunctionality as well as to tune its metal binding characteristics. The quinoline portion of the 
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structure was examined by cleavage of the HN–CH2 bond (site 1, purple) and modulating the 
functionalities at the R2 position (site 3, blue). Furthermore, simultaneous structural alterations at the R1 
and R2 positions (sites 2 and 3, green and blue, respectively) allowed the role of the dimethylamino group 
and the 4-(dimethylamino)phenol in ML’s activities to be illuminated. 
 
2.2.1. Design Rationale and Preparation for Structural Modifications to a Multifunctional 
Framework 
A series of aminoquinoline (AQ) derivatives based on our previously reported multifunctional ligand 
(ML) were generated to (i) develop a structure-reactivity understanding of ML’s multifaceted reactivity 
toward metal-free Aβ, metal–Aβ, ROS, and free radicals and (ii) reduce its relatively high binding affinity 
for Cu(II) and Zn(II) (i.e., dissociation constants for Cu(II) and Zn(II) in the picomolar and nanomolar 
range, respectively) that may potentially interfere with biologically essential metalloproteins.23 The AQ 
derivatives were obtained by subjecting ML to modifications at three sites (Figure 2.1). First, in order to 
determine the significance of the phenol or 4-(dimethylamino)phenol moieties in ML’s activities, AQ1-4 
were prepared by excision of the HN–(CH3)2 bond (site 1, Figure 2.1). The role of the dimethylamino 
moiety in directing ML’s multifunctionality was also evaluated by modifying site 2 through installation 
of a hydrogen atom (AQP1-4) or a dimethylamino group (AQDA1-4) (Figure 2.1). Further modifications 
to the metal binding site (site 3) from a hydrogen atom (in AQ1, AQP1, and AQDA1) or a methyl group 
(in AQ2, AQP2, and AQDA2) to an ester (in AQ3, AQP3, and AQDA3) or an alcohol moiety (in AQ4, 
AQP4, and ML) allowed us to examine the difference in denticity and electronics of the ligands (Figure 
2.1). Similar to ML, all AQ derivatives were also designed to adhere to Lipinski’s rules and calculated 
logBB values for potential drug-likeness and BBB permeability (Tables 2.1 and 2.2).23,25,26  
 
Table 2.1. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe) of AQDA1-3 and ML.a 
 
Calculation AQDA1 AQDA2 AQDA3 MLb Permeability rules 
MW 293 307 351 396 ≤ 450 
clogP 3.15 3.65 2.91 2.57 ≤ 5.0 
HBA 4 4 6 5 ≤ 10 
HBD 2 2 2 3 ≤ 5 
PSA 48.4 48.4 74.7 68.6 ≤ 90 Å2 
logBB −0.107 −0.323 –0.533 −0.496 < −1.0 (poor distribution) 
–logPe 4.30 ± 0.01 4.30 ± 0.01 4.30 ± 0.01 4.50 ± 0.01 
−logPe < 5.4 (CNS+) 
−logPe > 5.7 (CNS–) 
CNS+/− 
prediction CNS+ CNS+ CNS+ CNS+ CNS+; CNS– 
 
 
 32
Table 2.2. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe) of AQ1-AQ4 and AQP1-AQP4.a 
 
Calculation AQ1 AQ2 AQ3 AQ4 AQP1 AQP2 AQP3 AQP4 
Permeability 
rules 
MW 144 158 186 174 250 264 308 280 ≤ 450 
clogP 1.48 1.98 1.74 0.89 2.99 3.49 2.75 2.40 ≤ 5.0 
HBA 2 2 3 3 3 3 5 4 ≤ 10 
HBD 2 2 2 3 2 2 2 3 ≤ 5 
PSA 38.9 38.9 60.0 59.1 45.1 45.1 71.5 65.4 ≤ 90 Å2 
logBB –0.221 –0.136 –0.434 –0.610 –0.084 –0.008 –0.501 –0.473 
< –1 (poor 
distribution) 
–logPe 
4.20 ± 
0.01 
4.20 ± 
0.01 
4.30 ± 
0.01 
4.70 ± 
0.01 
4.40 ± 
0.01 
4.20 ± 
0.01 
5.05 ± 
0.08 
4.50 ± 
0.01 
–logPe < 5.4 
(CNS+) 
–logPe > 5.7 
(CNS–) 
CNS +/– 
Prediction 
CNS + CNS + CNS + CNS + CNS + CNS + CNS + CNS + CNS + 
 
aMW, molecular weight; clogP, calculated logarithm of the octanol-water partition coefficient; HBA, 
hydrogen bond acceptor atoms; HBD, hydrogen bond donor atoms; PSA, polar surface area; logBB = –
0.0148 x PSA + 0.152 x clogP + 0.139 (logBB < –1.0 poorly distributed in the brain); –logPe values, 
determined using the PAMPA-BBB assay, were calculated by the PAMPA 9 explorer software V. 3.5. 
Prediction of compound’s ability to penetrate the central nervous system (CNS) on the basis of literature 
values. Compounds categorized as CNS+ possess the potential ability to penetrate the BBB while those 
categorized as CNS– are expected to have poor BBB permeability. bReference 23. 
 
Synthetically, the structural derivatives were obtained via synthetic routes analogous to the one 
previously reported for ML.23,27-30 Starting from 2-methyl-8-nitroquinoline, the AQ derivatives, AQ3 and 
AQ4, were produced through a multi-step reaction (AQ1 and AQ2 were commercially available).31 First, 
the nitro precursor compound, methyl 8-nitroquinoline-2-carboxylate, was prepared by bromination of 2-
methyl-8-nitroquinoline followed by hydrolysis in 20% sulfuric acid to afford 8-nitroquinoline-2-
carboxylic acid. 8-nitroquinoline-2-carboxylic acid was then methylated with trimethylsilyldiazomethane 
(Me3SiCHN2), a safer alternative to diazomethane, to produce the precursor (i.e., methyl 8-nitroquinoline-
2-carboxylate) to AQ3 and AQ4. Hydrogenation of methyl 8-nitroquinoline-2-carboxylate in the presence 
of 10% palladium on carbon provided AQ3 at a modest yield (ca. 50%). Further reduction of AQ3 with 
sodium borohydride (NaBH4) generated AQ4. The derivatives containing an aminoquinoline and phenol 
(i.e., AQP1-4) or a 4-(dimethylamino)phenol (i.e., AQDA1-3) were constructed by a Schiff base 
condensation reaction of AQ1-4 with either salicylaldehyde (for AQP1-3) or 4-(dimethylamino)-2-
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hydroxybenzaldehyde (for AQDA1-3) followed by the reduction of the resultant imine with sodium 
triacetoxyborohydride as shown in Scheme 2.1. 
 
Scheme 2.1. Synthetic routes to AQ, AQP, and AQDA derivatives.  
 
 
2.2.2. Effect of AQ Derivatives on Metal-Free and Metal-Induced Aβ  Aggregation 
In order to determine the effect of structural modifications on the ability of AQ derivatives to 
modulate Aβ aggregation in both the absence and presence of metal ions [Cu(II) and Zn(II)], gel 
electrophoresis with Western blotting (gel/Western blot) utilizing an anti-Aβ antibody (6E10) and 
transmission electron microscopy (TEM) were performed to analyze the molecular weight (MW) 
distribution and morphological change of the resultant Aβ species, respectively. Two experiments were 
conducted to determine (i) the ability of the derivatives to prevent the formation of fibrillar aggregates 
(inhibition experiment, Figures 2.2a and 2.3a) and (ii) to dismantle preformed Aβ aggregates into smaller 
species (disaggregation experiment, Figures 2.6a and 2.7a). Generally, under the experimental conditions 
employed herein, compound-free Aβ samples with and without metal ions assemble into a distribution of 
large aggregates that are too big to penetrate into the gel matrix, which yields very little smearing in the 
gel/Western blots, but can be visualized via TEM.23,31,32 The administration of compounds, capable of 
interacting with Aβ, inhibiting the formation of high MW aggregates, and/or disassembling preformed 
aggregates, typically generates a distribution of smaller-sized Aβ species that can enter into the gel and 
produce a substantial amount of streaking compared to the samples containing only Aβ.23,31,32  
In the inhibition experiments, only the derivatives containing the 4-(dimethylamino)phenol moiety 
(i.e., AQDA1-3) were able to modulate the MW distribution of metal-free Aβ40 and Zn(II)–Aβ40 (Figure 
2.2b, 3rd column, lanes 1–3). In the case of Cu(II)–Aβ40, only one compound without the 4-
(dimethylamino)phenol, AQP1, in addition to AQDA1-3, produced detectable smearing in the high MW 
region of the gel/Western blot (> 100 kDa; Figure 2.2b, 2nd column, lane 1). The reactivity of AQP1 for 
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Cu(II)–Aβ40 may be a result of its relatively high binding affinity for Cu(II) compared to that of the other 
multifunctional derivatives (vide infra). The inhibitory reactivity of AQDA1-AQDA3 toward metal-free 
and metal-treated Aβ40 also appeared to be time dependent. Longer, darker bands (ca. 4-260 kDa) were 
detected on the gel/Western blot following later incubation periods (i.e., 24 h) of metal-free Aβ40 and 
metal–Aβ40 with AQP1 or AQDA1-AQDA3 (Figure 2.2b).  
 
 
Figure 2.2. Ability of compounds (AQ1-3, AQP1-4, and AQDA1-3) to control the formation of Aβ40 
aggregates in the absence and presence of metal ions [Cu(II) and Zn(II)]. (a) Scheme of the inhibition 
experiments. (b) Visualization of the resultant Aβ species from the inhibition experiments by gel/Western 
blot utilizing an anti-Aβ antibody (6E10). Experimental conditions: [Aβ40] = 25 μM; [CuCl2 or ZnCl2] = 
25 μM; [compound] = 50 μM; incubated for 4, 8, and 24 h; pH 7.4 (for metal-free and Zn(II) 
experiments) or 6.6 (for Cu(II) experiments); 37 °C; constant agitation. The control lane (without 
compound treatment) is identified by the letter “C”, and the lane number refers to the specific compound 
within each small molecule group (i.e., AQ, AQP, AQDA). 
 
AQ derivatives also had a similar aptitude for inhibiting the self-assembly of the more aggregation-
prone isoform, Aβ42.6,11,12 Only AQDA1-3 with the 4-(dimethylamino)phenol functionality perturbed the 
MW distribution of the resultant metal-free and metal-induced Aβ42 aggregates different from that of the 
control samples (Figure 2.3b, 3rd column, lanes 1-3). Unlike in the Aβ40 conditions, AQP1 was not 
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indicated to significantly ameliorate the aggregation of Cu(II)–Aβ42, which might be a result of the faster 
aggregation thus limiting the interaction with Cu(II) surrounded by Aβ42 (Figure 2.3b, 2nd column, lane 
1). TEM images of metal-free and metal-bound Aβ40 and Aβ42 samples treated with AQDA1-3 revealed a 
shift from the large Aβ aggregates and fibrils found in the compound-untreated samples of metal-free and 
metal-bound Aβ toward morphologies that are much smaller and more amorphous (Figure 2.4 for Aβ42; 
Figure 2.5 for Aβ40). Consistent with the gel/Western blot findings, the aminoquinoline derivative, AQ1, 
and aminoquinolinephenol derivative, AQP1, were not observed to significantly alter the size or 
morphology of metal-free Aβ or Zn(II)–Aβ (Figures 4 and S3). Some smaller and more unstructured 
aggregates, however, were identified in the Cu(II)–Aβ40 inhibition samples incubated with AQP1 (Figure 
2.5, middle column, inset). 
 
 
Figure 2.3. Capability of compounds (AQ1-3, AQP1-4, and AQDA1-3) to inhibit the formation of Aβ42 
aggregates in the absence and presence of metal ions [Cu(II) and Zn(II)]. (a) Scheme of the inhibition 
experiments. (b) Visualization of the resultant Aβ species from the inhibition experiments by gel/Western 
blot utilizing an anti-Aβ antibody (6E10). Experimental conditions: [Aβ42] = 25 μM; [CuCl2 or ZnCl2] = 
25 μM; [compound] = 50 μM; incubation for 4, 8, and 24 h; pH 7.4 (for metal-free and Zn(II) 
experiments) or 6.6 (for Cu(II) experiments); 37 °C; constant agitation. The control lane (without 
compound treatment) is identified by the letter “C”, and the lane number refers to the specific compound 
within each small molecule group (i.e., AQ, AQP, AQDA). 
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Figure 2.4. Morphologies of the resultant metal-free Aβ42 and metal–Aβ42 aggregates upon treatment 
with AQ1, AQP1, and AQDA1-3. (a) Scheme of the inhibition experiments. (b) TEM images for the 
Aβ42 samples (24 h incubation). Insets represent the minor species. 
 
 
Figure 2.5. Morphologies of the resultant metal-free and metal–associated Aβ aggregates. (a) Scheme of 
the inhibition experiments upon treatment with AQ1, AQP1, and AQDA1-3. (b) TEM images for the 
Aβ40 samples (24 h incubation). Insets represent the minor species.  
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We also evaluated the capacity of the multifunctional derivatives to interact with and degrade 
preformed Aβ40 and Aβ42 aggregates (i.e., disaggregation experiments; Figures 2.6a and 2.7a). The 
disaggregation experiments showed similar trends as those observed in the inhibition studies. Only 
compounds with the 4-(dimethylamino)phenol moiety (AQDA1-3) were able to disassemble preformed 
metal-free Aβ40/Aβ42 and metal–Aβ40/Aβ42 aggregates (Figures 2.6b, and 2.7b, 3rd column, lanes 1–3). 
Consistent with the observations from the Cu(II)–Aβ40 inhibition experiment, AQP1 also presented an 
ability to generate a distribution of smaller MW species only under Aβ40 conditions; however, the bands 
appeared at a higher MW region (i.e., 100–260 kDa), relative to the compounds containing the 4-
(dimethylamino)phenol moiety which produced a more disperse MW range of aggregates (i.e., ca. 4–260 
kDa). Overall, our in vitro gel/Western blot and TEM studies suggest the 4-(dimethylamino)phenol 
functionality as a critical moiety for the anti-amyloidogenic properties of ML. 
 
 
Figure 2.6. Ability of compounds (AQ1-3, AQP1-4, and AQDA1-3) to reverse preformed Aβ40 
aggregates in the absence and presence of metal ions [Cu(II) and Zn(II)]. (a) Scheme of the 
disaggregation experiments. (b) Visualization of the resultant Aβ species from the disaggregation 
experiments by gel/Western blot utilizing an anti-Aβ antibody (6E10). Experimental conditions: [Aβ40] = 
25 μM; [CuCl2 or ZnCl2] = 25 μM; [compound] = 50 μM; incubation for 4, 8, and 24 h; pH 7.4 (for 
metal-free and Zn(II) experiments) or 6.6 (for Cu(II) experiments); 37 °C; constant agitation. The control 
lane (without compound treatment) is identified by the letter “C”, and the lane number refers to the 
specific compound within each chemical group (i.e., AQ, AQP, AQDA). 
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Figure 2.7. Capability of compounds (AQ1-3, AQP1-4, and AQDA1-3) to reverse preformed Aβ42 
aggregates in the absence and presence of metal ions [Cu(II) and Zn(II)]. (a) Scheme of the 
disaggregation experiments. (b) Visualization of the resultant Aβ species from the disaggregation 
experiments by gel/Western blot utilizing an anti-Aβ antibody (6E10). Experimental conditions: [Aβ42] = 
25 μM; [CuCl2 or ZnCl2] = 25 μM; [compound] 50 μM; incubation for 4, 8, and 24 h; pH 7.4 (for metal-
free and Zn(II) experiments) or 6.6 (for Cu(II) experiments); 37 °C; constant agitation. The control lane 
(without compound treatment) is identified by the letter “C”, and the lane number refers to the specific 
compound within each chemical group (i.e., AQ, AQP, AQDA). 
 
2.2.3. Direct Interaction Between Soluble Metal-Free Aβ  and AQ Derivatives 
In order to elucidate the potential binding regions between Aβ40 and the AQ derivatives, 2D band-
Selective Optimized Flip-Angle Short Transient Heteronuclear Multiple Quantum Coherence (SOFAST-
HMQC) NMR was employed.23,31 Chemical shift perturbation (CSP) is indicative of an altered electronic 
environment around the assigned residue which is likely the result of interaction with the derivatives 
(Figures 2.8 and 2.9). Despite the various chemical alterations to the ML framework investigated herein, 
there are two primary structural regions of Aβ that show interaction with the AQ derivatives observed by 
NMR. Compounds altered either the N-terminal residues near the metal binding site of Aβ40 (i.e., 
predominantly E11 and V12) or the central hydrophobic residues within the self-recognition sequence 
(LVFFA).7,8,11,12 It was previously demonstrated that ML predominantly perturbs V12 and Q15, 
suggesting that the N-terminal contacts may be partially responsible for its efficacy and desirable for 
future chemical tools.23 
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Figure 2.8. Interactions of AQ1, AQP1, and AQDA1 with monomeric Aβ40, monitored by SOFAST-
HMQC NMR. (a-c) SOFAST-HMQC NMR spectra (zoomed in view from 7.9 to 8.4 ppm; top) and 
chemical shift perturbations (CSPs) (bottom) of Aβ40 upon treatment with (a) AQDA1, (b) AQP1, or (c) 
AQ1. Two horizontal lines represent the average chemical shift (dashed line) plus one standard deviation 
(dotted line). Residues which show no CSP are the result of unresolved peaks in the spectra. 
 
Of the AQ derivatives studied by NMR, both AQ1 and AQ2 have CSP profiles most similar to ML 
(Figures 2.8 and 2.9). These molecules are not shown to have any ML-like anti-amyloidogenic activity, 
which suggests that simply targeting the N-terminal metal binding site (in particular, metal binding 
residues H6, H13, and H14) is insufficient for such function. Predictably, the addition of the phenol group 
(shown in AQP1, AQP2, and AQP4) shifted the preferred interaction toward the more nonpolar and 
aromatic residues. Of these three compounds, only AQP4 demonstrated any interaction with N-terminal 
residues (E11; Figure 2.9d). Additionally, only AQP1 was observed to effectively modulate Cu(II)−Aβ40 
aggregation, which is likely associated with the relatively high affinity of AQP1 for Cu(II) (vide infra). 
Combined, these results further imply that anti-amyloidogenic activity is not as much a function of simply 
where on the monomer a compound binds but rather a function of a compound’s interaction site(s) and its 
ability to interact with other components of the system. 
The addition of the 4-(dimethylamino)phenol, instead of the phenol group, had a slightly unexpected 
result. While the added aromaticity promoted interactions of AQDA1-3 with the central self-recognition 
sequence (like AQP1 and AQP2), it also maintained contacts with more N-terminal residues (E11 and  
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Figure 2.9. Interactions of AQDA2, AQP2, AQ2, AQP4, and AQDA3 with monomeric Aβ40, monitored 
by SOFAST-HMQC NMR. (a-e) SOFAST-HMQC NMR spectra (top) and chemical shift perturbations 
(CSPs) (bottom) of Aβ40 upon treatment with (a) AQDA2, (b) AQP2, (c) AQ2, (d) AQP4, and (e) 
AQDA3. Two horizontal lines represent the average chemical shift (dashed line) plus one standard 
deviation (dotted line). Residues which show no CSP are the result of unresolved peaks in the spectra. 
 41
V12) by AQDA1 and AQDA2 which was similar to the interactions observed in both the nonreactive 
AQ1 and AQ2, along with the functional parent, ML (Figures 2.8 and 2.9). In addition, like ML, it is 
possible that having the slightly polar dimethylamino moiety on the framework appended to the added 
hydrophobicity of the phenol group remediates the shift toward hydrophobic residues seen for the AQP 
compounds. The dimethylamino functionality is indicated to be a moiety that is able to tune the 
interaction of hydrophobic compounds toward more polar peptide regions, functioning as a chemical 
rheostat. It is also coupled with consistent reactivity against Aβ. Thus, having modest hydrophilicity (in 
this case, instilled by the dimethylamino functionality) may promote the anti-amyloidogenic activity of 
the compounds, as observed in both ML and the AQDA derivatives. 
 
 
Figure 2.10. Docking studies of AQ derivatives with Aβ40 monomer. Top: The two lowest energy 
cartoon conformations of (a) AQ1, (b) AQ2, (c) AQP1, (d) AQP2, (e) AQP4, (f) AQDA1, (g) AQDA2, 
and (h) AQDA3 with Aβ40 (PDB 2LFM) by AutoDock Vina. Hydrogen bonding is indicated with dashed 
lines (2.0-2.7 Å). Bottom: Summary of calculated binding energies of the AQ series to each Aβ 
conformation. 
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The interactions between Aβ and the AQ derivatives examined by 2D NMR were further visualized 
and probed by docking studies that were performed employing AutoDock Vina46 and the previously 
reported NMR structure of monomeric Aβ40 (PDB 2LFM)43 (Figure 2.10). The docking results showed 
that for most conformations of Aβ, the ligands bound almost exclusively in the pocket formed by the 
folding of the N-terminal random coil and α-helix and their adducts with the peptide were stabilized by 
nonspecific and/or direct intermolecular interactions (e.g., hydrogen bonding, π–π stacking). These 
interactions had calculated binding energies ranging from –7.0 to –4.6 kcal/mol (Figure 2.10). Similar to 
the findings from our 2D NMR experiments, the AQP derivatives (AQP1, AQP2, and AQP4) containing 
the more hydrophobic phenol functionality were observed to penetrate more deeply into the N-terminal 
pocket and appeared to interact more tightly with the central self-recognition sequence. Conversely, AQ1 
and AQ2 appeared to dock more toward the N-terminal residues while the derivatives equipped with the 
4-(dimethylamino)phenol functionality (AQDA1-3) showed a tendency to maintain both close interaction 
with the N-terminal residues, mostly by hydrogen bonding, while simultaneously establishing close 
contacts with the α-helical central hydrophobic region. Overall, these docking findings support the 2D 
NMR investigations that identified the aptitude of the dimethylamino functionality to tune the interaction 
of hydrophobic compounds toward the N-terminal hydrophilic residues.  
 
2.2.4. Analysis of AQ Derivatives Incubated with Aβ40 by Ion Mobility–Mass Spectrometry 
To further explore the interactions between Aβ40 and the AQ derivatives studied herein, we applied 
nano-electrospray–ionization mass spectrometry (nESI–MS) combined with ion mobility–mass 
spectrometry (IM–MS), optimized for the detection of non-covalent protein complexes.33,34 The MS data 
presented in Figure 2.11 highlight that among the multifunctional derivatives, only AQP1 and AQP4 
were capable of binding Cu(II)-treated Aβ40. While no other small molecules were observed to form 
complexes with Cu(II)-associated Aβ40, a notable and replicable reduction in the total Cu(II)-bound Aβ 
species was identified upon incubation with many of the ligands studied (AQP1, AQDA1, AQDA2, and 
ML), when compared to the baseline levels prior to small molecule incubation supporting their metal 
chelation activity (Figure 2.12). In the absence of a source of Cu(II), no ligand binding was observed 
(data not shown).  
To gain further insight into the structures of the complexes between Cu(II)-treated Aβ40 and the AQ 
derivatives, we measured and compared the IM arrival time distributions for these complexes (Figure 2.11 
i; see Table 2.3 for the supporting collisional cross-section (CCS) data). Our results indicate that AQP1 
and AQP4 binding to Cu(II)-treated Aβ leads to a distinct conformation shift when compared to the  
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Figure 2.11. Mass spectrometric and ion mobility–mass spectrometric analyses of AQ1, AQ4, AQP1, 
AQP4, AQDA1-3, and ML upon addition of CuCl2. MS spectra of (a) AQ1, (b) AQ4, (c) AQDA1, (d) 
AQDA2, (e) AQDA3, (f) ML, (g) AQP1, and (h) AQP4. (i) IM-MS drift time analysis. Collision cross 
section data for all ion mobility data sets are presented in Table 2.3. L = ligand (i.e., AQ1, AQ4, 
AQDA1-3, ML, AQP1, AQP4). *Indicates a contaminant refractory to our purification methods. 
 
Table 2.3. Calculated collision cross section data from observed 4+ ligated Aβ40 species. 
 
 
 
*Indicates the dominant structural species observed. 
 
compound-untreated metal-free and metal-bound Aβ states. In particular, close analysis of the IM drift 
time presents a slight perturbation of the Cu(II)–Aβ40 conformations toward more expanded conformers  
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Figure 2.12. Analysis of the amount of copper-bound Aβ40 as a function of ligand concentration. 
Compared to baseline levels of metal-bound Aβ40, AQDA1, AQDA2, ML, and AQP1 are all shown to be 
capable of reducing the concentration of Cu(II)-associated peptide species.  
 
compared to compound-free Cu(II)-associated Aβ40. These data contrast the results for previously studied 
small molecules which induced conformational compaction upon co-incubation with Aβ.31,32,35 Such a 
difference in the conformations generated upon AQP1 treatment (i.e., the more expanded structures 
compared to the compaction observed previously)31,32,35 may suggest that AQP1’s ability to alter the Aβ40 
aggregation pathway in the presence of Cu(II) may be directed mainly by its metal chelation properties 
rather than its induction of structural alteration of Aβ. A metal chelation dependence would also further 
validate why AQP4 [the compound which binds Cu(II) much weaker than AQP1 (vide infra)] does not 
modulate the aggregation of copper-bound Aβ40 in vitro.  
On the basis of the absence of any observable Aβ–ligand complexes for the AQ derivatives equipped 
with the 4-(dimethylamino)phenol functionality (i.e., AQDA1, AQDA2, AQDA3), two mechanisms are 
proposed to rationalize the activities of these molecules as Aβ modulators. First, these remaining small 
molecules may target larger, higher-order oligomers that are too transient for IM–MS detection under the 
conditions used herein. While the analyses of the interactions between small molecules, such as these, and 
Aβ dimers are technically possible, the presence of Cu-based salt cluster chemical noise has prevented 
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this analysis.35 Second, AQDA1, AQDA2, and ML are shown to sequester Cu(II) from Aβ, and thus our 
data suggests the contribution of the ligands’ metal chelation properties toward its control of metal-
induced Aβ aggregation. 
 
2.2.5. Metal Binding Properties of AQ Derivatives 
UV-visible (UV-vis) and 1H NMR spectroscopy were first employed in order to probe the effects of 
structural modifications on the metal binding properties of the multifunctional derivatives. Upon co-
incubation of the ligands with increasing amounts of CuCl2 or ZnCl2 (Figures 2.13 and 2.14) new optical 
bands and/or changes in the absorbance intensity were observed. Decreases in the absorbance of the peaks 
at ca. 250/340 (for AQ1) and 250/400 nm (for AQ3) followed by the growth of new bands at ca. 300 
and/or 450 nm (for AQ1-3) were discernable as CuCl2 was titrated into solution (Figure 2.13a-c). AQ 
derivatives augmented with phenols (i.e., AQP1-4) produced new peaks at ca. 320 and 430 nm in the 
presence of CuCl2 (Figure 2.13d-g), while the compounds with the 4-(dimethylamino)phenol moiety (i.e., 
AQDA1-3) generated new optical bands at ca. 380 and 470 nm (Figure 2.13h-j).  
 
 
Figure 2.13. Cu(II) binding studies of AQ1-3, AQP1-4, and AQDA1-3. (a-j) UV-vis spectra of ligands 
[(a) AQ1, (b) AQ2, (c) AQ3, (d) AQP1, (e) AQP2, (f) AQP3, (g) AQP4, (h) AQDA1, (i) AQDA2, and 
(j) AQDA3; black lines] with the addition of increasing amounts of CuCl2 (colored lines; 30 min 
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incubation; room temperature). Experimental conditions: for AQ1 and AQ3, [M(II)]:[L] = 1:2, 20 mM 
HEPES, pH 7.4, 150 mM NaCl; for AQ2, [M(II)]:[L] = 1:2, CH3CN;  for AQP1-2, [M(II)]:[L] = 1:1, 20 
mM HEPES, pH 7.4, 150 mM NaCl; for AQP3, [M(II)]:[L] = 1:2, CH3CN; for AQP4, [M(II)]:[L] = 1:2, 
20 mM HEPES, pH 7.4, 150 mM NaCl; for AQDA1-3, [M(II)]:[L] = 1:1, 20 mM HEPES, pH 7.4, 150 
mM NaCl.  
 
 
Figure 2.14. Zn(II) binding experiments. (a-j) UV-vis spectra of [(a) AQ1, (b) AQ2, (c) AQ3, (d) AQP1, 
(e) AQP2, (f) AQP3, (g) AQP4, (h) AQDA1, (i) AQDA2, and (j) AQDA3; black lines] with the addition 
of increasing amounts of ZnCl2 (colored lines; 30 min incubation; room temperature). Experimental 
conditions: for AQ1, [M(II)]:[L] = 1:2, 20 mM HEPES, pH 7.4, 150 mM NaCl; for AQ2, [M(II)]:[L] = 
1:2, CH3CN; for AQ3, [M(II)]:[L] = 1:2, EtOH; for AQP1-2, [M(II)]:[L] = 1:1, 20 mM HEPES, pH 7.4, 
150 mM NaCl; for AQP3, [M(II)]:[L] = 1:2, EtOH; for AQP4, [M(II)]:[L] = 1:2, 20 mM HEPES, pH 7.4, 
150 mM NaCl; for AQDA1-3, [M(II)]:[L] = 1:1, 20 mM HEPES, pH 7.4, 150 mM NaCl. 
 
Administration of ZnCl2 into solutions of AQ derivatives resulted in less noticeable spectral changes 
when compared to the CuCl2 results (Figure 2.14). Optical shifts from ca. 350 to 300 nm were detected 
upon increased addition of ZnCl2 to solutions of AQ1 and AQ2 (Figure 2.14a,b). Incubation of AQP1, 
AQP2, and AQP4 with ZnCl2 caused various spectral changes at ca. 250, 300, and 350 nm (Figure 
2.14d,e,g). Similar to the CuCl2 experiments, the ZnCl2 binding peaks for the derivatives containing the 4-
(dimethylamino)phenol functionality were relatively red-shifted compared to the AQP derivatives (i.e., 
new peaks growing in at ca. 350 and 450 nm; Figure 2.14h-j). No significant changes in the UV-vis 
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spectra could be identified for AQ3 and AQP3 under the experimental conditions employed; therefore, 
1H NMR spectroscopy was utilized to further probe their Zn(II) binding. Introduction of 3.5 equiv of 
ZnCl2 to a CD3CN solution of AQ3 induced a slight downfield chemical shift of the quinoline protons, 
demonstrating the potential involvement of the nitrogen donor atoms from the primary amine and 
quinoline ring in Zn(II) coordination (Figure 2.15). No significant chemical shifts were observed when 
ZnCl2 was added to a solution of AQP3; however, this is most likely a result of its limited solubility 
under the experimental conditions. Overall, our UV-vis and NMR studies indicate the ability of the 
structural derivatives of ML to bind both Cu(II) and Zn(II).  
 
 
Figure 2.15. Zn(II) binding studies, measured by 1H NMR. 1H NMR spectra of AQ3 (red) with 3.5 equiv 
of ZnCl2 (black) were obtained at room temperature. Experimental conditions: CD3CN; [AQ3] = 5 mM; 
[ZnCl2] = 17.5 mM; 10 min incubation. Note that Zn(II) binding to AQP3 could not be determined due to 
limited solubility under experimental conditions. 
 
In order to comprehend the solution speciation of the AQ derivatives in the absence and presence of 
Cu(II) and attempt to determine the effects of structural variations on the Cu(II) binding affinity of our 
ligands, UV-vis variable-pH titration experiments were conducted. First, spectrophotometric titrations of 
the ligands (i.e., AQP1, AQP4, AQDA1-3) were used to estimate the acidity constants (pKa) [see Figure 
2.16; for AQP1, pKa2 = 3.67(4), pKa3 = 9.92(6); for AQP4, pKa2 = 3.78(8), pKa3 = 10.11(8); for AQDA1, 
pKa1 = 3.72(9), pKa2 = 6.61(5), pKa3 = 8.99(6); for AQDA2, pKa1 = 3.21(9), pKa2 = 4.82(6), pKa3 = 
7.69(4); for AQDA3, pKa1 = 2.30(8), pKa2 = 3.82(3), pKa3 = 6.73(5)]. The solution speciation diagrams 
depict the presence of three species for the phenol derivatives, AQP1 and AQP4 (anionic, neutral, and 
monoprotonated species; LH-1, L, and LH), and predict the neutral ligand (L) predominately being present 
at the physiological pH (i.e., 7.4; Figure 2.16a,b). Due to the protonation of the dimethylamino group, 
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AQDA derivatives contain an additional diprotonated species (LH2) in the pH range examined and exist 
in a mixture of neutral and cationic (for AQDA1) or anionic and neutral (for AQDA2 and AQDA3) 
species (Figure 2.16c-e). Overall, the relative abundance of the neutral form of the ligands at pH 7.4 (ca. 
100% for AQP1 and AQP4; ca. 50% for AQDA1-3) may explain their potential BBB penetration, as 
suggested by Lipinski’s rules, the PAMPA-BBB assay, and calculated logBB values (Tables 2.1 and 2.2). 
 
 
Figure 2.16. Solution speciation studies of AQP1, AQP4, and AQDA1-3. UV-vis variable-pH titration 
spectra (left) and solution speciation diagrams (right) of (a) AQP1 (pH 2–11), (b) AQP4 (pH 2–11), (c) 
AQDA1 (pH 2–10), (d) AQDA2 (pH 2–10), and (e) AQDA3 (pH 2–10) (FL = fraction of species at given 
pH). Acidity constants (pKa) of L (L = AQP1, AQP4, and AQDA1-3) are summarized in the table. 
Experimental conditions: [L] = 50 μM (L = AQP4 or AQDA1) or 25 μM (L = AQP1, AQDA2, and 
AQDA3); I = 0.10 M NaCl; room temperature. Charges are omitted for clarity. a The error in the last digit 
is shown in the parentheses. 
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Figure 2.17. Solution speciation studies of AQP1, AQP4, and AQDA1-3 in the presence of Cu(II). UV-
vis variable-pH titration spectra (left) and solution speciation diagrams (right) of (a) AQP1, (b) AQP4, 
(c) AQDA1, (d) AQDA2, and (e) AQDA3 upon incubation with Cu(II) (FCu = fraction of species at given 
pH). Stability constants (logβ) of Cu(II)−L complexes (L = AQP1, AQP4, and AQDA1-3) are 
summarized in the table. Charges are omitted for clarity. a The error in the last digit is shown in 
parentheses. Experimental conditions: [AQP1] = 25 μM, [CuCl2] = 12.5 μM, pH 2–11 (titrated from 
basic to acidic); [AQP4] = 100 μM, [CuCl2] = 50 μM, pH 2–9 (titrated from basic to acidic); [AQDA1] = 
25 μM, [CuCl2] = 12.5 μM, pH 2–8 (titrated from basic to acidic); [AQDA2] = 25 μM, [CuCl2] = 12.5 
μM, pH 2–8 (titrated from acidic to basic); [AQDA3] = 25 μM, [CuCl2] = 12.5 μM, pH 2–8 (titrated from 
acidic to basic); incubated for 1 h; I = 0.10 M NaCl; room temperature.  
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Once pKa values were obtained for the ligands of interest, solution speciation experiments in the 
presence of CuCl2 were carried out to determine if structural modifications to ML’s framework at sites 2 
and 3 could alter its high apparent dissociation constant for Cu(II) (picomolar Kd at pH 7.4), while still 
maintaining competitive metal binding with Aβ (e.g., nanomolar range).7,9,11,12,23 Based on the stability 
constants (logβ) and values of pCu (pCu ≈ –log[Cuunchelated]) (Figure 2.17), the approximate dissociation 
constants (Kd = [Cuunchelated]) for the multifunctional derivatives were determined. As summarized in the 
table in Figure 2.17, the more inert Cu(II)–ligand complexes were shown in the order of AQDA1, AQP1, 
AQP4, AQDA3, and AQDA2. Interestingly, the tridentate ligands, AQDA1 and AQP1, with hydrogen 
atoms in the R2 position, presented the strongest affinity for Cu(II) compared to the other tetradentate 
ligands measured herein (i.e., AQP4, AQDA3), thus possibly explaining the ability of AQP1 to modulate 
the aggregation of Cu(II)–Aβ40 (Figures 2.2 and 2.6). This trend may be explained by the ability of 
AQDA1 and AQP1 to form 1:2 complexes [Cu(II):ligand] in addition to the 1:1 stoichiometry observed 
for the other derivatives (Figure 2.17a,c).27 Comparison of the apparent Kd values of AQDA1 with AQP1 
and ML with AQP4 indicates that the dimethylamino functionality slightly increases the metal binding 
affinity, as would be expected with the installation of a electron donating group located para to the 
oxygen donor atom of the phenol. AQDA2 and AQDA3 were determined to have larger Kd values [lower 
binding affinity for Cu(II)] than ML. The slightly smaller Kd of AQDA3 for Cu(II), compared to 
AQDA2, is most likely due to the weak contribution from the ester functionality. Overall, tuning metal 
binding strengths of the multifunctional derivatives is able to be accomplished through structural 
modifications at the R1 and R2 positions.  
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Figure 2.18. Metal selectivity of AQP4 and AQDA1-3 for Cu(II) over other biologically relevant 
divalent metal ions. Gray bars represent the subsequent addition of CuCl2 (50 μM) to solutions containing 
ligand (50 μM) with (a) 1 equiv or (b) 20 equiv of the other divalent metal ions (MgCl2, CaCl2, MnCl2, 
FeCl2, CoCl2, NiCl2, and ZnCl2). The absorbance wavelengths of AQP4, AQDA1, AQDA2, and AQDA3 
used to calculate AM/ACu are listed as follows: 290 nm, 449 nm, 449 nm, and 338 nm, respectively. *Due 
to similar optical bands of the ligand upon binding to Cu(II) and the other metal ions, accurate metal ion 
selectivity cannot be obtained. 
 
Competition reactions, monitored by UV-vis, were also conducted to examine the selectivity of 
AQP4 and AQDA1-3 for Cu(II) over other biologically relevant divalent metal ions [i.e., Mg(II), Ca(II), 
Mn(II), Fe(II), Co(II), Ni(II), Zn(II)]. As shown in Figure 2.18, in the presence of equimolar (Figure 
2.18a) or excess metal ions (20 equiv; Figure 2.18b), the ligands still exhibited spectral changes 
consistent with the formation of Cu(II) complexes. Fe(II) did appear to competitively interact with AQP4, 
AQDA1, and AQDA2, especially at excess concentrations. It is also worth noting that the exact 
quantification of the selectivity for Cu(II) over Ni(II) and Zn(II) for AQP4 and Co(II) for AQDA1 could 
not be determined due to the optical overlap of their respective metal binding bands, but the overall 
spectral changes were suggestive of preferential binding to Cu(II) (Figure 2.18). Collectively, these 
results present that AQ derivatives can competitively bind to Cu(II) over other biologically available 
divalent metal ions and that their metal affinities can be modulated through structural modifications. 
 
2.2.6. Biological Properties: ROS Formation Control, Free Radical Scavenging Capacity, and 
Cytotoxicity 
The extent to which structural modifications affect the biological properties of our multifunctional 
derivatives was also investigated. The ability to control the redox cycling between Cu(I) and Cu(II) in 
order to reduce ROS production through Fenton-like chemistry was first analyzed by the 2-deoxyribose 
assay, which measures the capacity of ligands to control the formation of copper-catalyzed hydroxyl 
radicals.23,36 As depicted in Figure 2.19a, copper-mediated generation of hydroxyl radicals was most 
significantly reduced upon treatment with AQDA1. Relative to AQDA1, the other derivatives evaluated 
showed very little aptitude to attenuate hydroxyl radical formation, possibly due to their binding 
properties, including weaker binding affinity for Cu(II) compared that of AQDA1 or ML. Still, ML 
appeared to be about twice as efficient at controlling the formation of hydroxyl radicals relative to 
AQDA1 (A/A0 of ca. 0.40 for AQDA1; A/A0 of ca. 0.20 for ML).23 The enhanced ROS formation 
control of ML is most likely due to its tetradentate metal binding center, which can easily accommodate 
the preferred square planar geometry of Cu(II) but prohibit the generation of linear or tetrahedral 
geometries favored by Cu(I). In fact, based on crystallographic data reported for AQP1, AQDA1 may be 
able to facilitate a tetrahedral copper-binding mode depending on the metal-to-ligand stoichiometry and 
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the pH of the solution.27  
In order to evaluate the antioxidant capacity of the AQ derivatives, the Trolox equivalent antioxidant 
capacity (TEAC) assay which measures the ability of the multifunctional derivatives to quench preformed 
ABTS cation radicals (ABTS+; ABTS = 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)15,37 was 
performed using lysates of human neuroblastoma SK-N-BE(2)-M17 cells. Cell lysates was utilized in 
order to get a more accurate measure of the antioxidant capacity of the AQ derivatives in a more 
biologically relevant heterogeneous environment. As shown in Figure 2.19b, the compounds containing 
the phenol or 4-(dimethylamino)phenol functionalities were able to scavenge free radicals about two 
times more effectively than that of the water-soluble vitamin E analog, Trolox. These findings are in-line 
with the known antioxidant properties of phenols.38-40 The most efficient antioxidants, AQDA1 and 
AQDA2, were still less active than ML which was determined to be ca. 2.5 times as effective as Trolox,23 
indicating that the primary alcohol in the R2 position may contribute to the antioxidant activity of ML. In 
addition, an ester at the R2 site appeared to reduce both abilities of the compounds to control ROS 
generation and scavenge free radicals relative to those of the other multifunctional derivatives (Figure 
2.19a,b).  
 
 
Figure 2.19. Biological activities of small molecules. (a) Inhibitory activity of AQ1, AQ3, AQ4, 
AQDA1, and AQDA3 toward Cu-mediated ROS formation as determined by the 2-deoxyribose assay. 
The absorbance values are normalized to the ligand-free condition ([CuCl2] = 10 μM; [ligand] = 125 μM). 
(b) Antioxidant activity of AQ1-3, AQP1, AQP2, AQP4, and AQDA1-3, identified by the TEAC assay 
using cell lysates. The TEAC values are relative to that of the vitamin E analogue, Trolox (6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid).  
 
Finally, the MTT assay [MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] 
was employed to evaluate the toxicity of the AQ derivatives in the mouse Neuro-2a (N2a) neuroblastoma 
cell line with and without CuCl2 and ZnCl2 (Figures 2.20). Cell viability of ca. 80% was measured for 
N2a cells treated with 5 μM of the AQ derivatives in the absence and presence of metal ions (CuCl2 or 
ZnCl2) (Figure 2.20a,b). A little more fluctuation in cell viability was observed upon increasing the 
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concentration of compound to 10 μM with and without of metal ions, but still most derivatives appeared 
to retain values around ca. 75-85% (Figure 2.20c,d). In particular, with the exception of ML, the 
multifunctional derivatives containing the 4-(dimethylamino)phenol functionality are indicated to be 
relatively more cytotoxic. Overall, our cell studies suggest that the structural variations of a framework 
may also trigger its differing levels of toxicity in living cells. 
 
 
Figure 2.20. Cell viability of AQ1-4, AQP1-4, AQDA1-3, and ML in N2a cells in the absence and 
presence of Cu(II) and Zn(II). (a) Cu(II):ligand (1:1) (5 μM), (b) Zn(II):ligand (1:1) (5 μM), (c) 
Cu(II):ligand (1:1) (10 μM), and (d) Zn(II):ligand (1:1) (10 μM). Cell viability (%) was determined by the 
MTT assay compared to cells treated with DMSO only (1% v/v) [MTT = 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide]. Black, blue, and green bars indicate cell viability upon incubation 
with ligand only and ligand with CuCl2 or ZnCl2, respectively.  
 
2.3. Conclusions 
A series of derivatives, AQ1-4, AQP1-4, and AQDA1-3, were developed based on the 
structural framework of the multifunctional ligand, ML, in order to tune its affinity for Cu(II) 
and to establish a structure-reactivity understanding of ML’s activities to modulate metal-free 
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and metal-bound Aβ aggregation, control metal-mediated ROS formation, and scavenge free 
radicals. Only compounds augmented with the dimethylamino functionality displayed noticeable 
modulation of both metal-free and metal-treated Aβ aggregation in vitro, with the exception of 
AQP1 which exhibited its ability to regulate the aggregation of Cu(II)–Aβ40, which was most 
likely aided by its metal chelating properties (i.e., pCu = 11.44 at pH 7.4). Based on NMR 
investigations, this dimethylamino moiety appears to act to control the distribution of the 
compounds’ interaction with the N-terminal metal-binding region and/or the central self-
recognition sequence of Aβ40. ML was previously found to preferentially target the polar N-
terminal residues, which suggests that the dimethylamino group is at least partly responsible for 
Aβ interaction.23 Favoring these interactions may be important for directing the formation of 
stable ternary complexes of Aβ–metal–ligand. Under our MS and IM–MS conditions, only 
noncovalent interactions between Aβ and AQP1 or AQP4 when Cu(II) was present with slight 
structural elongation were observed, rather than compaction of the peptide which has been 
previously reported for other inhibitors.31,32,35 Preferential transient interactions with higher-order 
oligomers that cannot easily be detected by IM–MS may explain the absence of complexation 
peaks in the AQDA1-3-treated samples that most noticeably perturbed metal-free and metal-
treated Aβ aggregation in vitro. Structural modifications to ML also had drastic effects on its 
metal binding properties, ROS formation control, and free radical scavenging capacity. 
Substitution of the primary alcohol on ML with a hydrogen atom allowed for the formation of 
1:1 and 1:2 (metal:ligand) complexes, providing a higher binding affinity for Cu(II) with respect 
to the other AQ derivatives. Structural variations also had impacts on compounds’ abilities to 
control ROS formation and scavenge free radicals. AQDA1, with a hydrogen atom at the R2 site, 
was indicated to be the most efficient at controlling the generation of hydroxyl radicals, while the 
compounds containing the phenol or 4-(dimethylamino)phenol groups (AQP1-4 or AQDA1-3 
and ML) were much more potent antioxidants with respect to their AQ counterparts (AQ1-4). 
Conversely, the endowment with an ester, shown in AQ3, AQP3, or AQDA3, appeared to 
negatively alter the capacity to inhibit ROS generation and scavenge free radicals. Overall, by 
employing a series of AQ derivatives, a relationship between structures of the small molecules 
and reactivities toward targets found in AD (e.g., metal-free Aβ/metal–Aβ, metals, ROS) was 
established. These structure-reactivity insights, gleaned through our studies, may aid in further 
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design of more sophisticated multifunctional ligands, especially once the degree of transferability 
of these studies have been determined. 
 
2.4. Experimental Section 
 
2.4.1. Materials and Methods 
All reagents were purchased from commercial suppliers and used as received unless otherwise noted. 
Aβ40 and Aβ42 were purchased from Anaspec (Aβ42 = DAEFRHDSGYEVHHQKLVFFAEDVGSNKGA-
IIGLMVGGVVIA; Fremont, CA, USA). NMR and mass spectrometric analysis of small molecules were 
conducted on a 400 MHz Varian NMR spectrometer and a Micromass LCT Electrospray Time-of-Flight 
(TOF) mass spectrometer, respectively. Trace metal contamination was removed from buffers and 
solutions used for metal binding and Aβ experiments (vide infra) by treating with Chelex overnight 
(Sigma-Aldrich, St. Louis, MO, USA). Optical spectra were recorded on an Agilent 8453 UV-visible 
(UV-vis) spectrophotometer. TEM images were taken using a JEOL JEM-2100 transmission electron 
microscope (UNIST Central Research Facilities, Ulsan National Institute of Science and Technology, 
Ulsan, Republic of Korea). Absorbance values for biological assays, including cell viability assay, 
PAMPA-BBB, 2-deoxyribose assay, and TEAC assay, were measured on a Molecular Devices 
SpectraMax 190 microplate reader (Sunnyvale, CA, USA). Ion Mobility–Mass Spectrometry experiments 
investigating the interaction of AQ derivatives with Aβ in the absence and presence of Cu(II) were 
acquired using a Quadrupole-Ion Mobility-TOF (Q-IM-TOF) mass spectrometer (Waters Synapt G2, 
Milford, MA, USA) equipped with a nano-electrospray ionization (nESI) source. NMR studies of small 
molecules with Aβ were performed on a 600 MHz Bruker NMR spectrometer (University of Michigan, 
Ann Arbor, MI, USA). 
 
2.4.2. Syntheses 
The compounds, quinolin-8-amine (AQ1) and 2-methylquinolin-8-amine (AQ2), were purchased 
from TCI chemicals. 5-(Dimethylamino)-2-hydroxybenzaldehyde (DHB),28 methyl 8-aminoquinoline-2-
carboxylate (AQ3),29,31 (8-aminoquinolin-2-yl)methanol (AQ4),29,31 2-((quinolin-8-
ylamino)methyl)phenol (AQP1),29,30 and 4-(dimethylamino)-2-(((2-(hydroxymethyl)quinolin-8-
yl)amino)methyl)phenol (ML)23 were prepared by adapting previously reported methods. 
 
2.4.3. Preparation of 2-(((2-Methylquinolin-8-yl)amino)methyl)phenol (AQP2) 
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To a solution of dry ethyl acetate (16 mL) was added 2-methylquinolin-8-amine (AQ2) (300 mg, 1.89 
mmol). Salicylaldehyde (198 μL, 1.89 mmol) was slowly added to the reaction mixture. The reaction 
mixture was then protected from the light and allowed to stir overnight for 24 h. After 24 h, the reaction 
mixture was concentrated and dried. To a solution of dichloroethane (16 mL) was added sodium 
triacetoxyborohydride (804 mg, 3.78 mmol). The sodium triacetoxyborohydride solution was then slowly 
added to the dried reaction mixture and allowed to stir for 48 h (protected from the light). After 48 h, the 
reaction mixture was concentrated and purified by column chromatography (Al2O3, 1:10 ethyl acetate 
(EtOAc)/hexanes (Hx), Rf  = 0.23) to yield the final product (light yellow powder, 241 mg, 0.912 mmol, 
48%). 1H NMR (400 MHz, (CD3)2SO) / δ (ppm): 2.62 (3H, s), 4.41 (2H, d, J = 4.0 Hz), 6.57 (1H, d, J = 
8.0 Hz), 6.68 (2H, m), 6.81 (1H, d, J = 8.0 Hz), 6.96 (1H, d, J = 8.0 Hz), 7.03 (1H, t, J = 8.0 Hz), 7.18 
(2H, m), 7.34 (1H, d, J = 8.0 Hz), 8.05 (1H, d, J = 8.0), 9.07 (1H, s). 13C NMR (100 MHz, (CD3)2SO) / δ 
(ppm): 25.3, 42.1, 105.2, 113.6, 115.4, 119.2, 122.7, 125.7, 126.7, 127.1, 128.2, 136.6, 137.3, 144.2, 
155.6, 155.7. HRMS Calcd for C17H17N2O [M+H]+, 265.1341; found 256.1331. 
 
2.4.4. Preparation of Methyl 8-((2-hydroxybenzyl)amino)quinoline-2-carboxylate (AQP3) 
A solution of methyl 8-aminoquinoline-2-carboxylate (AQ3) (100 mg, 0.494 mmol) was utilized to 
prepare AQP3 following an identical procedure as the one described for AQP2. AQP3 was purified by 
column chromatography (SiO2, 1:5 EtOAc/dichloromethane (DCM), Rf = 0.72) to yield the final product 
(yellow-orange powder, 79.3 mg, 0.257 mmol, 52%). 1H NMR (400 MHz, (CD3)2SO) / δ (ppm): 3.91 
(3H, s), 4.46  (2H, s), 6.67 – 6.70 (2H, m), 6.82 (1H, d, J = 8.0 Hz), 7.02 (1H, t, J = 8.0 Hz), 7.07 (1H, d, 
J = 8.0 Hz), 7.19 (1H, d, J = 8.0 Hz), 7.41 (1H, t, J = 8.0 Hz), 8.04 (1H, d, J = 12.0 Hz), 8.34 (1H, d, J = 
12.0 Hz), 9.66 (1H, s). 13C NMR (100 MHz, (CD3)2SO) / δ (ppm): 40.3, 53.0, 105.8, 113.2, 115.5, 119.3, 
121.6, 125.2, 128.4, 129.0, 130.8, 137.1, 137.7, 144.3, 145.5, 155.7, 165.6. HRMS Calcd for C18H17N2O3 
[M+H]+, 309.1239; found 309.1231 
 
2.4.5. Preparation of 2-(((2-(Hydroxymethyl)quinolin-8-yl)amino)methyl)phenol (AQP4) 
A solution of (8-aminoquinolin-2-yl)methanol (AQ4) (100 mg, 0.574 mmol) was utilized to prepare 
AQP4 following an identical procedure as the one described for AQP2. AQP4 was purified by column 
chromatography (SiO2, 1:1 EtOAc/Hx, Rf = 0.50) to yield the final product (light brown powder, 64.8 mg, 
0.231 mmol, 40%). 1H NMR (400 MHz, (CD3)2SO) / δ (ppm): 4.41 (2H, d, J = 8.0 Hz), 4.70 (2H, d, J = 
8.0 Hz), 5.45 (1H, t, J = 8.0 Hz), 6.55 (1H, d, J = 8.0 Hz), 6.67 (1H, t, J = 8.0 Hz), 6.81 (1H, d, J = 8.0 
Hz), 6.92 (1H, t, J = 8.0 Hz), 6.95 – 7.04 (2H, m), 7.16 (1H, d, J = 8.0 Hz), 7.22 (1H, t, J = 8.0 Hz), 7.53 
(1H, d, J = 8.0 Hz), 8.15 (1H, d, J = 12.0 Hz), 9.56 (1H, s). 13C NMR (100 MHz, (CD3)2SO) / δ (ppm): 
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41.9, 65.2, 105.2, 113.5, 115.4, 119.2, 119.6, 125.7, 127.5, 127.7, 128.1, 136.7, 136.9, 144.6, 155.6, 
158.9. HRMS Calcd for C17H17N2O2 [M+H]+, 281.1290; found 281.1280. 
 
2.4.6. Preparation of 4-(Dimethylamino)-2-((quinolin-8-ylamino)methyl)phenol (AQDA1) 
To a solution of dry EtOAc (5.0 mL) was added quinolin-8-amine (AQ1) (100 mg, 0.694 mmol). 5-
(Dimethylamino)-2-hydroxybenzaldehyde (DHB) (115 mg, 0.694 mmol) was slowly added to the 
reaction mixture. The reaction mixture was then protected from the light and allowed to stir overnight for 
24 h. After 24 h, the reaction mixture was concentrated and dried. To a solution of DCE (5.0 mL) was 
added sodium triacetoxyborohydride (212 mg, 1.39 mmol). The sodium triacetoxyborohydride solution 
was then slowly added to the dried reaction mixture and allowed to stir for 24 h (protected from the light). 
After 24 h, the reaction mixture was concentrated and dissolved in dry methanol. Sodium borohydride 
(150 mg, 3.97 mmol) was added to the reaction mixture at 0 °C and allowed to stir for 2 h. After 2 h, the 
reaction mixture was quenched with sodium bicarbonate and H2O, extracted with DCM (3x), and purified 
by column chromatography (SiO2, 1:1 EtOAc/Hx, Rf = 0.43). The solid was recrystallized in DCM/Hx to 
afford the final product (light brown powder, 140 mg, 0.479 mmol, 69%). 1H NMR (400 MHz, 
(CD3)2SO) / δ (ppm): 2.63 (6H, s), 4.36 (2H, d, J = 4.0 Hz), 6.49 (1H, dd, J = 8.0 Hz, J = 4.0 Hz), 6.66 – 
6.69 (2H, m), 6.74 (1H, d, J = 4.0 Hz), 6.79 (1H, t, J = 8.0 Hz), 7.01 (1H, d, J = 8.0 Hz), 7.29 (1H, t, J = 
8.0 Hz), 7.46 (1H, dd, J = 8.0 Hz, J = 4.0 Hz), 8.16 (1H, dd, J = 6.8 Hz, J = 8.4 Hz), 8.69 (1H, dd, J = 2.4 
Hz, J = 4.0 Hz), 8.83 (1H, s). 13C NMR (100 MHz, (CD3)2SO) / δ (ppm): 41.8, 42.7, 105.2, 113.6, 113.7, 
115.4, 116.0, 122.1, 125.9, 128.2, 128.7, 136.4, 138.0, 144.8 145.0, 147.3, 147.6. HRMS Calcd for 
C18H19N3NaO [M+Na]+, 316.1426; found 316.1418. 
 
2.4.7. Preparation of 4-(Dimethylamino)-2-(((2-methylquinolin-8-yl)amino)methyl)phenol (AQDA2) 
A solution of 2-methylquinolin-8-amine (AQ2) (100 mg, 0.632 mmol) was utilized to prepare 
AQDA2 following an identical procedure as the one described for AQDA1. AQDA2 was purified by 
column chromatography (SiO2, 1:3 EtOAc/Hx, Rf = 0.33). The solid was recrystallized in EtOAc/Hx to 
afford the final product (light brown powder, 83.5 mg, 0.272 mmol, 43%).1H NMR (400 MHz, 
(CD3)2SO) / δ (ppm): 2.63 (3H, s), 2.68 (6H, s), 4.38 (2H, d, J = 8.0 Hz), 6.53 (1H, dd, J = 4.0 Hz, J = 8.0 
Hz), 6.64 (1H, t, J = 8.0 Hz), 6.68–6.73 (2H, m), 6.77 (1H, d, J = 8.0 Hz), 7.00 (1H, d, J = 8.0 Hz), 7.25 
(1H, t, J = 8.0 Hz), 7.36 (1H, d, J = 8.0 Hz), 8.07 (1H, d, J = 8.0 Hz), 8.86 (1H, s). 13C NMR (100 MHz, 
(CD3)2SO) / δ (ppm): 25.3, 41.9, 43.0, 105.4, 113.6, 113.7, 115.4, 116.0, 122.6, 125.9, 126.7, 127.1, 
136.6, 137.4, 144.5, 144.8, 147.6, 155.6. HRMS Calcd for C19H22N3O [M+H]+, 308.1763 found 308.1762. 
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2.4.8. Preparation of Methyl 8-((5-(dimethylamino)-2-hydroxybenzyl)amino)quinoline-2-
carboxylate (AQDA3) 
To a solution of dry EtOAc (15 mL) was added methyl 8-aminoquinoline-2-carboxylate (AQ3) (100 
mg, 0.494 mmol). 5-(Dimethylamino)-2-hydroxybenzaldehyde (DHB) (82.6 mg, 0.494 mmol) was 
slowly added to the reaction mixture. The reaction mixture was then protected from the light and allowed 
to stir overnight for 24 h. After 24 h, the reaction mixture was concentrated and dried. To a solution of 
DCE (15 mL) was added sodium triacetoxyborohydride (209 mg, 0.988 mmol). The sodium 
triacetoxyborohydride solution was then slowly added to the dried reaction mixture and allowed to stir for 
24 h (protected from the light). After 24 h, the reaction mixture was concentrated and purified by column 
chromatography (SiO2, 1:1 EtOAc/Hx, Rf = 0.16). The solid was recrystallized in EtOAc/Hx to afford the 
final product (yellow powder, 111 mg, 0.316 mmol, 64%). 1H NMR (400 MHz, (CD3)2SO) / δ (ppm): 
2.69 (6H, s), 3.99 (3H, s), 4.43 (2H, d, J = 4.0 Hz), 6.55 (1H, dd, J = 9.0 Hz, J = 3.0 Hz), 6.71 – 6.82 (4H, 
m), 7.13 (1H, d, J = 8.0 Hz), 7.47 (1H, t, J = 8.0 Hz), 8.06 (1H, d, J = 8.0 Hz), 8.38 (1H, d, J = 9.0 Hz), 
8.92 (1H, s). 13C NMR (100 MHz, (CD3)2SO) / δ (ppm): 41.4, 42.4, 52.6, 105.6, 112.8, 113.4, 114.9, 
115.7, 121.1, 124.9, 129.6, 130.4, 136.7, 137.2, 143.8, 144.3, 145.3, 147.2, 165.2. HRMS Calcd for 
C20H22N3O3 [M+H]+, 352.1661; found 352.1658. 
 
2.4.9. Aβ  Aggregation Experiments 
All experiments were performed according to previously published methods.23,31,32,35 Prior to 
experiments, Aβ40 or Aβ42 was dissolved in ammonium hydroxide (NH4OH, 1% v/v, aq), aliquoted, 
lyophilized overnight, and stored at –80 °C. For experiments described herein, a stock solution of Aβ was 
prepared by dissolving the lyophilized peptide in 1% NH4OH (10 μL) and diluting with ddH2O. The 
concentration of the solution was determined by measuring the absorbance of the solution at 280 nm (ε = 
1450 M-1cm-1 for Aβ40 and ε = 1490 M-1cm-1 for Aβ42). The peptide stock solution was diluted to a final 
concentration of 25 μM in the Chelex-treated buffered solution containing HEPES [20 μM; pH 7.4 (for 
metal-free and Zn(II) samples) pH 6.6 (for Cu(II) samples) and NaCl (150 μM)]. For the inhibition 
studies,23,31,32,35 compound (final concentration 50 μM, 1% v/v DMSO) was added to the sample of Aβ 
(25 μM) in the absence and presence of a metal chloride salt (CuCl2 or ZnCl2; 25 μM) followed by the 
incubation at 37 °C with constant agitation for 4, 8, and 24 h. For the disaggregation studies, Aβ with and 
without metal ions was incubated for 24 h at 37 °C with constant agitation prior to treatment with 
compound (50 μM). The resulting samples containing Aβ, a metal chloride salt, and a compound were 
incubated at 37 °C with constant agitation for 4, 8, and 24 h. 
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2.4.10. Gel Electrophoresis with Western Blotting 
The samples from the inhibition and disaggregation experiments were analyzed by gel electrophoresis 
with Western blot using anti-Aβ antibody (6E10).23,31,32,35 Each sample (10 μL) was separated on a 10–
20% Tris-tricine gel (Invitrogen, Grand Island, NY, USA). Following separation, the proteins were 
transferred onto nitrocellulose, which was blocked with bovine serum albumin (BSA, 3% w/v, RMBIO, 
Missoula, MT, USA) in Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) for 4 h at room 
temperature. The membranes were incubated with antibody (6E10, 1:2000, Covance, Princeton, NJ, USA) 
in a solution of 2% BSA (w/v in TBS-T) overnight at 4 °C. After washing, the horseradish peroxidase-
conjugated goat antimouse secondary antibody (1:5000) in 2% BSA was added for 1 h at room 
temperature. ThermoScientific SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, 
Rockford, IL, USA), Biosesang ECL Plus kit (Biosesang, Gyeonggi-do, Republic of Korea), or a 
homemade ECL kit41 was used to visualize the results on a ChemiDoc MP Imaging System (Bio-Rad, 
Hercules, CA, USA). 
 
2.4.11. Transmission Electron Microscopy (TEM) 
Samples for TEM were prepared according to previously reported methods.23,31,32,35 Glow-discharged 
grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) were treated with 
Aβ samples from the inhibition and disaggregation experiments (5 μL) for 2 min at room temperature. 
Excess sample was removed using filter paper followed by washing three times with ddH2O. Each grid 
was incubated with uranyl acetate (1% w/v ddH2O, 5 μL, 1 min). Upon removal of excess uranyl acetate 
with filter paper, the grids were dried for at least 30 min at room temperature before measurement. 
Images from each sample were taken on a JEOL JEM-2100 transmission electron microscope (UNIST 
Central Research Facilities, Ulsan National Institute of Science and Technology, Ulsan, Republic of 
Korea) at 120 kV and 25,000x magnification. 
 
2.4.12. 2D NMR Experiments 
The interactions of Aβ40 monomer with AQ derivatives was interrogated by 2D band-Selective 
Optimized Flip-Angle Short Transient Heteronuclear Multiple Quantum Coherence (SOFAST-HMQC) 
NMR at 10 °C.42 Uniformly 15N-labeled Aβ40 (rPeptide, Bogart, GA, USA) was dissolved in 1% NH4OH 
and lyophilized to ensure the absence of preformed aggregates. The peptide was re-dissolved in 3 μL of 
DMSO-d6 (Cambridge Isotope, Tewksbury, MA, USA) and diluted by buffer to a final peptide 
concentration of 80 μM (20 mM PO4, pH 7.4, 5 mM NaCl, 7% v/v D2O). Each spectrum was obtained 
using 64 complex t1 points and a 0.1 sec recycle delay on a Bruker Avance 600 MHz spectrometer 
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equipped with a cryoprobe. The data were processed using TOPSPIN 2.1 (Bruker) and assignment was 
performed using SPARKY 3.1134 using published assignments as a guide.43-45 Chemical shift 
perturbation (CSP) was calculated using the following equation: 
 
    

 
 
 
2.4.13. Docking Studies 
Flexible ligand docking studies for AQ derivatives against the Aβ40 monomer from previously 
determined aqueous solution NMR structure (PDB 2LFM)43 were conducted using AutoDock Vina.46 10 
conformations were selected from 20 conformations within the Protein Databank (PDB) file (1, 3, 5, 8, 
10, 12, 13, 16, 17, and 20). The MMFF94 energy minimization in ChemBio3D Ultra 11.0 was used to 
optimize the ligand structures for docking studies. The structural files of the AQ derivatives and the 
peptide were generated by AutoDock Tools and imported into PyRx,47 which were used to run AutoDock 
Vina.46 The search space dimensions were set to contain the entire peptide. The exhaustiveness for the 
docking runs was set to 1024. Docked poses of the ligand with Aβ were visualized using Pymol. 
 
2.4.14. Ion Mobility–Mass Spectrometry 
All nano-electrospray ionization MS (nESI–MS) combined with ion mobility-mass spectrometry 
(IM–MS) experiments were carried out on a Synapt G2 (Waters, Milford, MA).48,49 Samples were ionized 
using a nano-electrospray source operated in positive ion mode. MS instrumentation was operated at a 
backing pressure of 2.7 mbar and sample cone voltage of 40 V. Aliquots of Aβ40 peptides (final 
concentration, 20 μM) were sonicated for 5 sec prior to pre-incubation with or without a source of Cu(II) 
(copper(II) acetate, 20 μM) at 37 °C for 10 min. After pre-incubation, samples were titrated with or 
without ligand (AQ1, AQ4, AQP1, AQP4, AQDA1-3, or ML; final concentrations: 20, 40, 80, and 120 
μM) and incubated at 37 °C for 30 min prior to analysis. Solution conditions were 100 mM ammonium 
acetate (pH 7.5) with 1% v/v DMSO. For control purposes, all data are compared to incubations of Aβ40 
peptides with EGCG under the same conditions.35 Collision cross-section (CCS) measurements were 
externally calibrated using a database of known values in helium, with values for proteins that bracket the 
likely CCS and ion mobility values of the unknown ions.34,50 CCS values are the mean average of five 
replicates with errors reported as the least square product. This least square analysis combines inherent 
calibrant error from drift tube measurements (3%),50 calibration curve error, and twice the replicate 
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standard deviation error. Determination of the amount of Cu(II) bound to Aβ40 was calculated using the 
total ion count extracted from the peak of interest at its full width half maximum using methods 
previously described.51 All other conditions are consistent with previously published methods.32 
 
2.4.15. Metal Binding Experiments 
Metal binding properties of AQ1-3, AQP1-4, and AQDA1-3 were investigated by UV-vis and 1H 
NMR. UV-vis experiments were carried out in acetonitrile (for AQ2 and AQP3) or a Chelex-treated 
buffered solution containing 20 mM HEPES, pH 7.4, and 150 mM NaCl. To a solution of ligand, CuCl2 
or ZnCl2 was titrated up to 10 equiv at room temperature. The solutions were allowed to equilibrate 
before further addition of CuCl2 or ZnCl2. Zn(II) binding to AQ3 was probed by 1H NMR by slowly 
titrating up to 3.5 equiv of ZnCl2 (17.5 mM) at room temperature in CD3CN. To examine the metal 
selectivity of AQP4 and AQDA1-3 for Cu(II), 1 or 20 equiv of MgCl2, CaCl2, MnCl2, FeCl2, CoCl2, 
NiCl2, and ZnCl2 were first treated to a solution containing 50 μM ligand (AQP4 and AQDA1-3). The 
spectra were recorded after 10 min incubation at room temperature. The Fe(II) samples were prepared in 
an anaerobic N2-filled glove box. CuCl2 (50 μM) was then added to a solution of compound and a 
divalent metal chloride salt. The spectra were taken after an additional 10 min incubation period at room 
temperature. Quantification of metal selectivity was calculated by comparing and normalizing the 
absorption values of metal–ligand complexes at 290 (for AQP4), 440 (for AQDA1 and AQDA2), and 
338 nm (for AQDA3) to the absorption at these wavelengths before and after the addition of CuCl2 
(AM/ACu). 
 
2.4.16. Solution Speciation Studies 
The pKa values for AQP1, AQP4, and AQDA1-3 were determined through UV-vis variable-pH 
titrations based on a previously reported procedure.23,31,32,35 To obtain pKa values for the ligands (50 μM 
for AQP4 or AQDA1; 25 μM for AQP1, AQDA2, or AQDA3), HCl was titrated into the speciation 
solution (100 mM NaCl, pH 12, 10 mM NaOH) in small aliquots to obtain at least 30 spectra in the range 
of pH 2–11 (for AQP1 and AQP4) or pH 2–10 (for AQDA1-3). In addition, to investigate Cu(II) binding 
to the ligands at various pHs, small aliquots of HCl were titrated into the solutions containing a ligand and 
a metal chloride salt [[M(II)]:[L] = 1:2; [CuCl2] = 50 (for AQP4), 12.5 (for AQDA1 and AQDA2), and 
25 μM (for AQP1 and AQDA3)]. At least 30 spectra were measured over the range of pH 2–8. The 
acidity and stability constants were calculated by using the HypSpec program (Protonic Software, Leeds, 
UK).52,53 
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2.4.17. 2-Deoxyribose Assay 
The ability of AQ1, AQ3, AQ4, AQDA1, and AQDA3 to suppress the generation of hydroxyl 
radicals was determined by the 2-deoxyribose assay. The assay was preformed based on previously 
reported methods.23,36 Chelexed solutions were used, and reactions (total volume, 200 μL) were prepared 
by mixing, in the following order, buffer (50 mM NaH2PO4, pH 7.4), ligand (125 μM), CuCl2 (10 μM), 2-
deoxy-D-ribose (15 mM), H2O2 (200 μM), and sodium ascorbate (2 mM) and allowed to react for 1 h at 
37 °C with constant agitation. The reactions were quenched upon addition of trichloroacetic acid (200 μL 
of 2.8% m/v) and 2-thiobarbituric acid (200 μL of 1% w/v). After quenching, the reactions were heated at 
100 °C for 20 min, then allowed to cool for 5 min prior to measurement of their absorbance values at 532 
nm. Samples without ligand were prepared as a control. Experiments were preformed in triplicates. 
Normalized absorbance values (A/A0) were calculated by taking the absorbance (A) and dividing by the 
absorbance of the control (A0). 
 
2.4.18. Trolox Equivalent Antioxidant Capacity (TEAC) Assay 
The antioxidant activity of AQ1-3, AQP1-2, AQP4, and AQDA1-3 was determined by the TEAC 
assay using human neuroblastoma SK-N-BE(2)-M17 (M17) cell lysates and was conducted according to a 
protocol of the antioxidant assay kits purchased from Cayman Chemical Company (Ann Arbor, MI, 
USA) with minor modifications. The cell line purchased from ATCC (Manassas, VA, USA) was 
maintained in media containing 1:1 minimum Essential Media (MEM, GIBCO) and Ham’s F12K 
Kaighn’s Modification Media (F12K, GIBCO), 10% (v/v) fetal bovine serum (FBS, GIBCO), 100 U/mL 
penicillin (GIBCO), and 100 mg/mL streptomycin (GIBCO). The cells were grown and maintained at 37 
°C in a humidified atmosphere with 5% CO2. The cells were seeded in a 6 well plate and grown to 
approximately 80-90% confluence. Cell lysates were prepared following a previously reported method 
with modifications.54 M17 cells were washed once with cold PBS (pH 7.4, GIBCO) and harvested by 
gently pipetting off adherent cells with cold PBS. A cell pellet was generated by centrifugation (2,000 g 
for 10 min at 4 °C). This cell pellet was sonicated on ice (5 sec pulses five times with 20 sec intervals 
between each pulse) in 2 mL of cold Assay Buffer [5 mM potassium phosphate (pH 7.4) containing 0.9% 
NaCl and 0.1% glucose]. The cell lysates were centrifuged at 10,000 g for 10 min at 4 °C. The 
supernatant was removed and stored on ice until use. To a standard sample 96 microplate, 10 μL of the 
supernatant cell lysates was delivered followed by addition of compound, metmyoglobin (2.5 μM), ABTS 
(165 μM), and H2O2 (82.4 μM) in order. Compound concentration ranges utilized were as follows: Trolox 
(45, 90, 135, 180, 225, and 330 μM); AQ1, AQ3, AQP4, AQDA1, and AQDA2 (30, 50, 70, 90, 110, and 
135 μM); AQ2 (30, 70, 110, 150, 190, and 255 μM); AQP1 and AQP2 (20, 40, 60, 80, 100, and 120 
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μM); AQDA3 (30, 60, 90, 120, 150, and 180 μM). After 5 min incubation at room temperature on a 
shaker, absorbance values at 750 nm were recorded. The percent inhibition was calculated according to 
the measured absorbance (% inhibition = (A0 – A)/A0, where A0 is the absorbance of the supernatant of 
cell lysates) and was plotted as a function of compound concentration. The TEAC value of ligands was 
calculated as a ratio of the slope of the standard curve of the compound to that of Trolox. The 
measurements were conducted in triplicate. 
 
2.4.19. Parallel Artificial Membrane Permeability Adapted for the Blood-Brain Barrier (PAMPA-
BBB) Assay 
PAMPA-BBB experiments were carried out using the PAMPA Exploer kit (pION Inc., Billerica, 
MA, USA) with modifications to previously reported protocols.23,25,26,55 Each stock solution was diluted 
with Prisma HT buffer (pH 7.4, pION) to a final concentration of 25 μM (1% v/v final DMSO 
concentration). The resulting solution was added to wells of the donor plate (200 μL, 12 replicates). BBB-
1 lipid formulation (5 μL, pION) was used to coat the polyvinylidene fluoride (PVDF, 0.45 mM) filter 
membrane on the acceptor plate. This acceptor plate was placed on top of the donor plate forming a 
sandwich. Brain sink buffer (BSB, 200 μL, pION) was added to each well of the acceptor plate. The 
sandwich was incubated for 4 h at ambient temperature without stirring. UV-vis spectra of the solutions in 
the reference, acceptor, and donor plates were measured using a microplate reader. The PAMPA Explorer 
software v. 3.5 (pION) was used to calculate –logPe for each compound. CNS± designations were 
assigned by comparison to compounds that were identified in previous reports.25,26,55 
 
2.4.20. Cell Viability Measurements 
The mouse Neuro-2a (N2a) neuroblastoma cell line was purchased from the American Type Cell 
Collection (ATCC, Manassas, VA, USA). Cells were maintained in media containing 1:1 DMEM 
(GIBCO, Grand Island, NY, USA) and opti-MEM (GIBCO), supplemented with 5% (v/v) fetal bovine 
serum (FBS; GIBCO), 1% (v/v) L-glutamine (GIBCO), 100 U/mL penicillin, and 100 mg/mL 
streptomycin (GIBCO). The cells were grown and maintained at 37 C in a humidified atmosphere with 
5% CO2. Cell viability upon treatment of compounds was determined by the MTT assay [MTT = 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Sigma-Aldrich]. N2a cells were seeded in a 
96 well plate (15,000 cells in 100 μL per well). The cells were treated with compounds (5 or 10 μM, 1% 
v/v final DMSO concentration) with or without CuCl2 or ZnCl2 (5 or 10 μM), and incubated for 24 h with 
the cells. After incubation, MTT [25 μL; 5 mg / mL in phosphate buffered saline (PBS, pH 7.4, GIBCO)] 
was added to each well and the plate was incubated for 4 h at 37 °C. Formazan produced by the cells was 
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solubilized using an acidic solution of N,N-dimethylformamide (DMF, 50%, v/v aq) and sodium dodecyl 
sulfate (SDS, 20%, w/v) overnight at room temperature in the dark. The absorbance was measured at 600 
nm using a microplate reader. Cell viability was calculated relative to cells treated with an equivalent 
amount of DMSO. All Experiments were performed in triplicate. 
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Chapter 3. 
A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic 
Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and In Vivo 
Efficacy and Molecular Mechanisms 
 
 
 
 
 
 
 
The results presented in this chapter were previously published (Derrick, J. S.; Kerr, R. A.; Nam, Y.; Oh, 
S. B.; Lee, H. J.; Earnest, K. G.; Suh, N.; Peck, K. L.; Ozbil, M.; Korshavn, K. J.; Ramamoorthy, A.; 
Prαβhakar, R.; Merino, E. J.; Shearer, J.; Lee, J.-Y.; Ruotolo, B. T.; Lim, M. H. J. Am. Chem. Soc., 2015, 
137, 14785–14797). I thank Professor Brandon T. Ruotolo and Dr. Richard A. Kerr for the MS studies, 
Professor Joo-Yong Lee, Shin Bi Oh, and Nayoung Suh for in vivo analysis, Professor Jason Shearer and 
Kristy L. Peck for XAS measurements, Professor Merino and Kaylin G. Earnest for metabolic stability 
assessment, Professor Prabhakar and Dr. Mehmet Ozbil for molecular dynamics simulations, and 
Professor Ayyalusamy Ramamoorthy and Kyle J. Korshavn for 2D NMR assistance. Younwoo Nam and 
Hyuck Jin Lee were involved in the gel/Western blot, UV-vis, and TEM experiments. I was instrumental 
in the design and performance of experiments as well as the writing of the manuscript with the assistance 
of Professor Lim.  
  
 69
3.1. Introduction 
Alzheimer’s disease (AD), the most common form of all neurodegenerative diseases, has continued to 
expand in prevalence and remains unabated due to an inadequate understanding of disease pathology, 
which has significantly impaired efforts to establish effective strategies against the disorder.1-4 As such, 
fatalities resulting from this deadly malady have continued to increase to the point where today, almost 
one third of every senior citizen will be affected by AD or a related form of dementia.5 The costs 
associated with providing the long-term care and resources required by those suffering from AD have also 
reached staggering levels. This year alone, AD will cost the United States 226 billion dollars, and without 
intervention, this figure is expected to reach 1.1 trillion by 2050.5 Therefore, it is clear that if this trend is 
to be suppressed, we must develop a more detailed, molecular-level understanding of the convoluted and 
multilayered pathology of AD, which will then be able to provide the foundation toward the generation of 
new strategies against the disease. 
Illumination of the molecular mechanisms underlying AD is further obstructed by the absence of 
completely accurate model systems from which to study the ailment. For example, in vitro analyses often 
require the experimentalist to narrow the scope of their study to a few potential players (e.g., misfolded 
proteins) and often deviate from physiological relevancy.1-4 Similarly, in vivo studies are limited by the 
absence of accurate models that fully mimic human AD.6 Due to these inherent complexities along with 
the impossibility of addressing every potential factor contributing toward neuronal death in a single 
report, we have chosen to focus our investigation on the amyloid-β (Aβ) peptide, a hallmark of the 
disease which is known to aggregate to form characteristic senile plaques, and its interplay with metal 
ions [e.g., Cu(II), Zn(II)].1-4,7-14 Metal ions were incorporated into our studies because of their extensively 
explored involvement in the facilitation of Aβ aggregation pathways and generation of reactive oxygen 
species (ROS) via Fenton-like reactions in vitro.2-4,7-14 It is important, however, that we specify that by 
focusing our analysis on the aggregation and interaction of Aβ and metal ions, we are not implying that 
these are the sole causes of the disorder. 
The evidence suggesting that Aβ is implicated in the pathology of AD is incontrovertible.1-4,7-14 For 
example, Aβ oligomer load has been closely correlated with cognitive impairment and behavioral tests in 
transgenic AD mouse models.1,3 Furthermore, multiple cell and transgenic mouse studies have clearly 
identified Aβ as a contributor to the diminished mitochondrial function observed in AD.3 Aβ has also 
been indicated to induce kinases responsible for the phosphorylation of tau protein and the subsequent 
destabilization of microtubules.3 These findings are only a small number of the available reports that 
implicate Aβ in AD. The mechanisms by which Aβ may induce cellular death, however, have not been 
fully understood. In order to advance our understanding of these pathways, the use of chemical tools, 
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capable of elucidating the mechanism of these processes at the molecular level, will be of indispensable 
value.2,4,14-22 
To this end, we present a redox-active, compact amine derivative, DMPD (N,N-dimethyl-p-
phenylenediamine; Figure 3.2a), as a novel chemical tool for redirecting both metal-free Aβ and metal–
Aβ peptides into nontoxic, off-pathway peptide aggregates, via an approach mediated by intramolecular 
crosslinks between compound and peptide. Our strategy, the generation of covalently linked adducts 
composed of aggregation-prone peptides, was inspired by a recent study suggesting a covalent bond 
between catechol-type flavonoids and Aβ.23,24 In a previous report, a well-known, redox-active 
compound, DMPD,25-27 was indicated as a potential molecule of interest, among many others, in a brief 
calculation focused screening method and a fluorescence-based assay [i.e., thioflavin-T (ThT) assay].28 
Unfortunately, in addition to spectral interference between DMPD and ThT, making results of the assay 
inconclusive, the report did not present whether DMPD influences the Aβ aggregation pathways with 
elucidation of a mechanistic understanding of its activity with the peptide.28 Through our present studies, 
we demonstrate the ability of DMPD to redirect both metal-free and metal-induced Aβ aggregation 
pathways and consequently produce less toxic, off-pathway amorphous aggregates. Biophysical analyses 
and molecular dynamics (MD) simulations indicate molecular-level interactions of DMPD with both 
metal-free Aβ and metal–Aβ in vitro as well as its potential mechanism, based on the formation of 
intramolecular crosslinks between transformed DMPD and Aβ, for redirecting the peptide aggregation. 
Finally, the efficacy of our approach in biological settings [e.g., living cells, in vivo (i.e., the AD 5×FAD 
mouse model)29] was investigated. Treatment with DMPD mitigates Aβ-/metal–Aβ-induced toxicity in 
living cells and reduces the overall cerebral amyloid levels in 5×FAD mice. Additionally, cognitive 
defects of 5×FAD mice, as evaluated by the Morris water maze task, are significantly improved upon 
DMPD administration. Taken together, our in vitro and in vivo studies of a redox-active small molecule, 
along with the molecular-level mechanistic elucidation, illustrate that the strategy to generate Aβ–small 
molecule adducts could be an effective tactic to control and promote the formation of relatively less toxic, 
off-pathway aggregates. 
 
3.2. Results and Discussion 
 
3.2.1. Rational Selection of DMPD Toward Redirecting Both Metal-free and Metal-induced Aβ  
Aggregation In Vitro and in Biological Systems 
Although DMPD is a compact, simple compound, its structure (Figure 3.2a) includes moieties, 
suggested to be potentially essential for interactions with metal-free Aβ, metal–Aβ, and metal ions.2,4,14-16  
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Table 3.1. Brain uptake and antioxidant properties of DMPD. 
 
 
 
aMW, molecular weight; clogP, calculated logarithm of the octanol−water partition coefficient; HBA, 
hydrogen bond acceptor atoms; HBD, hydrogen bond donor atoms; PSA, polar surface area; logBB = 
−0.0148 Å x PSA + 0.152 Å x clogP + 0.139 (logBB > 3.0, readily crosses BBB; logBB < −1.0, poorly 
distributed to the brain); −logPe values were determined using the Parallel Artificial Membrane 
Permeability Assay (PAMPA), and average −logPe values were then calculated by the PAMPA 9 
Explorer software v. 3.5. bPrediction of a compound’s ability to penetrate the central nervous system 
(CNS) on the basis of literature values. Compounds categorized as CNS+ possess the ability to penetrate 
the BBB and are available in the CNS. Compounds assigned as CNS− have poor permeability through the 
BBB; therefore, their bioavailability into the CNS is considered to be minimal. cAntioxidant activity of 
DMPD, identified by the TEAC assay in EtOH. The TEAC value is relative to a vitamin E analogue, 
Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). 
 
The overall redox and structural characteristics of DMPD could indicate its direct interactions with both 
metal-free Aβ or metal–Aβ, as well as its subsequent ability to redirect peptide aggregation pathways via 
the generation of covalently linked adducts between compound and Aβ, as previously presented for 
catechol-type flavonoids.23,24 In addition, DMPD is shown to be biologically compatible based on our 
investigations. First, DMPD is potentially blood-brain barrier permeable and has antioxidant activity 
similar to that of a water-soluble vitamin E analogue, Trolox (Table 3.1). Secondly, as presented in Figure 
3.1, in phosphate buffered saline (PBS), DMPD is relatively stable with an approximate half-life (t1/2) of 
one day. Addition of hydrogen peroxide, however, leads to oxidation of DMPD (its cationic radical25-27) 
with a t1/2 value of 55 min. Lastly, DMPD has relative metabolic stability. Using FAME software,30 the 
sites of metabolism were predicted showing the alkylate aniline nitrogen as a site of metabolism reaction 
Calculationa DMPD Lipinski’s rules  and others 
MW 136 ≤ 450 
clogP 1.08 ≤ 5.0 
HBA 2 ≤ 10 
HBD 2 ≤ 5 
PSA 29.3 ≤ 90 
logBB –0.139 > 3.0 (readily) 
< -1.0 (poorly) 
PAMPA-BBB assay 
logPeb 
5.0 ± 0.2 
(CNS+) 
–logPe < 5.4 (CNS+) 
–logPe  > 5.7 (CNS-) 
TEAC assay DMPD Trolox 
Valuec 1.05 (0.04) 1.00 (0.02) 
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(Figure 3.1a). The metabolic stability of DMPD was also further analyzed employing human liver 
microsomes. We observed classic enzyme kinetics showing that the metabolic processing is between 30 
min and 120 min [t1/2 = 107 min ([DMPD] = 0.5 mM); Vmax, ca. 22.9 nM/min; KM, ca. 2.07 mM; Figure 
3.1]. Overall, DMPD is indicated to have moderate metabolic stability, as well as could be administered 
for its applications in vivo since its concentration would be much lower than the 2.07 mM KM for liver 
microsomes. 
 
 
Figure 3.1. Solution and metabolic stability of DMPD. (a) FAME calculation of DMPD. aPredicts the 
sites of metabolism, the atom where a metabolic reaction is initiated. The number reported is the 
probability of each atom being a site of metabolism. Therefore, the closer the number is to one, the more 
likely that atom is a site of metabolism [see Kirchmair, J. et al., J. Chem. Inf. Model 2013, 53, 2896–
2907]. (b) Stability of DMPD in DMSO and PBS. DMPD is shown to be degraded by ca. 20% in PBS for 
12 h. (c) Oxidation of DMPD by hydrogen peroxide (H2O2) in PBS (t1/2 = 55 min). Conditions: DMPD 
(0.5 mM); H2O2 (5 mM); pseudo-first order kinetics. (d) Metabolic stability of DMPD using liver 
microsomes. Based on Lineweaver–Burk analysis, the values of Vmax and KM (ca. 22.9 nM/min and ca. 
2.07 mM, respectively) are obtained. 
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Figure 3.2. Effects of DMPD toward metal-free/metal-induced Aβ40 aggregation in vitro. (a) Chemical 
structure of DMPD (N,N-dimethyl-p-phenylenediamine) and amino acid sequence of Aβ (the self 
recognition site is underlined and highlighed in red). (b) Scheme of the (I) inhibition or (II) 
disaggregation experiments. The metal-free samples were prepared in both the absence (left) and presence 
(right) of O2. (c) Analyses of the resultant Aβ species from (I) and (II) by gel electrophoresis with 
Western blotting (gel/Western blot) using an anti-Aβ antibody (6E10). For the experiment (I), the samples 
containing metal-free Aβ40 were prepared under anaerobic (left, white background) and aerobic (right, 
gray background) conditions. Conditions: Aβ (25 μM); CuCl2 or ZnCl2 (25 μM); DMPD (50 μM); 24 h; 
pH 6.6 (for Cu(II) experiments) or pH 7.4 (for metal-free and Zn(II) experiments); 37 °C; constant 
agitation. (d) TEM images of the Aβ40 samples prepared under aerobic conditions (from (c)). Inset: Minor 
species from TEM measurements. White and black scale bars indicate 200 and 500 nm, respectively. 
 
3.2.2. Effects of DMPD on Both Metal-Free and Metal-Induced Aβ  Aggregation In Vitro 
The influence of DMPD on the aggregation of both Aβ40 and Aβ42 was probed in the absence and 
presence of metal ions [i.e., Cu(II), Zn(II)]. Gel electrophoresis with Western blotting (gel/Western blot) 
using an anti-Aβ antibody (6E10) and transmission electron microscopy (TEM) were employed to 
analyze the molecular weight (MW) distribution and morphological change of the resultant Aβ species, 
respectively (Figures 3.2c,d, 3.3, and 3.4).18-22,31 As depicted in Figure 3.2b and Figure 3.3a, two different 
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experiments were conducted to assess whether DMPD can either inhibit the formation of metal-free/-
treated Aβ aggregates (I: inhibition experiment) or disassemble preformed metal-free/-associated Aβ 
aggregates (II: disaggregation experiment). Generally, small molecules able to inhibit the formation of 
Aβ fibrils or disassemble preformed Aβ aggregates will generate a distribution of smaller Aβ species that 
can penetrate into the gel matrix and will produce a significant amount of smearing compared to 
compound-free controls. Aβ samples without treatment with compounds contain large Aβ aggregates 
(i.e., mature fibrils), which can be observed by TEM, but are too big to enter the gel matrix (restricted to 
the entrance where the sample is loaded) and therefore do not produce smearing or bands in the 
gel/Western blot. 
 
 
Figure 3.3. Effects of DMPD on metal-free and metal-induced Aβ42 aggregation. (a) Scheme of (I) 
inhibition and (II) disaggregation experiments. (b) Analyses of the resultant Aβ species from I and II by 
gel/Western blot using an anti-Aβ antibody (6E10). Conditions: Aβ (25 μM); CuCl2 or ZnCl2 (25 μM); 
DMPD (50 μM); 24 h; pH 6.6 (for Cu(II) experiments) or pH 7.4 (for metal-free and Zn(II) experiments); 
37 °C; constant agitation. (c) TEM images of the Aβ42 samples from (b). White scale bars indicate 500 
nm. 
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In the inhibition experiment (I, Figure 3.2b), different MW distributions were observed for DMPD-
treated Aβ40 with and without metal ions compared to the untreated analogs. TEM images revealed the 
generation of small amorphous Aβ aggregates with respect to the large clusters of fibrils generated in the 
absence of DMPD (Figure 3.2c,d). DMPD exhibited a similar ability to inhibit aggregate formation with 
Aβ42 (Figure 3.3b). In the disaggregation experiment (II, Figure 3.2b), DMPD indicated more noticeable 
effects on the transformation of preformed metal-free Aβ40 and metal–Aβ40 aggregates than for the Aβ42 
conditions visualized by gel/Western blot (Figure 3.2c, right and Figure 3.3b, right); however, the 
generation of shorter, more dispersed fibrils, relative to the DMPD-untreated Aβ42 controls, was indicated 
by TEM (Figure 3.3b,c). Moreover, in order to determine the effect of DMPD on Aβ aggregation in a 
heterogeneous in vitro environment, the inhibition experiment was performed in a cell culture medium. 
Upon treatment of DMPD to Aβ40 in a cell culture medium, a distinguishable variation in the MW 
distribution of Aβ species was still observed (Figure 3.4), but this distribution was different from that 
shown in a buffered solution (Figure 3.2c, left). Therefore, these results support that the small 
monodentate ligand, DMPD, is able to redirect both metal-free Aβ and metal–Aβ species into off-
pathway, relatively smaller and/or less structured peptides aggregates, which has been suggested to be 
less toxic,16,20,21 in a buffered solution and a heterogeneous matrix. 
 
 
Figure 3.4. Effect of DMPD toward metal-free and metal-induced Aβ40 aggregation in a cell culture 
medium. Gel/Western blot analyses of the resultant Aβ40 species upon treatment with DMPD in a cell 
culture medium containing 1:1 Minimum Essential Media (MEM) and Ham’s F12K Kaighn’s 
Modification Media (F12K), 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL 
streptomycin. Conditions: Aβ (25 μM); CuCl2 or ZnCl2 (25 μM); DMPD (50 μM); 24 h; 37 °C; constant 
agitation. The experimental scheme is depicted in Figure 3.2b. 
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Figure 3.5. Interactions of DMPD with monomeric Aβ and fibrillar Cu(II)–Aβ, observed by 2D NMR 
spectroscopy and Cu K-edge X-ray absorption spectroscopy, respectively. (a) 2D 1H–15N SOFAST-
HMQC NMR investigation of DMPD with 15N-labeled Aβ40. (b) Chemical shift perturbations (CSPs) of 
Aβ40 were determined upon addition of DMPD (Aβ : DMPD = 1 : 10). On the chemical shift plot, the 
dashed and dotted lines represent the average CSP and one standard deviation above the average, 
respectively. Relatively noticeable CSPs were observed around the hydrophobic residues of the peptide. 
*Residues could not be resolved for analysis. (c) Molecular dynamics (MD) simulations of the Aβ40–
DMPD complex. DMPD and Aβ40 are shown to interact directly with the hydrophobic region of the Aβ40 
monomer in its lowest energy conformation (see Figure 3.6). The chemical structure of DMPD is colored 
as follows: Carbon, orange; hydrogen, white; nitrogen, blue. The self-recognition site of Aβ40 is 
highlighted in light violet. (d) Left: X-ray absorption near edge structure (XANES) region of the Cu K-
edge X-ray absorption spectrum of DMPD-incubated Cu(I)- (red) and Cu(II)-loaded (blue) Aβ42 fibrils. 
Top right (blue): Magnitude FT and FF (inset) extended X-ray absorption fine structure (EXAFS) of 
DMPD-incubated Cu(II)-loaded Aβ42 fibrils showing the experimental data (solid line), simulated 
spectrum (dashed line), and difference spectrum (dotted line). Shell #1 (N scatterer): n = 2.3(2); r = 
1.889(3) Å; σ2 = 0.0041(4) Å2; ε2 = 0.93. Bottom right (red): Magnitude FT and FF (inset) EXAFS of 
DMPD-incubated Cu(I)-loaded Aβ42 fibrils showing the experimental data (solid line), simulated 
spectrum (dashed line), and difference spectrum (dotted line). Shell #1 (N scatterer): n = 2.2(2); r = 
1.882(4) Å; σ2 = 0.0033(1) Å2; ε2 = 0.85.   
 
3.2.3. Proposed Mechanism of DMPD’s Control Against Aβ  Aggregation Pathways 
 
(i) Interaction of DMPD with Metal-Free Aβ  Monomers 
The interaction of DMPD with metal-free Aβ monomers was examined by 2D NMR spectroscopy 
and MD simulations (Figure 3.5a-c). 2D band-Selective Optimized Flip-Angle Short Transient 
Heteronuclear Multiple Quantum Correlation (SOFAST-HMQC) NMR experiments were first employed 
to identify the interaction of DMPD with monomeric Aβ40. When DMPD was titrated into 15N-labeled 
Aβ40, relatively noticeable chemical shift perturbations (CSPs) were shown for six amino acid residues 
(particularly for L17, F20, G33, G37, V39, and V40; Figure 3.5a,b). These residues in the self-recognition 
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(residues 17-21) and C-terminal hydrophobic regions (Figure 3.2a) are reported to be crucial for Aβ 
aggregation and cross β sheet formation via hydrophobic interactions.10,16 The CSP presented for V40 
may be due to intrinsic C-terminal disorder rather than interaction with DMPD.31 The distribution of 
observed CSPs suggests that DMPD could interact with the amino acid residues in Aβ40 near the self-
recognition and hydrophobic regions. 
 
 
Figure 3.6. Conformations of the Aβ40–DMPD complexes as determined by molecular dynamics (MD) 
simulations. (a-c) Complexes of DMPD with Aβ40 (PDB 1BA4). DMPD is shown to interact with Aβ40. 
Atoms of DMPD are colored as follows: Carbon, orange; hydrogen, white; nitrogen, blue. The self-
recognition site of Aβ40 is also highlighted in light violet. Gibb’s binding energies (ΔGbinding) for each 
conformation are summarized in the table (bottom). 
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To further probe the interaction between metal-free, monomeric Aβ40 and DMPD, docking and MD 
simulation studies32,33 were also performed. Simulations indicate multiple interactions (Figure 3.5c, and 
Figure 3.6): (i) a potential binding pocket is formed through hydrogen bonding (2.08 Å) of the amine 
group (–NH2) of DMPD with the O atom of the backbone carbonyl between L17 and V18; (ii) the 
aromatic ring of DMPD associates with G38 via a N–H–π interaction (3.16 Å); (iii) the methyl group (–
CH3) of the dimethylamino moiety of DMPD further stabilizes the Aβ–DMPD interaction by the C–H–
π (with the aromatic ring of F19) interaction (4.10 Å). The observation from docking and MD simulation 
investigations was in agreement with the NMR findings (vide supra). Thus, 2D NMR and docking/MD 
simulation studies demonstrate the direct interaction of DMPD with metal-free Aβ species, as suggested 
from the results of both inhibition and disaggregation experiments above (Figure 3.2 and Figure 3.3), 
along with the mass spectrometric (MS) analysis (vide infra, Figure 3.12). 
 
(ii) Interaction of DMPD with Copper–Aβ  Monomers and Fibrils 
Cu K-edge XAS was applied to Cu(I)- and Cu(II)-loaded Aβ42 monomers and fibrils to gain insights 
into the nature of the interaction between copper–Aβ complexes and DMPD. The XAS data for Cu(I)-
loaded Aβ42 fibrils following DMPD incubation are consistent with a linear 2-coordinate Cu(I)(N/O)2 
environment (Figure 3.5d, red). The X-ray absorption near edge structure (XANES) region of the XAS 
spectrum exhibited a prominent pre-edge feature at 8985.2(2) eV corresponding to the Cu (1s → 4pz) 
transition. Such a feature is characteristic of linear Cu(I).34 Analysis of the extended X-ray absorption fine 
structure (EXAFS) region yielded a model consistent with the copper center ligated to two N or O ligands 
at 1.88 Å. We note that the identity of the ligands to the Cu(I) center could not be definitively determined. 
Although there are peaks in the magnitude Fourier Transformed EXAFS spectrum in the range of r’ = 
2.0–4.0 Å that may result from multiple scattering pathways from histidine imidazole rings, but they 
could not be modeled as such. Surprisingly, the Cu(II)-loaded Aβ42 fibrils treated with DMPD yielded 
nearly identical XAS data indicating the complete reduction of Cu(II) to a linear 2-coordinate Cu(I)(N/O)2 
center (blue, Figure 3.5d). This reduction of Cu(II) to Cu(I) is not a result of photoreduction in the X-ray 
beam. Cu(II) fibrils (or monomers; vide infra) show no indication of photoreduction under identical 
experimental conditions,34,35 while studies of DMPD-incubated Cu(II) fibrils do not present 
photochemistry following repeated EXAFS scans under the experimental conditions employed (i.e., the 
Cu(II) is already reduced to Cu(I) prior to X-ray exposure) (Figure 3.7).  
Copper-loaded Aβ42 monomers incubated with DMPD afforded a dramatically different result 
compared to the DMPD-untreated samples. In the absence of DMPD, XAS studies showed a spectrum 
for the Cu(II)-loaded Aβ42 monomers consistent with a square planar Cu(II)(N/O)4 metal-center with two 
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imidazole ligands bound to Cu(II), while the Cu(I)-loaded Aβ42 monomers contained copper within a 
linear bis-His coordination environment.34 The XAS data for Cu(II)-loaded Aβ42 monomers following 
DMPD incubation was indicative of a complex mixture of reduced Cu(I) and oxidized Cu(II) centers. The 
reduced samples following treatment with DMPD presented that Cu(I) was also contained in a mixture of 
coordination environments and geometries, making it impossible to yield a physically meaningful 
solution to the EXAFS data. The different behaviors of copper-loaded Aβ42 monomers versus fibrils could 
be the result of either different incubation times necessitated to avoid monomer aggregation, or could be 
indicative of different fundamental chemistry with DMPD. Taken together, the overall observations from 
the XAS studies suggest the possible redox interaction of the small monodentate ligand (DMPD) with 
copper–Aβ complexes. 
 
 
Figure 3.7. XANES region of the XAS spectrum for DMPD-incubated Cu(II)-loaded Aβ42 fibrils 
following one (solid), two (dashed), and three (dotted) scans on the same spot. Total exposure time for 
each scan is ca. 45 min. 
 
(iii) Transformation of DMPD in the Absence and Presence of Aβ  and Metal Ions 
To elucidate how DMPD redirects Aβ peptides into less toxic, off-pathway unstructured Aβ 
aggregates, the chemical transformation of DMPD with Aβ was analyzed under various conditions, in 
addition to its interactions with metal-free and metal-bound Aβ (vide supra). Time-dependent optical 
changes of DMPD were first monitored in the absence and presence of Aβ40 with and without CuCl2 in  
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Figure 3.8. Transformation of DMPD with or without Cu(II) and/or Aβ40, monitored by UV-vis. (a and 
b) UV-vis spectra of DMPD with or without CuCl2 in the absence and presence of Aβ under aerobic 
conditions. (c) UV-vis spectra of DMPD with or without Aβ under anaerobic conditions. Blue, red, and 
green lines correspond to incubation for 0, 4, and 24 h, respectively. Conditions: Aβ (25 μM); CuCl2 (25 
μM); DMPD (50 μM); pH 6.6 (for Cu(II) experiments) or pH 7.4 (for metal-free experiments); room 
temperature; no agitation. (a and c) DMPD +/– Aβ40; (b) [DMPD + CuCl2] +/– Aβ40.  
 
buffered solutions (Figure 3.8). DMPD treated with Aβ40 in both the absence and presence of Cu(II) 
exhibited spectral shifts, different from the Aβ40-free condition (Figure 3.8a,b). The optical bands at ca. 
513 and 550 nm, indicative of the formation of a cationic radical of DMPD25-27 through an oxidative 
degradation route (Figure 3.8a,b, bottom), were not observed even after a 24 h incubation of DMPD with 
Aβ (Figure 3.8a,b, top). Upon addition of DMPD into a solution containing Aβ40, a red shift in the optical 
band of DMPD (from 295 to 305 nm) immediately occurred (Figure 3.9). Upon incubation over 4 h, a 
new optical band at ca. 340 or 350 nm with an isosbestic point at ca. 270 nm began to grow in (Figure 
3.8a,b, top). These optical bands at ca. 250 and 340 or 350 nm are expected to be indicative of generating 
a possible adduct of benzoquinoneimine (BQI) or benzoquinone (BQ) with proteins (or peptides; via 
amine or thiol groups), respectively.23,24,27,36-41 The absence of a clean isosbestic point at the early 
incubation time points is most likely due to the formation of BQ from DMPD and possibly some 
contribution from the production of transient complexes between Aβ and CI or BQI (vide infra) The UV-
vis spectrum of BQ (Figure 3.10a) is identical to the optical spectra of DMPD with Aβ40 at 2 and 4 h 
under aerobic conditions indicating that DMPD is transformed into BQ before the bands at 250 and 340 
or 350 nm begin to grow in, indicative of the covalent adduct formation with Aβ. Furthermore, Aβ40 
treated to a solution of BQ under identical conditions exhibits one clean isosbestic point over the course 
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of the 24 h experiment (Figure 3.10b). These results support that the optical changes at the early time 
points are mainly caused by the generation of BQ from DMPD. Overall, DMPD could be transformed 
through a different pathway in the presence of Aβ40, potentially producing a modified DMPD conjugate 
with Aβ40, compared to the Aβ40-absent case. 
 
 
Figure 3.9. UV-vis spectra of DMPD with or without Aβ40 and/or metal ions. (a) DMPD ± Aβ40; (b) 
DMPD ± [CuCl2 + Aβ40]; (c) DMPD ± [ZnCl2 + Aβ40]. Black and red lines represent the absence and 
presence of Aβ40, respectively. Conditions: Aβ40 (25 μM); CuCl2 or ZnCl2 (25 μM); DMPD (50 μM); pH 
6.6 (for Cu(II) experiment) or pH 7.4 (for metal-free and Zn(II) experiments); room temperature; no 
agitation. The spectra were obtained right after addition of metal ions and/or Aβ40. 
 
 
Figure 3.10. Transformation of benzoquinone (BQ) in the presence of Aβ40. (a) UV-vis spectrum of BQ 
under aerobic conditions. (b) UV-vis spectrum of BQ with Aβ40 under aerobic conditions. Blue, red, and 
green lines correspond to incubation periods of 0, 4, 24 h, respectively. Conditions: Aβ40 (25 μM); BQ 
(50 μM); HEPES buffer (1 mM, pH 7.4); room temperature, no agitation.  
 
In order to gain a better understanding on the spectrophotometric observations indicative of the 
transformation of DMPD when Aβ is present (vide supra), additional studies were carried out. First, the 
UV-vis spectra of DMPD were measured in an anaerobic environment with or without Aβ to ascertain the 
involvement of dioxygen (O2) in the conversion of DMPD. Previous studies report that DMPD can be 
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singly or doubly oxidized to form a cationic radical or a cationic quinoid species, respectively.25-27 The 
spectral alterations of DMPD, apparent in an O2 atmosphere in both the absence and presence of Aβ40, 
were not observed in an anaerobic condition even after 24 h incubation (Figure 3.8c). In addition, 
modulation of Aβ aggregation by DMPD was not observed under the anaerobic condition, distinguishable 
from that under the aerobic setting (Figure 3.2c, left). Furthermore, inhibition and disaggregation 
experiments of BQ with Aβ40 and Aβ42 were performed in the absence and presence of metal ions (Figure 
3.11). BQ exhibited an ability to control and alter the MW distribution of Aβ40 and Aβ42 with and without 
metal ions in a very similar manner to that which was observed for DMPD. Therefore, O2 is necessary for 
the transformation of DMPD (DMPDtransformed; e.g., BQ) and the capability of DMPDtransformed to redirect 
Aβ aggregation into less toxic, off-pathway amorphous Aβ aggregates. 
 
 
Figure 3.11. Effects of BQ on metal-free and metal-induced Aβ40 and Aβ42 aggregation. (a) Scheme of 
(I) inhibition and (II) disaggregation experiments. (b & c) Analyses of the resultant Aβ species [(b) Aβ40 
and (c) Aβ42] from I and II by gel/Western blot using an anti-Aβ antibody (6E10). Conditions: Aβ (25 
μM); CuCl2 or ZnCl2 (25 μM); BQ (50 μM); 24 h; pH 6.6 (for Cu(II) experiments) or pH 7.4 (for metal-
free and Zn(II) experiments); 37 °C; constant agitation.  
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(iv) Analysis of Aβ–DMPDtransformed Complexes 
MS analysis of DMPD-treated Aβ40 samples was further performed in order to identify the formation 
of Aβ40–ligand complexes. New peaks appeared corresponding to the addition of 103.93 ± 0.04 Da to Aβ 
(Figure 3.12a, i) proposed to be a covalently bound conversion product of DMPD (e.g., BQ; shown as 5 
in Figure 3.12d). To support our proposed mode of Aβ–DMPD interaction, via the transformation of 
DMPD, the interactions of Aβ40 with the structurally homologous BQ were examined under identical 
experimental conditions. Our data indicates that BQ binds to Aβ40 (Figure 3.12b), with a mass shift that is 
consistent with DMPD incubations (104.1 ± 0.1 Da). 
 
 
Figure 3.12. Analysis of the resulting species upon interaction of Aβ40 with DMPD or BQ by mass 
spectrometry (MS) and ion mobility–mass spectrometry (IM–MS), as well as a proposed mechanism. (a) 
MS analysis showing the complex formation of Aβ40 (25 μM) with DMPDtransformed (50 μM) (red lines) in 
the 4+ and 5+ charge states ([Aβ + DMPDtransformed]4+ and [Aβ + DMPDtransformed]5+) (i). IM–MS was 
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applied to the 4+ charge state to resolve the conformational rearrangement of Aβ40 upon addition and 
conversion of DMPD to DMPDtransformed (ii). Extracted arrival time distributions support the existence of 
two resolvable structural populations [collision cross section (CCS) data, inset tables]. The interaction 
with DMPDtransformed trapped the peptide in a more packed conformation (dominant peak = 1) when 
compared to the apo form (dominant peak = 2). (b) MS analysis showing the complex formation of Aβ40 
(25 μM) with BQ (50 μM) supports that BQ binds readily to the peptide (red) (i). In line with the DMPD 
data presented above, BQ-containing samples support a mass gain of 104 Da attributed to covalent 
binding with K16 (Figure 3.11). IM–MS was applied to the 4+ charge state to resolve the conformational 
rearrangement of Aβ40 upon binding BQ. Extracted arrival time distributions indicate the existence of 
three resolvable structural populations (CCS data, inset table) (ii). The first two of these conformations 
support, within least square error analysis, CCS values consistent with the DMPD-bound data (Figure 
3.12a). (c) Comparison of tandem MS/MS sequencing using the quadrupole isolated 5+ charge state (trap 
collision energy 90 V) of Aβ405+ (top) and [Aβ + DMPDtransformed]5+ (bottom). Analysis of these data in 
addition to the MS and IM–MS support the attachment of DMPDtransformed to Aβ40 through a covalent 
modification of the peptide via K16 resulting in an observed mass shift of 103.93 ± 0.04 Da calculated 
from internal monoisotopic calibration data sets. (d) Proposed mechanistic pathways between DMPD and 
Aβ. DMPD may undergo an oxidative transformation under aerobic conditions to generate a cationic 
imine (CI)–Aβ complex (1). CI could then generate BQI (shown in 2) through hydrolysis. Once 
hydrolyzed, BQI is proposed to undergo further hydrolytic conversion to generate BQ (shown in 3). Our 
MS studies support that BQ forms covalently bound protein-ligand adducts (4) that are capable of 
forming intramolecular crosslinks (5) that trap Aβ in an altered conformational geometry compatible with 
our IM–MS dataset. 
 
 
Figure 3.13. MS/MS sequencing of the samples containing BQ and Aβ40. Complimenting DMPD 
analysis (Figure 3.12), studies were performed on incubated samples of Aβ40 with BQ. Consistent with 
[Aβ40 + DMPD] analyses, an adduct of 104.1 ± 0.1 Da was identified to be covalently linked to K16.  
 
Tandem MS (MS/MS) in conjunction with collision induced dissociation (CID) for the 5+ ligand 
bound charge state was carried out to determine the nature of the  Aβ40–DMPDtransformed (Figure 3.12c) 
and Aβ40–BQ complexes detected (Figure 3.13). MS/MS data supports that both DMPDtransformed and BQ 
covalently link to Aβ40 via K16, with observed masses consistent with the above analysis. Whilst this 
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ligated mass difference is too small to support a single covalent bond formation between Aβ and 
DMPDtransformed/BQ (106.1 Da expected due to the release of two protons upon the formation of an Aβ–
DMPDtransformed covalent bond), it does agree well with the generation of a second covalent bond between 
Aβ and DMPDtransformed/BQ (104.1 Da expected from the concomitant loss of two additional protons 
upon the formation of the second covalent bond). This data therefore supports that DMPDtransformed/BQ is 
capable of crosslinking Aβ, and is consistent with the data previously published for α-synuclein.24 Based 
on this conclusion, we sought to confirm if DMPDtransformed/BQ is capable of forming inter- and/or 
intramolecular crosslinks using MS/MS. BQ-bound Aβ40 dimer dissociation data indicates that BQ 
primarily forms intramolecular crosslinks (Figure 3.14). 
 
 
Figure 3.14. MS studies of the BQ-bound Aβ dimer. (a) MS/MS analysis used to identify if BQ was 
capable of forming intermolecular crosslinks in Aβ dimers (M: Aβ monomer; D: Aβ dimer). Upon 
quadrupole isolation of the BQ-bound 5+ Aβ40 dimer ion (b), it was subjected to collisional activation and 
subsequent fragmentation (c). These results support that BQ forms intramolecular crosslinks, with masses 
corresponding to intact monomeric apo and BQ-bound peptides suggesting these conclusions. 
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In addition, IM–MS studies of the 4+ charge state were carried out in order to assess the Aβ-bound 
state conformers adopted. When compared to the Aβ control, Aβ–DMPDtransformed complexes possessed a 
significantly decreased ion mobility (IM) arrival time, indicative of a more compact Aβ40 structure 
(Figure 3.12a, ii). Consistent with this data, Aβ40–BQ binding also leads to a similar reduction in IM 
arrival time, again supporting the production of a more compact species than the form adopted by the 
compound-untreated Aβ (Figure 3.12b, ii). Combining this data with observations from our MS/MS 
analysis, we conclude that the DMPDtransformed/BQ crosslinking traps Aβ in a relatively compact 
conformational state that is likely off-pathway with respect to amyloid fibril formation. 
 
(v) Proposed Mechanism 
Based on these optical and MS results, the covalent bond formation within Aβ–DMPDtransformed 
complexes could occur via a possible mechanistic pathway, as described in Figure 3.12d. In the presence 
of Aβ, under aerobic conditions, DMPD could first undergo a two-electron oxidative transformation to 
generate a cationic imine (CI)–Aβ complex (1). CI could be converted via hydrolysis to BQI (shown in 
2) that could further hydrolyze its imine to generate BQ (shown in 3). BQ is then capable of forming a 
covalently bound Aβ–BQ adduct through interactions with a primary amine containing residue (4; Aβ + 
106.1 Da), such as K16, that further crosslinks to an additional residue with a similar functional group (5; 
Aβ + 104.1 Da), consistent with our MS studies and BQ–protein conjugates previously reported.37-41 The 
covalent complexation of Aβ with BQ could direct the structural compaction, suggested from IM–MS 
analysis (Figure 3.12a,b), and could account for DMPD’s redirection of peptide aggregation pathways 
into amorphous Aβ aggregates,16,20,21 as found in the gel/Western blot and TEM studies (vide supra). 
 
3.2.4. Attenuation of Metal-Free Aβ-/Metal–Aβ-Induced Toxicity in Living Cells by DMPD 
The regulation of Aβ-/metal–Aβ-triggered cytotoxicity by DMPD was examined using human 
neuroblastoma SK-N-BE(2)-M17 (M17) cells. DMPD was incubated for 24 h with M17 cells pretreated 
with Aβ40 in both the absence and presence of Cu(II) or Zn(II). Viability was increased by ca. 10–20% 
when DMPD was introduced to metal-free Aβ40- or metal–Aβ40-treated M17 cells, relative to the 
untreated cells (Figure 3.15), as measured by the MTT assay. Note that DMPD displayed low toxicity in 
the range of the tested concentrations (0–100 or 0–50 μM in the absence and presence of metal ions, 
respectively; > 80% cell survival; Figure 3.15a-c). Thus, DMPD could ameliorate cytotoxicity induced by 
metal-free Aβ and metal–Aβ.  
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Figure 3.15. Cytotoxicity of DMPD in the absence and presence of metal ions, and its effect toward 
metal-free/metal-treated Aβ40-triggered cytotoxicity. The cytotoxicity of (a) DMPD only (2.5-100 μM; 
1% v/v DMSO); DMPD (2.5-50 μM) with (b) CuCl2 or (c) ZnCl2 in a ratio of 1:1 using the human 
neuroblastoma SK-N-BE(2)-M17 (M17) cells. (d) Viability (%) of M17 cells incubated with Aβ40 (10 
μM), CuCl2 or ZnCl2 (10 μM), and/or DMPD (20 μM) for 24 h. Cell viability, determined in M17 cells 
by the MTT assay, was calculated in comparison to that treated with DMSO only (1% v/v). Error bars 
represent standard error from three independent experiments.  
 
 
Figure 3.16. Monitoring changes in body weight. No significant difference in body weight was observed 
between the vehicle- and DMPD-treated 5×FAD mice. Body weights of male (squares; n = 6 for each 
treatment) or female (circles; n = 5 for each treatment) 5×FAD mice were measured for 30 days 
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immediately before the daily injection of vehicle (black) or DMPD (1 mg/kg/day, i.p.; gray), starting 
from 3 months of age. All values represent mean + SEM. 
 
 
Figure 3.17. Reduction of cerebral amyloid pathology by DMPD in the 5×FAD mice. After the total 30 
daily i.p. injections of vehicle or DMPD (1 mg/kg/day), the brain tissues were collected from the 5×FAD 
mice at 4 months of age. (a) Bars denote the amounts of SDS-soluble, FA-soluble, or total (PBS plus SDS 
plus FA) Aβ40/Aβ42 peptides in the whole brains, which were calculated from three independent sandwich 
Aβ ELISA assays (n = 14–17). (b) Representative microscopic images of 4G8-immuno 
stained (brown) or Congo red stained (red) brain sections of 5×FAD mice show that DMPD significantly 
reduced the burden of amyloid deposits in the brain. Ctx, cortex; Hip, hippocampus. Scale bar = 100 μm. 
(c) The load of 4G8-immunoreactive amyloid deposits and the total number of congophilic amyloid 
plaques in the microscopic photographs of the identical cortical areas (b) were measured in five brain 
sections taken from each animal. All values represent mean ± SEM (n = 7). *P < 0.05, **P < 0.01, or 
***P < 0.001 by unpaired two-tail t-test. 
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3.2.5. In Vivo Efficacy of DMPD Against Amyloid Pathology and Cognitive Impairment 
In order to validate the beneficial effects of DMPD on AD pathogenesis in vivo, we administered the 
compound to male 5×FAD mice via the intraperitoneal route at 1 mg/kg/day for 30 days from 3 months of 
age. After 30 total daily treatments of DMPD, the mice were subjected to biochemical analysis for 
cerebral amounts of Aβ40/Aβ42 and histopathological evaluations of the amyloid deposition load. 5×FAD 
mice were selected for this study since they develop early and severe phenotypes of AD and behavioral 
dysfunction.29 At the conclusion of the compound treatment period, there was no significant difference in 
gross appearance or body weight between the vehicle- and DMPD-treated 5×FAD mice (Figure 3.16). 
Quantification of cerebral Aβ peptides by the enzyme-linked immunosorbent assay (ELISA) revealed 
that the total levels of Aβ40/Aβ42 containing PBS-, sodium dodecyl sulfate (SDS)-, and formic acid (FA)-
soluble Aβ species which represent soluble, moderately soluble, and completely insoluble Aβ species, 
respectively, were decreased by ca. 66% and 46%, respectively, compared to the vehicle-treated 5×FAD 
mice (Figure 3.17a). The levels of SDS-soluble Aβ40/Aβ42 were more drastically reduced by DMPD (ca. 
69% and 61%, respectively) than those of FA-soluble Aβ40/Aβ42 levels (ca. 52% and 37%, respectively). 
Furthermore, substantial reductions in amyloid deposits were detected in 5×FAD mice treated with 
DMPD, determined by analyzing the loads of amyloid precursor protein (APP)/Aβ-immunoreactive 4G8- 
and Congo red-stained compact amyloid plaques (by ca. 23% and 20%, respectively) (Figure 3.17b,c). 
Overall, these results indicate that DMPD is able to delay or reverse the amyloid pathogenesis in the brain 
of AD model mice. 
To evaluate the capacity of DMPD to improve cognitive deficits in AD model mice, we tested 4-
month-old 5×FAD mice employing the Morris water maze (MWM) test for spatial learning and memory 
during the final five consecutive days of compound treatment. As demonstrated previously,22,29 the 
5×FAD mice exhibited impaired spatial learning, showing enhanced difficulty in locating the hidden 
escape platform in a pool of water compared to their littermate, wild-type mice (Figure 3.18a). In contrast, 
the repetitive administration of DMPD prominently improved the learning and memory capability in the 
5×FAD mice, relative to those of the vehicle-treated wild-type mice (Figure 3.18a).  
Three hours after the final MWM test, we performed the probe trials, where the escape platform was 
removed and the mice located its previous position in the water for 60 sec, representing their performance 
of long-term memory retention. DMPD-treated animals took distinguishably less time to reach the 
platform area and spent significantly more time in the target quadrant (North West, NW), where the 
platform had been hidden, than vehicle-treated 5×FAD mice (Figure 3.18b,c). Therefore, our behavioral 
analysis suggests that DMPD is capable of rescuing cognitive defects in 5×FAD mice. 
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Figure 3.18. Cognitive enhancement by DMPD in the 5×FAD AD mouse model. Using the Morris water 
maze task, spatial learning and memory activities were compared in the 5×FAD and their littermate wild-
type mice after thirty consecutive vehicle or DMPD (1 mg/kg/day, i.p.) treatments. (a) The escape latency 
time was daily measured for the final five days of the drug treatment. (b) The probe trials were performed 
on the day of the final treatment to assess the time when the mice spent to reach the escape platform. (c) 
Upper circular images display the representative swimming paths for the mice to locate the escape 
platform in the water maze for 60 sec. Lower graphs show the time how long they spent in the target 
quadrant (NW, highlighted in gray). The statistical comparisons were performed between 5×FAD and 
their wild-type littermate mice with vehicle (pound), or between consecutive vehicle and DMPD 
treatments in 5×FAD mice (asterisk), according to the one-way ANOVA followed by a Student-Neuman-
Keuls post hoc test. *P < 0.05, **,##P < 0.01 or **,###P < 0.001 (n = 17 for wild-type mice or n =14 for 
vehicle- or DMPD-treated 5xFAD mice). 
 
3.3. Conclusions 
AD continues to present a major socioeconomic burden to our society. The absence of treatments and 
reliable diagnostics for this disease has demanded significant efforts to be made toward the identification 
of its underlying origins. For this aspect, the development of chemical tools capable of discerning and/or 
regulating pathognomonic factors of interest has been critical for the establishment of our current 
understanding of AD and will prove to be a central resource as we continue to unravel the intricacies of 
the disorder. 
For instance, the use of small molecular tools (i.e., oligomer stabilizers) able to specifically interact 
with and conformationally modulate small, soluble Aβ has been important for establishing oligomers as 
pathological factors.4 The adverse effects of metal ion dyshomeostasis and miscompartmentalization in 
AD have been validated by utilizing ionophores [e.g., clioquinol (CQ), PBT2] that bind and chauffeur 
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metal ions [i.e., Cu(II), Zn(II)] from extracellular Aβ plaques across the plasma membrane where it 
induces a signaling pathway, ultimately activating matrix metalloproteinases, among other enzymes, 
which assists in the breakdown and clearance of metal-free and metal-bound Aβ plaques.4,42,43 
Furthermore, a metal–Aβ specific tool, L2-b, has been designed to provide direct, in vivo evidence of the 
potential role of metal-bound Aβ species in AD pathogenesis.19,22 Upon administration, L2-b, targeted 
and modulated metal–Aβ species in the brains of 5×FAD mice, significantly reduced the overall amyloid 
deposits, as well as mitigated cognitive dysfunction thus indicating metal–Aβ as a pathological factor of 
AD.22 Chemical tools have also been utilized to address the challenges associated with determining the 
interconnections between multiple facets of AD.4,16,21 A multifunctional ligand (ML) was designed to 
elucidate some of these pathological factors (e.g., metal-free and metal–Aβ aggregation, oxidative stress) 
associated with neuronal death in AD.21 ML was shown to exhibit an advantageous control and 
promotion of protein aggregates toward off-pathway, unstructured species in the absence and presence of 
metal ions; control the generation of ROS by limiting the redox cycling of the copper center; decrease 
toxicity in living cells.21 Collectively, these results not only identify the vital value of chemical tools to 
elaborate our comprehension of the disorder, but also assist in the further identification of novel pathways 
to investigate. 
In the current study, a compact chemical tool, DMPD, is presented for the redirection of Aβ 
aggregation in the absence and presence of metal ions into nontoxic, off-pathway aggregates through a 
novel approach (i.e., intramolecular crosslinks with aggregation-prone peptides upon transformation of a 
redox-active small molecule). DMPD’s reactivity could be related to its interactions with metal-free 
Aβ and metal–Aβ, along with its redox characteristics, as indicated through multiple biophysical 
approaches. Mechanistically, DMPD is observed through optical and MS analyses to modulate peptide 
aggregation pathways through its oxidation and successive hydrolytic transformations to generate more 
structurally compact quinoid-peptide adducts, compared to the compound-untreated Aβ, through 
intramolecular covalent crosslinking (i.e., Aβ–BQ). Moreover, the site-specific covalent modification of 
Aβ via primary amine-containing residues, such as K16, a critical residue for the formation of cross β 
sheet structures within the self-recognition sequence of the peptide,1-4,8-11 could further illuminate 
DMPD’s reactivity in vitro. DMPD was also evaluated in living cells and in vivo to determine the 
efficacy and beneficial effects associated with its administration in biological settings. Particularly, the 
ELISA quantification of the cerebral amyloid content of DMPD-treated 5×FAD mice showed a 
significant reduction in SDS-soluble forms of Aβ40 and Aβ42 (ca. 60–70% reductions) which are 
indicative of toxic, soluble pools of Aβ peptides.44-46 When evaluated by FA-soluble Aβ40/Aβ42 levels and 
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amyloid plaque loads,46 the nontoxic, amyloid deposits/aggregates were relatively less influenced by 
DMPD (ca. 20–50% reductions). Therefore, these in vivo analyses also support that DMPD could 
preferentially influence on the toxic soluble forms of Aβ peptides with the less reactivity toward the 
insoluble amyloid aggregates or deposits. In addition, memory and learning capabilities of 5×FAD mice 
were restored upon DMPD treatment as evaluated by the Morris water maze task. Still, further 
investigations to address remaining questions, such as the specificity of DMPD to generate protein 
crosslinks and the location and time of DMPD’s transformation in vivo are warranted. 
Taken together, the findings of DMPD’s reactivity with the amyloidogenic peptide, Aβ, presented in 
this work, demonstrate novel, pivotal principles that can be applied toward amyloid aggregation control 
and the establishment of further chemical tools: (i) formation of intramolecular crosslinks between small 
molecules and peptides may be an effective method to control the self-assembly of amyloidogenic 
peptides; (ii) effective strategies can still be developed without the need to build up chemical complexity, 
shown presently within the field. 
 
3.4. Experimental Section 
 
3.4.1. Materials and Methods. 
All reagents were purchased from commercial suppliers and used as received unless otherwise stated. 
N,N-Dimethyl-p-phenylenediamine (DMPD) was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Aβ40 and Aβ42 were purchased from AnaSpec (Fremont, CA, USA) (Aβ42 = DAEFRHDSGYEVHHQKL-
VFFAEDVGSNKGAIIGLMVGGV-VIA). An Agilent 8453 UV-visible (UV-vis) spectrophotometer 
(Santa Clara, CA, USA) was used to measure optical spectra. Anaerobic reactions were performed in an 
N2-filled glove box (Korea Kiyon, Bucheon-si, Gyeonggi-do, Korea). Transmission electron microscopic 
(TEM) images were taken using a Philips CM-100 transmission electron microscope (Microscopy and 
Image Analysis Laboratory, University of Michigan, Ann Arbor, MI, USA) or a JEOL JEM-2100 
transmission electron microscope (UNIST Central Research Facilities, Ulsan National Institute of Science 
and Technology, Ulsan, Republic of Korea). Absorbance values for cell viability assay were measured on 
a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA). All ion mobility–mass 
spectrometry (IM–MS) experiments were carried out on a Synapt G2 (Waters, Milford, MA, USA). NMR 
studies of Aβ with DMPD were conducted on a 900 MHz Bruker spectrometer equipped with a TCI 
triple-resonance inverse detection CryoProbe (Michigan State University, Lansing, MI, USA). 
 
3.4.2. Aβ  Aggregation Experiments 
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Experiments with Aβ were conducted according to previously published methods.18-22 Aβ40 or Aβ42 
was dissolved in ammonium hydroxide (NH4OH, 1% v/v aq), aliquoted, lyophilized overnight, and stored 
at –80 °C. For experiments described herein, a stock solution of Aβ was prepared by dissolving 
lyophilized peptide in 1% NH4OH (10 μL) and diluting with ddH2O. The concentration of Aβ peptides in 
the solution was determined by measuring the absorbance of the solution at 280 nm (ε = 1450 M–1cm–1 
for Aβ40; ε = 1490 M–1cm–1 for Aβ42). The peptide stock solution was diluted to a final concentration of 
25 μM in Chelex-treated buffered solution containing HEPES [4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (20 μM); pH 6.6 for Cu(II) samples; pH 7.4 for metal-free and Zn(II) 
samples] and NaCl (150 μM). For the inhibition studies, DMPD [50 μM; 1% v/v dimethyl sulfoxide 
(DMSO)] was added to the samples of Aβ (25 μM) in the absence and presence of a metal chloride salt 
(CuCl2 or ZnCl2, 25 μM) followed by incubation at 37 °C with constant agitation for 24 h. For the 
disaggregation studies, Aβ with and without metal ions was incubated for 24 h at 37 °C with constant 
agitation prior to the treatment with a compound (50 μM). The resulting Aβ aggregates were incubated 
with DMPD for 24 h at 37 °C with constant agitation. 
 
3.4.3. Gel Electrophoresis and Western Blot 
The samples from the inhibition and disaggregation experiments were analyzed by gel electrophoresis 
with Western blotting using an anti-Aβ antibody (6E10).18-22 Each sample (10 μL) was separated on a 10–
20% Tris-tricine gel (Invitrogen, Grand Island, NY, USA) and the protein samples were transferred onto 
nitrocellulose membrane which was blocked with bovine serum albumin (BSA, 3% w/v, Sigma-Aldrich, 
St. Louis, MO, USA) in Tris-buffered saline containing 0.1% Tween-20 (TBS-T; 1.0 mM Tris base, pH 
8.0, 1.5 mM NaCl) for 2 h at room temperature. The membranes were incubated with a primary antibody 
(6E10, Covance, Princeton, NJ, USA; 1:2000) in a solution of 2% w/v BSA (in TBS-T) overnight at 4 °C. 
After washing with TBS-T (3x, 10 min), the horseradish peroxidase-conjugated goat antimouse secondary 
antibody (1:5000; Cayman Chemical Company, Ann Arbor, MI, USA) in 2% w/v BSA (in TBS-T) was 
added for 1 h at room temperature. SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific, Rockford, IL, USA) was used to visualize protein bands. 
 
3.4.4. Transmission Electron Microscopy (TEM) 
Samples for TEM were prepared according to previously reported methods.18-22 Glow-discharged 
grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) were treated with 
Aβ samples from the inhibition and disaggregation experiments (5 μL) for 2 min at room temperature. 
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Excess buffer was removed by blotting carefully with filter paper then washed twice with ddH2O. Each 
grid was incubated with uranyl acetate staining solution (1% w/v ddH2O, 5 μL) for 1 min. Excess stain 
was blotted off and the grids were air dried at room temperature for at least 20 min. Images from each 
sample were taken on a Philips CM-100 (80 kV) or a JEOL JEM-2100 TEM (200 kV) at 25,000x 
magnification. 
 
3.4.5. Computational Procedure 
A multistep computational strategy was utilized to explore Aβ40–DMPD interactions. In the first step, 
100 ns MD simulations in an aqueous solution were conducted to obtain the equilibrated structure of the 
Aβ40 monomer. These simulations were performed using the GROMACS program (version 4.0.5)47 and 
GROMOS96 53A6 force field.48 The starting structure of the Aβ40 monomer was extracted from the NMR 
structures determined in aqueous SDS micelles at pH 5.1 (model 2, PDB 1BA4).49 The root-mean-square 
deviations (RMSD) indicated that the system reached the equilibration during the time frame of the 
simulations. In the next step, to include the flexibility of the Aβ40 monomer into the docking procedure, 
100 snapshots were taken at 1 ns interval throughout the simulation. These snapshots were used for the 
rigid docking of the DMPD molecule using the AutoDock Vina 1.1.2 software.50  In this procedure, the 
receptor was kept fixed, but the ligand was allowed to change its conformation. The DMPD molecule was 
built using the GaussView program (B3LYP/Lanl3DZ)51,52 and optimized at the level of theory using the 
Gaussian03 program.53 In the docking procedure, the size of the grid was chosen to occupy the whole 
receptor–ligand complex. Each docking trial produced 20 poses with an exhaustiveness value of 20. The 
docking procedure provided 2000 poses. Based on binding energies and the composition of interacting 
sites, 20 distinct poses were selected for short-term (5 ns) MD simulations in an aqueous solution. From 
these 20 different simulations, 5 structures were derived and further 20 ns simulations were performed 
using the same program and force field. These simulations provided a binding site that includes L17, F19, 
and G38 residues of the Aβ40 monomer. The tools available in the GROMACS program package and the 
YASARA software (v. 13.2.2)54 were utilized for analyzing trajectories and simulated structures. 
For all simulations, the starting structures were placed in a truncated cubic box with dimensions of 
7.0 × 7.0 × 7.0 nm. This dismissed unwanted effects that may arise from the applied periodic boundary 
conditions (PBC). The box was filled with single point charge (SPC) water molecules. Few water 
molecules were replaced by sodium and chloride ions to neutralize the system. The starting structures 
were subsequently energy-minimized with a steepest descent method for 3000 steps. The results of these 
minimizations produced the starting structure for the MD simulations. The MD simulations were then 
carried out with a constant number of particles (N), pressure (P), and temperature (T) [i.e., NPT 
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ensemble]. The SETTLE algorithm was used to constrain the bond length and angle of the water 
molecules,55 while the LINCS algorithm was used to constrain the bond length of the peptide.56 The 
Particle-Mesh Ewald (PME) method was implemented to treat the long-range electrostatic interactions.57 
A constant pressure of 1 bar was applied with a coupling constant of 1.0 ps. The peptide, water molecules, 
and ions were coupled separately to a bath at 300 K with a coupling constant of 0.1 ps. The equation of 
motion was integrated at each 2 fs time steps using leap-frog algorithm.58 
 
3.4.6. 2D Band-Selective Optimized Flip-Angle Short Transient (SOFAST)–Heteronuclear Multiple 
Quantum Correlation (HMQC) NMR Spectroscopy 
NMR titration experiments were performed following a previously reported method.20,21,31 NMR 
samples were prepared with 15N-labeled Aβ40 (rPeptide, Bogart, GA, USA) which was lyophilized in 1% 
NH4OH by resuspending the peptide in 100 μL of 1 mM NaOH (pH 10). The peptide was then diluted 
with 200 mM phosphate buffer (pH 7.4), 1 M NaCl, D2O, and water to yield a final peptide concentration 
of 80 μM. Each spectrum was obtained using 256 complex t1 points and a 1 sec recycle delay at 4 °C. The 
2D data were processed using TopSpin 2.1 (Bruker, Billerica, MA, USA). Resonance assignments were 
carried out by computer-aided resonance assignment (CARA) using published assignments for Aβ as a 
guide.59,60 Compiled chemical shift perturbation (CSP) was calculated using the following equation: 
 
 
 
3.4.7. Cu K-edge X-ray Absorption Spectroscopy 
Aβ42 was monomerized as previously described.61,62 Aβ42 fibrils were grown according to established 
protocols.63 Following monomerization or fibrillization, all samples were handled under an anaerobic 
atmosphere (N2) in a COY anaerobic chamber (COY Laboratory, Grass Lake, MI, USA). Aβ42 was 
dissolved in a 4:1 mixture of 10 mM N-ethylmorpholine buffer (pH 7.4) and glycerol (glycerol is used as 
a deicing agent) followed by addition of one equivalent of CuCl2. Aβ42 monomers were maintained at 5 
°C and all procedures performed rapidly to avoid aggregation. Following the addition of CuCl2, 2 equiv of 
ascorbate was treated with the resulting samples to reduce the Cu(II)-loaded Aβ42 peptides to Cu(I). 
DMPD (2 equiv; in DMSO) was then introduced to each solution. Final Aβ42 concentrations were 250 
μM. DMPD was incubated with the copper-loaded fibrils for 24 h. To avoid aggregation [confirmed by 
gel permeation chromatography studies];61,62 copper-loaded Aβ42 monomers were incubated for 15 min. 
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Following incubation with DMPD, the solutions were injected into Lucite sample holders with 
Kapton tape windows and quickly frozen in liquid nitrogen. All data were recorded on beamline X-3b at 
the National Synchrotron Light Source (Brookhaven National Laboratories, Upton, NY, USA). Samples 
were maintained at ~18 K throughout data collection by means of a He Displex cryostat. Energy 
monochromatization was accomplished with a Si(111) double crystal monochromator and a low angle Ni 
mirror was used for harmonic rejection. Data were collected as fluorescence spectra using a Canberra 31 
element Ge solid-state detector with a 3 micron Ni filter placed between the sample and detector, and 
calibrated against a simultaneously collected spectrum of Cu-foil (first inflection point 8980.3 eV). Count 
rates were between 15–30 kHz, and deadtime corrections yielded no improvement to the quality of the 
spectra. Data were collected in 5 eV steps from 20–200 eV below the edge (averaged over 1 sec), 0.5 eV 
steps from 20 eV below the edge to 30 eV above the edge (averaged over 3 sec), 2 eV steps from 30–300 
eV above the edge (averaged over 5 sec), and 5 eV steps from 300 eV above the edge to 13 k (averaged 
over 5 sec). Each data set represents the average of 16 individual spectra. Known glitches were removed 
from the averaged spectra. The X-ray beam was repositioned every 4 scans, and no appreciable 
photodamage/photoreduction was noted. Data were analyzed as previously reported using the software 
packages EXAFS123 and FEFF 7.02. Errors are reported as ε2 values.64,65  
 
3.4.8. Mass Spectrometric Studies 
All ion mobility–mass spectrometry (IM–MS) experiments were carried out on a Synapt G2 (Waters, 
Milford, MA, USA). Samples were ionized using a nano-electrospray source operated in positive ion 
mode. MS instrumentation was operated at a backing pressure of 2.7 mbar and a sample cone voltage of 
40 V. Data were analyzed using MassLynx 4.1 and DriftScope 2.0 (Waters, Milford, MA, USA). The m/z 
scale was calibrated using 20 mg/ml aqueous cesium iodide. Accurate mass values for covalently bound 
ligands were calculated using the monoisotopic peak difference between apo and ligand bound states. 
Collision cross-section (CCS) measurements were calibrated externally using a database of known 
protein, and protein complex CCS values in helium66,67 with errors reported as the least square analysis 
output for all measurements. This least square analysis combines inherent calibrant error from drift tube 
measurements (3%), the calibration R2 error and two times the replicate standard deviation error. 
Lyophilized Aβ40 (AnaSpec, Fremont, CA, USA) was prepared at a concentration of 25 μM in 1 mM 
ammonium acetate (pH 7.0). Aliquots of Aβ40 were then incubated with or without 50 μM DMPD or BQ 
(1% v/v DMSO) for 24 h at 25 °C without constant agitation. After incubation, all samples were 
lyophilized overnight prior to re-suspension of the samples in hexafluoro-2-propanol (HFIP, Sigma-
Aldrich, St Louis, MO, USA) ([Aβ40] = 50 μM) and sonicated under pulse settings for 5 min. Samples 
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were diluted 50%, to a final Aβ40 concentration of 25 μM, using 1 mM ammonium acetate (0.5 mM final 
concentration) immediately prior to mass analysis. 
 
3.4.9. Animals and Drug Administration 
Animal studies using the 5×FAD mouse model of AD were performed in accordance with the 
Guidelines for Laboratory Animal Care and Use of the Asan Institute for Life Sciences, Asan Medical 
Center (Seoul, Korea). 5×FAD transgenic mice overexpressing mutant human APP695 [K670N/M671L 
(Swedish), I716V (Florida), and V717I (London)] and PSEN1 (M146L and L286V) are characterized by 
early development of pathological marks of AD, such as Aβ deposits, neurodegeneration, and behavioral 
disabilities.29 5×FAD mice were produced and maintained on a B6/SJL hybrid background with free 
access to chow and drinking water under a 12 h light/dark cycle. 
In this study, female and male 5×FAD mice were daily administered with freshly prepared vehicle 
(1% v/v DMSO in 20 mM HEPES, pH 7.4, 150 mM NaCl) or DMPD (1 mg/kg of body weight) by 
intraperitoneal injection for 30 days using Ultra-FineTM II insulin syringes (Becton Dickinson, Franklin 
Lakes, NJ, USA), starting from three months of age. The animals were weighed immediately before the 
injection. After the final injection and behavioral assessment, the mice were sacrificed under deep 
anesthesia. A necropsy was performed to evaluate the drug-induced systemic damage. 
 
3.4.10. Tissue Preparation  
The right cerebral hemispheres were snap-frozen with liquid nitrogen for biochemical analyses. 12-
μm-thick sagittal sections were collected from the left hemispheres using a cryostat (HM550; Microm, 
Walldorf, Germany) and mounted onto 1% poly-L-lysine-coated glass slides for histological evaluations. 
 
3.4.11. Aβ40/Aβ42 Quantification 
The right hemispheres were subjected to sandwich ELISA assays for quantitative measurement of 
Aβ40 and Aβ42 in the whole brain according to previously described methods.22,68 Briefly, the protein 
homogenates were prepared in PBS (pH 7.4) containing Complete™ Protease Inhibitor cocktail (Roche 
Diagnostics, Mannheim, Germany), in 2% SDS (aq), and then in 70% formic acid (FA) by serial 
centrifugations. The EC buffer-diluted protein fractions were measured using the human Aβ40/Aβ42 
ELISA kit (Invitrogen), where FA-fractions were neutralized with 1 M Tris (pH 11.0). The colorimetric 
quantifications were determined at 450 nm with the Synergy H1 Hybrid microplate reader (BioTek, 
Winooski, VT, USA), and the cerebral Aβ40/Aβ42 levels were calculated as moles per gram of wet brain 
tissue. 
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3.4.12. Quantification of Aβ  Plaques 
In order to examine the extracellular Aβ deposits, immunohistochemistry was conducted on the brain 
sections using an anti-human Aβ4(17-24) antibody (4G8, 1:1000; Covance, Princeton, NJ, USA). After 
immunological reactions with 4G8 and biotinylated anti-mouse secondary antibody (Vector Laboratories, 
Burlingame, CA, USA), the tissue sections were developed with 0.015% diaminobenzidine and 0.001% 
H2O2 (in PBS; Vector Laboratories) and examined under a light microscope (Eclipse 80i; Nikon, Tokyo, 
Japan). In addition, the congophillic amyloid plaques were detected by staining the tissues with 
Accustain® Congo Red amyloid staining solution (Sigma-Aldrich, St. Louis, MO, USA). The loads of 
amyloid deposits in the cortex were given as the percent area of 4G8-immunoreactive deposits or the total 
number of congophilic plaques in the randomly selected cortex areas. 
 
3.4.13. Behavioral Evaluation 
Spatial learning and memory performance was tested using the Morris water maze (MWM) task.22 
The maze consisted of a circular water pool with a cylindrical platform (15 cm in diameter) hidden 0.5 cm 
under the surface of opaque water at the center of a target quadrant. The mice experienced three trials 
every day to swim and locate the hidden platform for a maximum of 60 sec, which were performed at 3 h 
after each drug injection over a period of five consecutive days starting on the day of the 26th drug-
injection. The time and swimming track spent to reach the platform were analyzed on SMART Video 
Tracking System (Harvard Apparatus, Holliston, MA, USA). Three hours after the final MWM task, the 
mice entered the water again to swim without the platform for 60 sec and the time spent in each quadrant 
area was recorded. 
 
3.4.14. Statistics 
All values are presented as the means ± standard errors of the mean (SEMs). Statistical analysis was 
performed using the unpaired t-test, or the one-way analysis of variance (ANOVA) followed by a 
Student-Neuman-Keuls post hoc test. Differences with P values < 0.05 were considered significant. 
 
3.4.15. Trolox Equivalent Antioxidant Capacity (TEAC) Assay 
The assay was performed according to previously reported methods with slight modifications.21 To 
generate turquoise ABTS cation radicals [ABTS•+; ABTS = 2,2'-azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid)] diammonium salt; Sigma-Aldrich, St Louis, MO, USA], ABTS (7.0 mM) with potassium 
persulfate (2.5 mM) was dissolved in 5 mL water and incubated for 16 h in the dark at room temperature. 
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The resulting solution of ABTS•+ was diluted with EtOH to obtain an absorbance of ca. 0.7 at 734 nm. 
ABTS•+ solution (200 μL) was added to the wells of a clear 96 well plate and incubated at 30 °C for 5 min 
in the plate reader. Various final concentrations of DMPD or Trolox (Trolox = 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid; dissolved in EtOH) were added and incubated with the ABTS•+ 
solution at 30 °C for 10 min. The percent inhibition was calculated according to the measured absorbance 
at 734 nm [% inhibition = 100 × (A0 − A)/A0] and was plotted as a function of ligand concentration. The 
TEAC value of compounds was calculated as a ratio of the slope of the compound to that of Trolox. The 
measurements were carried out in triplicate. 
 
3.4.16. Parallel Artificial Membrane Permeability Adapted for the Blood-Brain Barrier (PAMPA-
BBB) Assay. 
PAMPA-BBB experiments were carried out using the PAMPA Explorer kit (pION Inc., Billerica, 
MA, USA) with modification to previously reported protocols.19,21 Each stock solution was diluted with 
Prisma HT buffer (pH 7.4, pION) to a final concentration of 25 mM (1% v/v final DMSO concentration). 
The resulting solution was added to wells of the donor plate (200 μL, number of replicates = 12). BBB-1 
lipid formulation (5 μL, pION) was used to coat the polyvinylidene fluoride (PVDF, 0.45 μM) filter 
membrane on the acceptor plate. This acceptor plate was placed on top of the donor plate forming a 
sandwich. Brain sink buffer (BSB, 200 μL, pION) was added to each well of the acceptor plate. The 
sandwich was incubated for 4 h at ambient temperature without stirring. UV−vis spectra of the solutions 
in the reference, acceptor, and donor plates were measured using a microplate reader. The PAMPA 
Explorer software v. 3.5 (pION) was used to calculate −logPe for each compound. CNS+/− designations 
were assigned by comparison to compounds that were identified in previous reports.19,21 
 
3.4.17. Metabolic Stability Measurements 
From a stock solution of DMPD (500 mM), diluted solutions (final concentrations of 5 mM and 10 
mM; 150 μL) were prepared in phosphate buffered saline (PBS). For the assay, a buffer solution [50 mM 
phosphate buffer (pH 7.4), 1 mM EDTA (pH 8), and 3 mM MgCl2] and a solution of NADPH (10 mM in 
ddH2O) were prepared. To an eppendorf tube, buffer (1308.75 μL), 10 mM NADPH (37.5 μL), and 
DMPD (150 μL) were added. Then, human liver microsomes (3.75 μL) were treated and the resulting 
solution was briefly vortexed. Immediately, an aliquot of the resulting solution (150 μL) was thoroughly 
mixed with acetonitrile (CH3CN; 150 μL) in a plastic HPLC vial and then sealed. Aliquots were taken 
every 30 min for 4 h for analysis. Samples were analyzed by high performance liquid chromatography 
[for the sample containing DMPD (0.5 mM), stationary: 95% CH3CN and 5% H2O, mobile: 95% H2O, 
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5% CH3CN, and 0.1% formic acid; for the sample containing DMPD (1 mM), stationary: 95% CH3CN 
and 5% H2O, mobile: 95% H2O and 5% CH3CN]. The calculated concentrations from the aliquots were 
plotted against time (min). The line of best fit was calculated using the first-order kinetic equation {[A]t = 
[A]o x e-kt, where [A]o is the initial concentration of DMPD; t is time; k is the rate (dependent variable)}. 
The values of the rate (k) for DMPD (0.5 mM and 1.0 mM) were determined to be 6.5 nM/min and 15 
nM/min, respectively. When the concentration was doubled, the rate also doubled, in agreement with 
first-order kinetics. Using a plot of the inverse of substrate concentration against the inverse of the rate, 
the values of Vmax (maximum rate) and KM (binding constant) were calculated using the Lineweaver-Burk 
equation. 
 
3.4.18. Cell Viability Measurements 
The human neuroblastoma SK-N-BE(2)-M17 (M17) cell line was purchased from the American Type 
Culture Collection (ATCC, Manassas, VA, USA). The cell line was maintained in media containing 1:1 
Minimum Essential Media (MEM; GIBCO, Life Technologies, Grand Island, NY, USA) and Ham’s 
F12K Kaighn’s Modification Media (F12K; GIBCO), 10% (v/v) fetal bovine serum (FBS; Atlanta 
Biologicals, Flowery Branch, GA, USA), 100 U/mL penicillin (GIBCO), and 100 mg/mL streptomycin 
(GIBCO). The cells were grown and maintained at 37 °C in a humidified atmosphere with 5% CO2. M17 
cells were seeded in a 96-well plate (15,000 cells in 100 μL per well) according to previously reported 
methods.18-21 These cells were treated with various concentrations of DMPD (0–10 μM, 1% v/v DMSO) 
in the absence and presence of CuCl2 or ZnCl2 (1:1 metal/ligand ratio) with and without Aβ40 
(Aβ:metal:ligand = 10:10:20 μM). After 24 h incubation at 37 °C, 25 μL MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide; 5 mg/mL in phosphate buffered saline (PBS), pH 7.4, GIBCO] was 
added to each well and the plates were incubated for 4 h at 37 °C. Formazan produced by the cells was 
dissolved in a solution containing N,N-dimethylformamide (DMF, 50% v/v aq, pH 4.5) and sodium 
dodecyl sulfate (SDS, 20% w/v) overnight at room temperature. Absorbance at 600 nm was measured on 
a microplate reader. 
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Chapter 4. 
Tunable Divalent Metal Tetramethylcyclam Complexes: Hydrolytic  
Reactivities Toward Amyloidogenic Proteins and Mechanisms  
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4.1. Introduction  
A comprehensive understanding of the etiology of Alzheimer’s disease (AD), the most 
common form of dementia, is still elusive even after more than a century of research. The 
consequence of our inability to unravel the intricacies of AD pathology has directly impeded the 
design and development of effective strategies against the disorder.1-5 As a result, the numbers 
affected by AD have continued to rise.6 Such an increase in prevalence translates into billions of 
dollars annually to provide the necessary care and resources.6 Therefore, in order to reverse these 
trends, more significant efforts to decipher the disease etiology and modes of actions of existing 
preventative strategies must be made.1 
Since senile plaques predominately composed of amyloid-β (Aβ), an aggregation-prone 
peptide known to assemble into distinctive fibrillar structures, have been identified as a hallmark 
of AD, a wealth of data has accumulated implicating it as a key contributor to 
neurodegeneration.1-5,7-9 Unfortunately, a detailed molecular-level understanding has yet to be 
resolved. Current focus has been on the soluble oligomers that have been suggested to be 
relatively more toxic than the fibrils.1-5,7,8 Traditionally, small molecule inhibitors have been used 
to target the self-recognition sequence (i.e., KLVFF) and the hydrophobic C-terminus of Aβ to 
prevent its aggregation.1,4,7,8 As a new approach, the utilization of transition metal complexes able 
to modulate the aggregation of Aβ has recently emerged.7-16 In addition to their ability to catalyze 
difficult chemical reactions that are not easily facilitated by organic molecules, the capacity of 
metal complexes to access various oxidation states, coordination numbers, and stereochemistry 
can further endow singular approaches as well as provide a degree of tunability that is not easily 
achieved in small molecules.7-16 One such approach to amyloid management is the cleavage of 
Aβ’s amide bonds to produce peptide fragments that generate off-pathway and less toxic species. 
Co(III)(cyclen) derivatives (the structure of cyclen is shown in Figure 4.1) have been reported to 
hydrolyze the unactivated amide bonds in Aβ and other non-amyloidogenic and biologically 
essential proteins.7,17-23 Given the high stability of amide bonds under physiological conditions 
(i.e., half-life of ca. 200 years), it is remarkable that such simple metal complexes are able to 
catalyze the reaction.20,22 Unfortunately, apart from a single study, very little has been carried out 
to understand and utilize this approach for amyloid management.20 For example, in an effort to 
achieve some degree of selectivity, more than eight-hundred Co(III)(cyclen) derivatives 
augmented with exotic organic linkers were generated; however, only two complexes exhibited 
cleavage activity.20 This synthetically cumbersome tactic identifies our limited comprehension of 
this methodology and thus retards our ability to rationally design effective metal complexes for 
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peptide cleavage. Instead of using and evaluating such metal complexes, these macrocyclic 
polyamine ligands (i.e., cyclen and cyclam; Figure 4.1) have been mostly employed as exogenous 
metal chelators to combat metal-facilitated Aβ toxicity.7,19,24-29 In addition to the inherent 
problems associated with metal chelation therapy in AD,1 these ligands, due to the macrocyclic 
effect, possess high binding affinities and poor metal ion selectivity which may severely limit 
their biological applications.7,19,24-29 Furthermore, unlike macrocyclic polyamine metal complexes, 
the apo ligands (i.e., cyclen and cyclam) are unable to modulate metal-free Aβ which also 
aggregates to produce toxic oligomers.1,2,4,19,24,27-29 Therefore, it is clear that further studies are 
warranted into the generation and application of metal macrocyclic polyamine complexes as 
hydrolytic cleavage agents.  
Herein, we report a novel approach to tune the hydrolytic cleavage activity of a series of 
divalent metal tetra-N-methylated cyclam complexes [M(II)(TMC); M = Co, Ni, Cu, and Zn; 
where M(II)(TMC) is used as an abbreviation for our complexes rather than describing the exact 
coordination sphere] based on the choice of metal centers. TMC was selected for its distinct 
properties (e.g., stereochemistry, coordination number) and its ability to accommodate different 
oxidation and spin states of the metal centers, which we predicted would impart different 
reactivities of M(II)(TMC) from those of the analogous cyclen complexes, and for the simplicity 
through which they can be synthesized and structurally modified. Interestingly, among the four 
M(II)(TMC) complexes, only Co(II)(TMC) is able to significantly inhibit Aβ aggregation and 
disassemble preformed Aβ fibrils. Mass spectrometric investigations reveal that all M(II)(TMC) 
complexes possess varying capacities to hydrolyze Aβ. The anti-amyloidogenic activity of 
Co(II)(TMC) is suggested to be a result of its enhanced aptitude to hydrolyze Aβ, relative to that 
of the other complexes.  
Through studies by UV-visible (UV-vis) and electron paramagnetic resonance (EPR) 
spectroscopy [including electron nuclear double resonance (ENDOR) and electron spin echo 
envelope modulation (ESEEM)], X-ray crystallography, and density function theory (DFT), it has 
been indicated that the superior cleavage activity of Co(II)(TMC) may be attributed to a 
combination of its distorted structure which promotes more facile substrate entry and the 
formation of its more stable pentacoordinate aqua complex which can more easily facilitate the 
generation of nucleophilic hydroxide anions, relative to the other complexes. In addition, the 
biological applicability of Co(II)(TMC) is suggested showing its potential blood-brain barrier 
(BBB) permeability, relatively low cytotoxicity, and preferential cleavage of amyloidogenic 
proteins over highly structured proteins, such as ubiquitin.30 Taken together, our studies not only 
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represent, to the best of our knowledge, the first Co(II) complex able to modulate the aggregation 
pathways of Aβ via hydrolytic cleavage, but also that the degree of hydrolytic excision can be 
easily tuned through the choice of the metal center. Moreover, the balance between cleavage 
efficiency and selectivity is established by our studies with Co(II)(TMC) showing that high 
potency is not required to affect the aggregation characteristics of amyloidogenic peptides. In fact, 
preference toward amyloidogenic peptides over biologically essential and highly structured 
peptides was achieved by sterically restraining the binding site. Finally, the mechanistic insights 
gleamed in our studies will be combined with the metal center dependence to direct the rational 
design of a series of next-generation tunable cleavage agents. 
 
4.2. Results and Discussion  
 
 
Figure 4.1. Chemical structures of macrocyclic polyamines and their metal complexes. (a) Chemical 
structures of cyclen, cyclam, and M(II)(TMC) (trans-I and trans-III isomers). Cyclen = 1,4,7,10-
tetraazacyclododecane; cyclam = 1,4,8,11-tetraazacyclotetradecane; TMC = 1,4,8,11-tetramethyl-
1,4,8,11-tetraazacyclotetradecane. ORTEP diagrams of (b) [Co(TMC)(NO3)](NO3) and (c) 
[Ni(TMC)(CH3CN)](NO3)2 with ellipsoids drawn at the 30% probability level. Noncoordinated nitrate 
anions and hydrogen atoms are omitted for clarity. Selected distances (Å) and angles are summarized in 
Table 4.1. 
 
4.2.1. Design Rationale and Preparation of M(II)(TMC) Complexes 
In order to further probe the application of metal macrocyclic polyamine complexes as anti-
amyloidogenic agents, a series of divalent metal tetramethylcyclam complexes, M(II)(TMC) [M = 
Co, Ni, Cu, and Zn; Figure 4.1a], were prepared and evaluated for their ability to modulate Aβ 
aggregation pathways. Instead of cyclen, TMC was chosen as the ligand for the metal complexes 
because of its distinctive stereochemistry (e.g., trans-I versus trans-III; Figure 4.1a) and 
coordination spheres [e.g., square planar, square pyramidal, trigonal bipyramidal (TBP), and 
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octahedral geometries], as well as its accommodation of different oxidation and spin states of the 
metal centers.31-37 We hypothesize that such properties of TMC may confer a certain degree of 
tunability in their interactions with Aβ that is absent in the octahedral Co(III)(cyclen) 
complexes.26,31-37 In addition, M(II)(TMC) complexes can also be easily synthesized in high yields 
and modified via substitution reactions, which will aid in further development of more selective 
and reactive complexes.31 The M(II)(TMC) complexes were prepared following well-established 
methods of refluxing TMC and Co(NO3)26H2O, Ni(NO3)26H2O, Cu(ClO4)26H2O, or 
Zn(ClO4)26H2O for 12 h in CH3CN.31,37 
 
4.2.2. Effects of M(II)(TMC) on Aβ  Aggregation  
To evaluate the ability of M(II)(TMC) complexes to influence the aggregation pathways of 
Aβ40 and Aβ42, gel electrophoresis with Western blotting (gel/Western blot) and transmission 
electron microscopy (TEM) were employed to analyze the molecular weight (MW) distribution 
and morphology of the resultant Aβ species, respectively. Two different experiments were 
conducted to determine the ability of M(II)(TMC) complexes to either prevent the aggregation of 
monomeric Aβ (Figure 4.2a) or to disassemble preformed Aβ fibrils into smaller species (Figure 
4.3a). Under our experimental conditions, compound-untreated samples assemble into large 
aggregates that can be visualized by TEM, but are too large to penetrate into the gel matrix thus 
producing limited smearing on the gel/Western blot. The administration of compounds, able to 
interact with Aβ and either (i) inhibit the formation of high MW aggregates and/or (ii) 
disassemble preformed aggregates, typically generates a distribution of smaller Aβ species that 
are capable of entering into the gel and inducing a significant amount of smearing compared to 
the samples containing Aβ only.  
In the inhibition experiment (Figure 4.2), a time-dependent change in the MW distribution of 
Aβ40 species was observed only for the samples treated with Co(II)(TMC). No smearing was 
discernable at the 4 h incubation time point; however, after 8 h, noticeable bands (ca. 10–15 and > 
260 kDa) were identified and darker and more significant smearing was detected upon further 
incubation to 24 h (ca. 10–260 kDa; Figure 4.2b, top). The aptitude of Co(II)(TMC) to inhibit 
Aβ42 aggregation appeared to be diminished compared to Aβ40. A slight difference in the MW 
distribution of Aβ42 species was noticeable at the 4, 8, and 24 h time points (Figure 4.2b, bottom). 
Zn(II)(TMC) also seemed to slightly alter the MW distribution of Aβ42 at the 24 h time point in 
the gel/Western blot, but TEM images revealed mostly large clusters of fibrils, similar to those 
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observed in the samples containing Aβ42 only and Aβ42 treated with the ligand (TMC), 
Cu(II)(TMC), and Ni(II)(TMC) (Figure 4.2b,c). In agreement with the gel/Western blot data, a 
distinct transformation into a distribution of smaller, thinner, and needle-like species or 
amorphous aggregates (see the inset TEM image) was discerned upon incubation of Aβ42 with 
Co(II)(TMC) (Figure 4.2c).  
 
 
Figure 4.2. Capability of M(II)(TMC) (M = Co, Ni, Cu, and Zn) to control the aggregation pathways of 
Aβ40 and Aβ42. (a) Scheme of the inhibition experiment. (b) Analysis of the resultant Aβ40 (top) and Aβ42 
(bottom) species from the inhibition experiment visualized by gel electrophoresis with Western blotting 
(gel/Western blot) using an anti-Aβ antibody (6E10). Conditions: Aβ (25 μM); M(II)(TMC) (50 μM); 
incubated for 4, 8, or 24 h; pH 7.4; 37 °C; constant agitation. Lanes: “C” denotes the control lane (without 
compound treatment); (1) Aβ + TMC; (2) Aβ + Co(II)(TMC); (3) Aβ + Ni(II)(TMC); (4) Aβ + 
Cu(II)(TMC); (5) Aβ + Zn(II)(TMC). (c) TEM images for the Aβ42 samples (24 h incubation) from (b). 
Insets represent the minor species. 
 
Similar trends were also displayed in the disaggregation experiment (Figures 4.3 and 4.4). Only 
Co(II)(TMC) was able to reverse the assembly of preformed Aβ40 and Aβ42 aggregates. The reactivity 
toward Aβ40 also appeared to be correlated to the incubation period with no significant bands detected 
until 8 and 24 h (Figure 4.3b, top). Homologous to the Aβ40 conditions, the extent to which Co(II)(TMC) 
was able to disaggregate preformed Aβ42 aggregates also varied with the length of incubation; however, 
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unlike Aβ40, the most significant change in the MW distribution was discernable at the 4 h time point 
(Figure 4.3b, bottom). The dissimilarity may be attributed to the increased aggregation propensity of 
Aβ42, relative to that of Aβ40.1-5,7 Administration of Co(II)(TMC) also perturbed the morphologies of Aβ40 
and Aβ42 aggregates from the deposits of large and long fibrils that were detected in the complex-
untreated Aβ controls to much smaller clusters of thin and needle-like species similar to those in the 
inhibition experiment (Figures 4.3c and 4.4). 
 
 
Figure 4.3. Ability of M(II)(TMC) (M = Co, Ni, Cu, and Zn) to disaggregate preformed Aβ40 and Aβ42 
aggregates. (a) Scheme of the disaggregation experiment. (b) Analysis of the resultant Aβ40 (top) and 
Aβ42 (bottom) species from the disaggregation experiment visualized by gel electrophoresis with Western 
blotting (gel/Western blot) using an anti-Aβ antibody (6E10). Conditions: Aβ (25 μM); M(II)(TMC) (50 
μM); incubated for 4, 8, or 24 h; pH 7.4; 37 °C; constant agitation. Lanes: “C” denotes the control lane 
(without compound treatment); (1) Aβ + TMC; (2) Aβ + Co(II)(TMC); (3) Aβ + Ni(II)(TMC); (4) Aβ + 
Cu(II)(TMC); (5) Aβ + Zn(II)(TMC). (c) TEM images for the Aβ40 and Aβ42 samples (24 h incubation) 
from (b). Insets represent the minor species. 
 
Our gel/Western blot and TEM investigations indicate that only Co(II)(TMC) is capable of 
modulating the aggregation pathways of Aβ40 and Aβ42, while Ni(II)(TMC), Cu(II)(TMC), and 
Zn(II)(TMC) do not, despite the relatively high affinity binding sites in Aβ for Cu(II) and Zn(II) 
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(i.e., Kd = ca. 10-9 M and 10-6 M, respectively).1-5,7 In addition, the time-dependent nature of 
Co(II)(TMC)’s reactivity, particularly in the disaggregation experiments, further suggests that 
Co(II)(TMC) may be interacting predominately with intermediate to high MW aggregates over 
monomeric Aβ because no reactivity is observed until Aβ has been pre-incubated with the 
complex for 8 or more hours (Figures 4.2 and 4.3). The potential preference of Co(II)(TMC) to 
interact with intermediate MW aggregates may also explain why the gel/Western blot studies 
showed the most significant smearing at the 4 h time point in the disaggregation experiments with 
the more aggregation-prone Aβ42 isoform.1-5,7 
 
 
Figure 4.4. Ability of M(II)(TMC) (M = Ni, Cu, and Zn) to alter the morphology of preformed Aβ40 and 
Aβ42 aggregates. (a) Scheme of the disaggregation experiment. (b) TEM images for the Aβ40 and Aβ42 
samples (24 h incubation). Insets represent the minor species.  
 
4.2.3. Mechanistic Studies  
 
(i) Competition Experiments: Evaluating the Strength of the Interaction Between 
Co(II)(TMC) and Aβ40 
In order determine why only Co(II)(TMC) can noticeably affect the aggregation pathways of 
Aβ, detailed studies to elucidate a mode of action were preformed. First, to evaluate the strength 
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of the interaction between Co(II)(TMC) and Aβ40, a competition experiment was conducted and 
monitored by gel/Western blot. Increasing amounts of sodium azide (NaN3) and sodium cyanate 
(NaOCN) (0–200 equiv) were added into a reaction mixture containing fresh Aβ40 and 
Co(II)(TMC) (Figure 4.5a). Due to the sterics associated with all four N-methyl moieties 
positioned on the same side of the macrocyclic plane, M(II)(TMC) complexes bind most strongly 
to small and linear ligands, such as N3–, OCN–, and OH–, as opposed to larger ligands (e.g., 
imidazole) to yield either square pyramidal or TBP structures (Figure 4.5c).26,31,32,34-48 Therefore, 
since the formation of octahedral M(II)(TMC) complexes is unlikely due to the folding down of 
the macrocyclic ring which prohibits binding of a ligand at the second axial position, 
Co(II)(TMC) can only interact with Aβ40, N3–, OCN–, or H2O/OH–.26,31,32,34-48 Surprisingly, 
Co(II)(TMC) maintained its ability to inhibit Aβ40 aggregation in aqueous conditions until 100 
equiv of NaOCN or 200 equiv of NaN3 were present (Figure 4.5b).  
 
 
Figure 4.5. Competition experiments. (a) Reaction scheme. (b) Visualization of the Aβ40 species upon 
addition of sodium azide (NaN3; 0–200 equiv; blue) or sodium cyanate (NaOCN; 0–200 equiv; green) by 
gel/Western blot utilizing an anti-Aβ antibody (6E10). Conditions: Aβ40 (25 μM); NaN3 or NaOCN (0–5 
mM); Co(II)(TMC) (50 μM); incubated for 24 h; pH 7.4; 37 °C; constant agitation. (c) Scheme and 
chemical equation of the complexation reaction of Co(II)(TMC) with the experimentally reported 
equilibrium constants obtained from spectrophotometric titrations.33 *Indicates that the stability constant 
for the pentacoordinate imidazole complex was not obtained for Co(II)(TMC) and the reported value (< 
0.30) is from Ni(II)(TMC).32  
 115 
Based on previously measured equilibrium constants for the formation of pentacoordinate 
Co(II)(TMC) complexes, these results likely suggest that Co(II)(TMC) does not interact with Aβ 
via ligand association with its histidine residues (i.e., His6, His13, and His14) as has been 
extensively reported for most metal complexes.9-11,13-15,32 Equilibrium constants greater than 1 
were reported for the formation of pentacoordinate Co(II)(TMC) with the axial coordination site 
occupied by OCN– (K = 3.82), N3– (K = 2.57), and OH– (K = 5.28) (Figure 4.5c).32 The larger 
equilibrium constant for OCN– explains why only 100 equiv of NaOCN were required to prevent 
Co(II)(TMC) from inhibiting Aβ40 aggregation while 200 equiv were necessary for NaN3 to 
produce similar results (Figure 4.5b,c).32 Coordination of an imidazole to Ni(II)(TMC) was 
indicated to be much less favorable (K < 0.30) (Figure 4.5c).32 The equilibrium constant for 
imidazole binding was determined only for Ni(II)(TMC) because of the sensitivity of its optical 
spectrum to changes in the coordination sphere; however, the equilibrium constant for imidazole 
binding to Co(II)(TMC) should be much less than those of N3–, OCN–, and OH– based on the 
trend reported by Micheloni et al. (Figure 4.5c).32 Collectively, these experiments suggest that (i) 
Co(II)(TMC) is able to competitively interact with Aβ most likely through an interaction that is 
independent of histidine coordination or that (ii) Co(II)(TMC)’s anti-amyloidogenic activity is 
dependent on the formation of an aqua or hydroxo complex ([Co(TMC)(H2O)]2+ or 
[Co(TMC)(OH)]+) which may provide the nucleophilic hydroxide source required to catalyze the 
hydrolytic cleavage of amide bonds. The latter explanation would be the most consistent with the 
previously measured equilibrium constants and with our spectroscopic and time-dependent DFT 
(TDDFT) studies which identified the [M(TMC)(H2O)]2+ complexes as the most 
thermodynamically stable species (vide infra). 

(ii) Hydrolytic Cleavage of Aβ  by M(II)(TMC) Complexes 
In order to determine if the enhanced ability of Co(II)(TMC) to modulate Aβ aggregation is 
linked to protein fragmentation, matrix assisted laser desorption ionization–mass spectrometry 
(MALDI–MS) analyses were carried out on Aβ40 samples incubated for 24 h with M(II)(TMC) 
(Figure 4.6). An immediate difference was noticeable in the MALDI–MS spectrum for the Aβ40 
samples treated with Co(II)(TMC). The normalized signal intensity of the singly-charged Aβ40 
monomer peak (i.e., Aβ40+) at 4328.15 m/z was noticeably reduced upon 24 h incubation with 
Co(II)(TMC) (Figure 4.6a). Such a significant signal suppression of the singly-charged Aβ40 
monomer was not observed in the samples treated with Ni(II)(TMC), Cu(II)(TMC), or 
Zn(II)(TMC) (Figure 4.6a).  
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Figure 4.6. MALDI–MS analysis of the Aβ40 samples incubated with M(II)(TMC) (M = Co, Ni, 
Cu, and Zn). (a) Mass spectra of singly-charged Aβ40. The peak intensities are normalized to Aβ40 
in the absence of M(II)(TMC). (b) The magnified low m/z range of the mass spectra. Aβ(1-12) 
[m/z = 1424], Aβ(1-18) [m/z = 2167], and Aβ(14-38) [m/z = 2587] are indicated in light green, 
cyan, and red, respectively. All measurements were conducted with the addition of an internal 
standard, melittin (5 μM), and calibrated based on the linear correlation between the concentration 
and the signal intensity (Figure 4.7). (c) MALDI–MS spectra for Aβ40 incubated with 
Co(II)(TMC) at different pH values. The peak intensity is normalized to that of Aβ40 without 
M(II)(TMC) (a, top spectrum). (d) Magnified spectrum (x 40) for each sample. All samples were 
measured with the addition of an internal standard of melittin (5 μM). (e) The amount of 
remaining singly-charged Aβ40 after M(II)(TMC) treatment is estimated and summarized in the 
table. 
 
To identify whether the Aβ40 signal reduction was a result of a decrease in the monomeric 
Aβ40 concentration upon incubation with Co(II)(TMC) or due to variation of Aβ40 ionization 
efficiencies in the presence of Co(II)(TMC), we utilized an internal standard to obtain quantitative 
information from the mass spectra. An internal standard of melittin, a principle component in 
honey bee venom,49 was selected and added to the MS samples prior to analysis. By comparing 
the signal intensity of the internal standard in the Aβ40–Co(II)(TMC) sample to the Aβ control and 
ensuring that there was no significant differences in the peak intensity, we were able to verify that 
the Aβ40 peak suppression was not due to differences in ionization efficiency and was most likely 
a result of a reduction in the monomeric, singly-charged Aβ40 concentration. To further elucidate  
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Figure 4.7. Calibration plot of the internal standard, melittin. Internal standards were prepared at different 
concentrations (100 nM–20 μM). The signal intensity for each sample was measured using MALDI-MS. 
The y-axis indicates the ratio of the signal intensity for the standards to the sum of intensities for the 30 
most dominant peaks. The linear regression of the data is given by the red line (y = 0.0205x – 0.0015; R2 
= 0.9976). 
 
the relative concentration of singly-charged Aβ40 in the absence and presence of M(II)(TMC), a 
calibration plot was constructed utilizing the melittin internal standard in a concentration range of 
100 nM–20 μM (R2 = 0.99; Figure 4.7). As depicted in Figure 4.6e, while all M(II)(TMC) 
complexes caused a minor decrease in the concentration of Aβ40 from ca. 7 μM in the Aβ40 
control to ca. 6–7 μM in samples treated with Ni(II)(TMC), Cu(II)(TMC), and Zn(II)(TMC), 
incubation with Co(II)(TMC) generated a much more significant reduction in the concentration of 
the singly-charged Aβ40 monomer [ca. 2.8 μM (60% reduction); Figure 4.6a]. Additionally, upon 
closer inspection of the low m/z range of the Co(II)(TMC)-treated mass spectrum, three new 
peaks were detected at 1424, 2167, and 2587 m/z, corresponding to the N- and C-terminal 
hydrolytic cleavage fragments, Aβ1-12, Aβ1-18, and Aβ14-38, respectively (Figure 4.6b). The Aβ1-18 
and Aβ14-38 fragments were also identified in the Aβ40 samples incubated with Cu(II)(TMC) and 
Zn(II)(TMC) while only the Aβ1-18 peak was identified in the Ni(II)(TMC)-treated spectrum. 
Furthermore, the reduction in the concentration of the singly-charged Aβ40 monomer also 
appeared to be indirectly correlated with the increase in the relative signal intensity of the Aβ 
fragments (Figure 4.6). It should be noted that the peak intensities of the fragmented Aβ were 
outside the dynamic range of the melittin calibration plot; thus, an accurate quantification of the 
concentration from interpolation of the spectral signal intensity could not be obtained. 
Nevertheless, the extent to which M(II)(TMC) complexes are observed to fragment Aβ40 appears 
to be consistent with the trend observed in the suppression of the Aβ40 peak. Co(II)(TMC) was 
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found produced the largest degree of Aβ cleavage and monomer degradation while Cu(II)(TMC) 
and Zn(II)(TMC) exhibited an activity less than Co(II)(TMC), and Ni(II)(TMC) presented the 
least efficient cleavage (Figure 4.6). 
Overall, our initial MALDI–MS investigations suggest that the anti-amyloidogenic activity of 
Co(II)(TMC) is at least partially due to its ability to cleave Aβ, likely via hydrolysis of the amide bonds. 
To further support the hydrolytic mode of action for Aβ cleavage which has been proposed for other 
Co(III)(cyclen) complexes, MALDI–MS samples of Aβ40 incubated with Co(II)(TMC) were prepared at 
different pHs (e.g., pH = 6.6, 7.4, 8.5; Figure 4.6c-e).18,20,50-55 Due to the high pH sensitivity of hydrolysis, 
we expected to observe significant differences in both the Aβ40 peak suppression and fragment signal 
intensity as the pH of the solution was altered with maximum cleavage occurring around neutral pH as 
has been previously reported for Co(III)(cyclen) complexes.18,22,50,51,56,57 As expected, no significant 
fragmentation and very little Aβ40 peak reduction were observed in the Aβ40 samples incubated with 
Co(II)(TMC) for 24 h at pH 6.6 (Figure 4.6c-e). Upon increasing the pH a noticeable difference in 
Co(II)(TMC)’s proteolytic activity was observed in the mass spectra (Figure 4.6c-e). Under 
physiologically relevant (i.e., pH 7.4) and slightly basic (i.e., pH 8.5) conditions, incubation with 
Co(II)(TMC) significantly decreased the Aβ40 peak intensity. Through the use of the internal standard 
calibration plot we were able to determine that Co(II)(TMC) was slightly more reactive under moderately 
basic solution conditions ([Aβ40]+ = 2.8 μM at pH 7.4; [Aβ40]+ = 2.3 μM at pH 8.5; Figure 4.6c-e). In 
addition, the signal intensity of the Aβ14-38 fragment (2587 Da) was highest in the pH 8.5 sample (Figure 
4.6d). The overall pH dependence of Co(II)(TMC)’s cleavage activity supports its hydrolytic mechanism 
and it appears from our MALDI–MS studies that the anti-amyloidogenic activity of Co(II)(TMC) is a 
result of its enhanced ability to catalyze the hydrolysis of Aβ, relative to the other M(II)(TMC) 
complexes. It is, however, interesting that Co(II)(TMC) is slightly more reactive at pH 8.5 when 
structurally similar Co(III)(cyclen) complexes are most reactive at neutral pH.22,50,51,57 The dissimilarity in 
pH optimization may suggest a difference in the hydrolytic mechanism between Co(II)(TMC) and 
Co(III)(cyclen) (e.g., predominant activation of water by Co(II)(TMC) rather than amide bond activation 
suggested for Co(III)(cyclen)22,50,51,57; vide infra). 
 
(iii) Adduct Formation of M(II)(TMC) Complexes with Aβ  
Electrospray ionization–mass spectrometry (ESI–MS) and ion mobility–mass spectrometry 
(IM–MS) were employed to determine whether the anti-amyloidogenic activity of Co(II)(TMC) 
was also partially a result of its ability to coordinate to Aβ and generate structurally altered Aβ–
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Co(II)(TMC) conformers, similar to the mode of action reported for anti-amyloidogenic platinum 
and Co(III) Schiff base complexes.13-15  
 
 
Figure 4.8. ESI–MS spectra of Aβ40 incubated with M(II)(TMC) (M = Co, Ni, Cu, and Zn). Inset spectra 
indicate the magnification between 1500 and 1750 m/z. Colored peaks are assigned above the spectra. 
 
As shown in Figure 4.8, the peaks consistent with Aβ40 bound to all four metal complexes 
[e.g., Aβ40 + M(II)(TMC)] were detected. The Co(II)(TMC) spectrum, however, did have a 
unique peak at 1652.40 m/z that was assigned to Aβ40 bound to two equivalents of Co(II)(TMC) 
[i.e., Aβ40 + 2Co(II)(TMC)], which was not observed in the spectra of the other complexes 
(Figure 4.8). Additionally, the spectra of Cu(II)(TMC) and Zn(II)(TMC) also had two distinctive 
signals at 1575.83 and 1576.86 m/z, respectively. These peaks, absent in those of Co(II)(TMC) 
and Ni(II)(TMC), corresponded to the addition of a water molecule and a labile metal ion (Cu(II) 
and Zn(II), respectively) to Aβ40 [i.e., Aβ40 + M(II) + M(II)(TMC) + H2O]. This data suggests that 
a small amount of Cu(II) and Zn(II) may be removed from TMC possibly by chelating to the N-
terminal Cu(II) and Zn(II) binding sites (e.g., His6, His13, His14) in Aβ.1-5,7-9 The partial metal  
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Figure 4.9. The low m/z regions of the ESI–MS spectra for (a) Aβ40, (b) [Aβ40 + Co(II)(TMC)], (c) [Aβ40 
+ Ni(II)(TMC)], (d) [Aβ40 + Cu(II)(TMC)], and (e) [Aβ40 + Zn(II)(TMC)]. The newly generated Aβ40 
fragments formed upon M(II)(TMC) treatment are labeled in blue. Ions only detected in the samples 
treated with Co(II)(TMC) or Cu(II)(TMC) are labeled in red and green, respectively. All fragments are 
listed in Table A.3. 
 
ion removal from Cu(II)(TMC) and Zn(II)(TMC) may explain why they did not significantly 
modulate the aggregation pathways of Aβ. Macrocyclic polyamines have been found to be only 
active against amyloidogenesis in the presence of metal ions [e.g., Cu(II)] because it is the metal 
complexes generated in situ rather than the apo-ligands that are active.19,24,25,27-29 Therefore, if Aβ 
is able to remove Cu(II) and Zn(II) from their respective M(II)(TMC) complexes, it should hinder 
them unreactive, thus explaining the absence of detectable reactivity in the gel/Western blot 
experiments and the generation of large networks of fibrils similar to those found in metal-bound 
Aβ [i.e., Cu(II)–Aβ, Zn(II)–Aβ] controls, indicated by TEM (vide supra; Figures 4.2 and 4.3).58-61 
In addition to observing Aβ40–M(II)(TMC) adducts, Aβ fragments similar to those shown in the 
MALDI–MS studies were also distinguished, further supporting hydrolytic cleavage as the mode 
of action of Co(II)(TMC) (Figure 4.9). Moreover, +5-charged Aβ40 was not detected upon 
incubation with Co(II)(TMC) and Zn(II)(TMC), and the trace amounts of +5-charged Aβ40 were 
observed with the addition of Cu(II)(TMC). It is widely accepted that extended species in the 
solution phase tend to be transferred into higher charge state ions in the gas phase.62 Therefore, 
the more expanded, +5-charged Aβ40 may be more readily accessible to M(II)(TMC) than the 
lower charge state Aβ40 (e.g., +3-charged Aβ40; Figure 4.9), which did not show any significant 
signal depression in the ESI–MS spectra upon administration of M(II)(TMC). Overall, the 
reduction of +5-charged ion intensities also reflects the cleavage activities of M(II)(TMC) 
complexes showing the same tendencies found in the  MALDI–MS experiments.  
IM–MS studies on the +3 charge state were further carried out to assess the conformers adopted upon 
Aβ binding to M(II)(TMC) (Figure 4.10). When compared to the Aβ40 control, the adduct of Aβ with 
M(II)(TMC) had a slightly longer drift times, indicative of more expanded structures, which may be 
consistent with the single-site binding of M(II)(TMC) to Aβ40, but there was no noticeable difference 
between Co(II)(TMC) and the other metal complexes (Figure 4.10). Therefore, in agreement with the 
findings from the isomerization experiments, IM–MS studies suggest that the structural variation of Aβ as 
a result of coordination to M(II)(TMC) complexes is not the reason why Co(II)(TMC) shows reactivity in 
vitro. Taken together, our MS investigations suggest that the ability of Co(II)(TMC) to modulate Aβ 
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aggregation pathways could be a result of its more active hydrolytic cleavage of Aβ, relative to that of the 
other M(II)(TMC) complexes. 
 
 
Figure 4.10. ESI–IM–MS spectra of Aβ403+ or complex ions of Aβ40 with M(II)(TMC) (M = Co, Ni, Cu, 
and Zn). The drift time values with the maximum intensity are indicated in the spectra. 
 
(iv) Isomerization of M(II)(TMC) Complexes 
 The ability of M(II)(TMC) complexes to form Aβ adducts and, in the case of Co(II)(TMC), 
to competitively interaction with Aβ40 in the presence of NaN3 and NaOCN was unexpected given 
the steric constraints associated with the trans-I conformation (Figure 4.1).31,32 The most notable 
difference between M(II)(TMC) complexes and other platinum and Co(III) complexes for the 
anti-amyloidogenic activity is that the M(II)(TMC) complexes in the trans-I conformation only 
have one sterically confined coordination site available for Aβ to bind whereas the other 
complexes possess two open coordination sites that can facilitate Aβ binding.13-15,20,26,31 
Isomerization of the trans-I complexes to the less sterically strained trans-III isomer which forms 
octahedral complexes in solution may explain the Aβ–M(II)(TMC) adduct formations observed in 
our MS investigations and the competitive interaction between Aβ and Co(II)(TMC) (Figure 4.1). 
Additionally, the noticeable anti-amyloidogenic activity of Co(II)(TMC) may also be elucidated if 
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this complex is able to undergo more facile isomerization, relative to the other M(II)(TMC) 
complexes. Moore and co-workers have shown that trans-I-M(II)(TMC) isomerization to trans-
III-M(II)(TMC) is highly dependent on solution conditions.33 Therefore, we monitored the UV-vis 
spectra of Co(II)(TMC), Ni(II)(TMC), and Cu(II)(TMC) under similar conditions as our in vitro 
aggregation studies to determine (i) if trans-III-M(II)(TMC) complexes can be generated and (ii) 
if Co(II)(TMC) is more easily isomerized, possibly explaining its superior anti-amyloidogenic 
activity (Figure 4.11). 
 
 
Figure 4.11. Analysis of the potential isomerization of trans-I-M(II)(TMC) (M = Co, Ni, and Cu) 
complexes by UV-vis. Conditions: Co(II)(TMC) (20 mM), Ni(II)(TMC) (10 mM), or Cu(II)(TMC) (2.5 
mM); pH 7.4; 37 °C; no agitation. 
 
The peaks at ca. 479, 550, and 730 nm [for Co(II)(TMC)]; ca. 394, 510, and 658 nm [for 
Ni(II)(TMC)]; ca. 615 nm [for Cu(II)(TMC)] were consistent with previous literature reports of the trans-
I complexes (Figure 4.11).32,34,37 With the exception of Ni(II)(TMC), only slight increases in the 
absorbance of the trans-I-M(II)(TMC) complexes over the course of the experiment were observed and 
there was no indication of any λmax blue shifts, suggestive of the generation of octahedral trans-III 
complexes (Figure 4.11).32-35 Ni(II)(TMC) did, however, show some significant optical changes in the 
first ca. 4 h of the experiment. This spectral variation at 394, 510, and 658 nm was found to be consistent 
with previous reports that indicate the slow establishment of an equilibrium between a low-spin four 
coordinate complex to a distorted, high-spin five coordinate structure.63,64 Therefore, our spectral data 
suggests that isomerization does not occur under our in vitro gel/Western blot conditions and that the 
possibility of Aβ coordinated to M(II)(TMC) via a bis-His coordination mode is unlikely. 
 
(v) X-ray Structural Characterization of M(II)(TMC) 
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Crystals suitable for X-ray analysis for [Co(TMC)(NO3)](NO3) and 
[Ni(TMC)(CH3CN)](NO3)2 were obtained by slow diffusion of diethyl ether into CH3CN 
solutions of Co(II)(TMC) and Ni(II)(TMC) complexes (see Figure 4.1b,c, respectively). The 
structural data obtained was used to compare the structures of Co(II)(TMC) and Ni(II)(TMC) 
nitrate complexes to each other and to the previously reported Cu(II)(TMC) and Zn(II)(TMC) 
perchlorate complexes.35,42,43,46,47 It should be noted that the degree of distortion in the 
M(II)(TMC) complexes is highly dependent on the identity of the ligand occupying the open 
coordination site. For this reason, comparison to calculations that can provide structural 
information for M(II)(TMC) complexes with identical ligands at the fifth coordination site was 
also conducted (vide infra).  
 
Table 4.1. Selected crystallographic metrics for Co(II)(TMC) and Ni(II)(TMC). The two sets of 
measurements for Ni(II)(TMC) correspond to the two unique structures found in the asymmetric unit.  
 
Co(II)(TMC) Ni(II)(TMC) 
Co–N1 2.181 Å Ni–N1 2.116 / 2.076 Å 
Co–N2 2.184 Å Ni–N2 2.134 / 2.184 Å 
Co–N3 2.172 Å Ni–N3 2.132 / 2.096 Å 
Co–N4 2.189 Å Ni–N4 2.113 / 2.153Å 
Co–O1 2.360 Å Ni–N5 2.023 / 2.015 Å 
Co–O2 2.217 Å Distance above macrocyclic plane 0.221 / 0.252 Å 
Distance above 
macrocyclic plane 0.532 Å N1–Ni–N2 92.57 / 95.02° 
N1–Co–N2 91.57° N2–Ni–N3 85.28 / 84.31° 
N2–Co–N3 83.64° N3–Ni–N4 94.54 / 93.89° 
N3–Co–N4 90.99° N4–Ni–N1 85.13 / 86.07° 
N4–Co–N1 83.55° N1–Ni–N5 95.50 / 100.47° 
N1–Co–O1 84.79° N2–Ni–N5 95.62 / 90.26° 
N1–Co–O2 105.28° N3–Ni–N5 95.49 / 105.81° 
O1–Co–N3 107.74° N4–Ni–N5 97.30 / 91.37° 
N1–N2–N3–N4* 28.48° N1–N2–N3–N4* 1.92 / 24.02° 
 
*The reported dihedral angles (i.e., N1–N2–N3–N4) are the averaged angles of the two measurements 
obtained by defining the angle by the N1–N3 or N2–N4 axis.  
 
As shown in Figure 4.1, both Co(II)(TMC) and Ni(II)(TMC) complexes were in the expected trans-I 
conformation. Interestingly, a nitrate molecule bound to the syn face of the macrocycle of Co(II)(TMC) in 
an unusual bidentate fashion forming a distorted six coordinate complex. The asymmetric unit of 
Ni(II)(TMC) contained two complexes, each with an CH3CN ligand at the axial site, but with one being 
slightly more distorted than the typically perfect square pyramidal complexes previously reported (Figure 
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4.1c shows the square pyramidal structure that is more consistent with previous literature reports).38,40,45 
To better quantify the degree of distortion, the averaged dihedral angles between the two intersecting 
planes defined by the four N donor atoms with N1–N3 and N2–N4 axes were calculated and reported in 
Table 4.1 (i.e., for the N1–N3 axis: plane 1 is defined by N1, N2, and N3 and plane 2 is defined by N1, 
N3, and N4; for the N2–N4 axis: plane 1 is defined by N1, N2, and N4 and plane 2 is defined N2, N3, and 
N4; Figure 4.1b,c). The dihedral angle of 28.48° for Co(II)(TMC) was larger than those obtained from 
previous crystallographic data [i.e., average dihedral angles of 5.9° for Ni(II)(TMC), 24.06° for 
Cu(II)(TMC), and 16.38° for Zn(II)(TMC)].35,38-40,42,43,45-48 The Ni(II)(TMC) structure shown in Figure 
4.1c had a dihedral angle of 1.92° (i.e., almost all 4 N atoms coplanar) while the slightly more distorted 
structure was determined to be 24.02° which was still less than that of Co(II)(TMC). In addition, Co(II) 
was positioned the farthest above the macrocyclic plan (i.e., 0.532 Å) compared to ca. 0.221 Å (or 0.252 
Å) for Ni(II)(TMC), 0.303 Å for Cu(II)(TMC), and 0.484 Å for Zn(II)(TMC).35,38-40,42,43,45-48 Furthermore, 
TDDFT predicted structures of the water-bound ground-state M(II)(TMC) complexes (i.e., 
[M(TMC)(H2O)]2+) also presented a noticeable distortion in the structure of Co(II)(TMC); however, 
Zn(II)(TMC) also had comparable dihedral angles and distances of its metal center sitting above the 
macrocyclic plane (Table 4.2). More facile substrate entry (e.g., Aβ entry) to the metal center may be 
facilitated by the distortion in M(II)(TMC) complexes and by the metal ion sitting farther above the 
macrocyclic plane because it reduces the adverse steric effects associated with all four methyl groups 
located on the same side of the macrocyclic plane where the axial ligands coordinate (Figure 
4.1b,c).26,31,32,34-48 Overall, crystallographic and TDDFT results suggest that structures may help to explain 
why Co(II)(TMC), showing the more distorted conformation, exhibits enhanced anti-amyloidogenic 
properties compared to the other M(II)(TMC) complexes (vide infra). 
 
Table 4.2. Selected distances and angle measurements of TDDFT-predicted M(II)(TMC) complexes. 
  
Measurement Co(II)(TMC) Ni(II)(TMC) Cu(II)(TMC) Zn(II)(TMC) 
Distance above 
macrocyclic plane 0.377 Å 0.033 Å 0.207 Å 0.372 Å 
N1–N2–N3–N4* 26.75° 0.01° 25.31° 27.56° 
 
*The reported dihedral angles (i.e., N1–N2–N3–N4) are the averaged angles of the two measurements 
obtained by defining the angle by the N1–N3 or N2–N4 axis.  
 
(vi) EPR Studies of Co(II)(TMC) 
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Figure 4.12. EPR measurements of Co(II)(TMC). (a) (i) X-band CW-EPR spectrum of Co(II)(TMC) 
(solid black) and its simulated spectrum (dashed black); (ii) W-band Electron Spin Echo-detected EPR 
spectrum (solid blue) of Co(II)(TMC) and its simulated spectrum (dashed blue). The following 
parameters were used in the simulation: g = [2.42, 2.42, 2.21], ACo = [0, 60,0] G, D ≥ 13 cm-1, E/D = 0.3 
(b) 1H Davies ENDOR spectra of Co(II)(TMC) in H2O (black) and in D2O (blue).The subtracted 1H 
ENDOR spectrum is shown in red. 2H Mims ENDOR in D2O (black). (c) Q-band three pulse time-domain 
(left) and the frequency domain (right) ESEEM spectra of Co(II)(TMC). The blue dashed line in the 
frequency domain indicates the 17O Larmor frequency at each field.  
 
In order to characterize the structure of Co(II)(TMC) in solution, continuous wave and pulsed 
multi-frequency EPR techniques were employed. The X-band CW-EPR of Co(II)(TMC) exhibits 
a rhombic spectrum with the g tensor, geff = [6.3, 2.7, 1.7] which arises from high-spin, Co(II) (S = 
3/2) (Figure 4.12a, i). The hyperfine coupling from 59Co (100%, I = 7/2) was observed around g ≈ 
6. To extract more accurate spin Hamiltonian parameters, the multi-frequency EPR experiments 
were performed. The W-band (94 GHz) EPR displays a rhombic signal similar to the X-band EPR; 
however, the hyperfine splitting from 59Co cannot be observed (Figure 4.12a, ii). Simulations of 
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the X-band and W-band CW-EPR were carried out simultaneously to obtain more accurate spin 
Hamiltonian parameters (Figure 4.12a, dashed lines). The zero-field splitting parameter, D, of 
high-spin Co(II) is supposed to be large, hence being insensitive in X-band; however, it becomes 
more sensitive when simulating the W-band EPR spectrum. The spin Hamiltonian parameters 
obtained from the simulations are similar to those that have a five-coordinated species. In 
particular, a E/D of ca. 0.3 indicates that the complex has a distorted coordination geometry.65-67 
Thus, the CW-EPR indicates that Co(II)(TMC) has a distorted five-coordinated geometry, 
consistent with the UV-vis and TDDFT results. 
 
 
Figure 4.13. 1H-ENDOR spectra of CoCl26H2O at different magnetic fields. 
 
To examine if water is bound to Co(II)(TMC), we conducted the 1H as well as 2H ENDOR 
experiments (Figure 4.12b). The 1H ENDOR spectrum exhibits doublets centered at the larmor 
frequency of a proton and separated by its hyperfine coupling, A: ν± = νH ± A/2. The hyperfine 
coupling of A ca. 6.3 MHz signal in 1H ENDOR appears also in the sample prepared in D2O but 
the ENDOR intensity is decreased significantly. In addition, the 2H ENDOR was conducted to 
confirm the existence of the exchangeable proton(s). The 2H ENDOR exhibits the doublet 
centered at the 2H Larmor frequency and is split by ca. 1.0 MHz. The magnitude of the hyperfine 
coupling (1.0 MHz) is comparable to the proton hyperfine coupling of 6.3 MHz if scaled by the 
magnetogyric ratio of γ(1H/2H). Thus, 1H and 2H ENDOR indicate that there is an exchangeable 
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proton(s). To verify if the exchangeable proton is originated from water bound to Co(II), the 1H 
ENDOR experiment on CoCl2 was performed in H2O. Figure 4.13 presents that the largest 
hyperfine coupling of a proton is ca. 6.4 MHz at g ≈ 3.5. The magnitude of the hyperfine coupling 
of 1H is comparable to the one we observed in Co(II)(TMC). Taken together, these results support 
that the 1H ENDOR signal observed in the Co(II)(TMC) spectrum arises from the 1H-bound water 
to the cobalt center.  
 
 
Figure 4.14. Q-band ESEEM time-domain (left) and Fourier transformed frequency domain spectra 
(right) of CoCl26H2O. The red dashed line indicates the 17O Larmor frequency at each field. 
 
Moreover, we have also carried out the 17O ESEEM experiment on the Co(II)(TMC) sample prepared 
in 17O-labeled water. Figure 4.12c displays the time-domain and the frequency-domain three-pulse 
ESEEM, respectively. The time-domain spectra (Figure 4.12c, left) displayed the ratio of 17O/16O to 
eliminate contributions from other nuclei and also τ, the time between the first and the second pulse, was 
chosen to maximize the modulation of the 17O nuclei. The time-domain ESEEM exhibits the modulation 
arising from 17O, and the Fourier-transformed frequency domain further confirms that 17O is coupled to 
Co(II) by showing the 17O peak around the larmor frequency of the 17O nucleus. To validate the 
magnitude of the hyperfine coupling of 17O ligated to the Co(II) center, the 17O ESEEM experiments on 
CoCl2 prepared in 17O-labeled water (70% enrichment) were performed (Figure 4.14). The 17O three-pulse 
ESEEM of CoCl2 shows the similar field-dependent 17O modulation pattern as seen for Co(II)(TMC) 
prepared in H217O, which indicates that the 17O signal arises from the water coordinated to the metal ion 
(Figure 4.14). Overall, our EPR results demonstrate that water is the ligand bound to the distorted 
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pentacoordinated (possibly, TBP) Co(II)(TMC) complex in solution, supporting the activation of water by 
Co(II)(TMC) as the hydrolytic mechanism (vide infra). 
 
4.2.4 Computational Mechanistic Insights  
 
Table 4.3. Relative Gibbs free energies (a) of [M(TMC)(L)]2+/+ complexes (M = Co, Ni, Cu, or Zn; L = 
H2O or OH–), and experimental and TDDFT-calculated pKa values. The Gibbs free energy change (b) for 
the ligand exchange of the coordinated water molecule with the carbonyl group of the amide bond. 
 
(a) ΔG 
(kcal/mol) 
Co Ni Cu Zn S = 1/2 S = 3/2 S = 0 S = 1 
L 
H2O 5.6 0 0(ii) 5.1 0 0 
OH– (i) 29.2 11.9 43.4 10.2 24.8 16.9 
pKa 
Exp / DFT 
8.5 / 8.7 
(to Co(S = 3/2)-OH) 
10.1 / 7.5(iii) 
(to Ni(S = 1)-OH) NA/18.2 NA/12.4 
(b)                                       M–OH2 + Amide → M–Amide + OH2 
ΔG 
(kcal/mol) 5.74 NA
(iv) 5.09 3.95 
 
(i) ΔGsolv(H+) = –265.9 kcal/mol was used.73 (ii) The four-coordinate [Ni(TMC)]2+ complex. (iii) The 
dissociation of a hydrogen bond is not considered in the computations. (iv) Data is not available (NA) 
because the ground state of the Ni(II)(TMC) complex is four-coordinate. 
 
(i) Characterization of M(II)(TMC) Complexes in Aqueous Solutions  
Regarding a possible mechanism by which the hydrolysis of Aβ’s amide bonds is facilitated 
by the Co(II)(TMC) complex, it needs to be assessed whether a water molecule can be activated 
to a hydroxide ion by coordinating to the Co(II)(TMC) complex (Figure 4.17b, i and iii). To 
elucidate the axial ligand of the M(II)(TMC) complexes in aqueous solutions, their water- and 
hydroxo-ligated forms in possible spin states were calculated, and their ground states were 
defined on the basis of their computed relative free energies and the reproducibility of ligand-field 
(LF) transitions observed in the electronic absorption spectra. As summarized in Table 4.3, in 
aqueous solutions, the axial ligand positions of all M(II)(TMC) complexes are observed to have a 
water molecule as an axial ligand rather than a hydroxide ligand, except for the case of the 
Ni(II)(TMC) complex, which stays four-coordinated without having an axial ligand in its ground 
singlet state. Specifically, the ground state of the cobalt complex is calculated to have a quartet 
cobalt center with an axial water ligand. The ligand field calculated from this ground-state 
[Co(TMC)(H2O)]2+ complex (S = 3/2) also agrees well with spectroscopic data; amongst the four 
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species calculated for Co(II)(TMC), the UV-vis absorption feature observed at ca. 476 nm 
(21,000 cm-1) with a relatively low intensity can be best matched with the TDDFT-predicted LF 
transition of the ground-state complex (Figure 4.15a). The Ni complex is predicted to have a four 
coordinate singlet ground state due to the Jahn-Teller distortion. To have an axial ligand, either 
H2O or OH–, the Ni center would need to convert to a triplet spin state. Consistent with these 
predictions, the TDDFT-calculated LF transition of the four-coordinate [Ni(TMC)]2+ complex 
agrees the best with the UV-vis spectrum (Figure 4.15b). For the Cu(II) and Zn(II) complexes, 
with no possible variation in the spin state, water-coordinated complexes are predicted to be the 
ground state. This cannot be spectroscopically validated for the Zn(II) complex due to the absence 
of its LF transitions, while for the Cu(II) complex, its TDDFT computation matches 
unambiguously with the UV-vis spectrum (Figure 4.15c and Table 4.3). 
 
 
Figure 4.15. Computational examination of M(II)(TMC) complexes. (a) Experimental UV-vis spectrum 
of (i) Co(II)(TMC) in aqueous solutions (red) and the TDDFT-predicted spectra of [Co(TMC)(H2O)]2+ (S 
= 3/2) (solid black), [Co(TMC)(OH)]+ (S = 3/2) (dashed black), [Co(TMC)(H2O)]2+ (S = 1/2) (solid gray), 
and [Co(TMC)(OH)]+ (S = 1/2) (dashed gray); (ii) experimental UV-vis spectrum of Ni(II)(TMC) in 
aqueous solutions (red) and the TDDFT-predicted spectra of [Ni(TMC)]2+ (S = 0) (solid black), 
[Ni(TMC)(OH)]+ (S = 0) (dashed black), [Ni(TMC)(H2O)]2+ (S = 1) (solid gray), and [Ni(TMC)(OH)]+ (S 
= 1) (dashed gray); (iii) experimental UV-vis spectrum of Cu(II)(TMC) in aqueous solutions (red) and the 
TDDFT-predicted spectra of [Cu(TMC)(H2O)]2+ (solid black) and [Cu(14-TMC)(OH)]+ (dashed black). 
(b-d) Calculated structures of (a) [Co(TMC)(H2O)]2+, (b) [Ni(TMC)]2+, (c) [Cu(TMC)(H2O)]2+, and (d) 
[Zn(TMC)(H2O)]2+. (e-f) The overlay of the ground-state M(II)(TMC) structures presented from the side 
and top. 
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Figure 4.16. Solution speciation studies of Co(II)(TMC) and Ni(II)(TMC). UV-vis variable-pH titration 
spectra (left) and the solution speciation diagrams (right) of (a) Co(II)(TMC) (pH 4.5–11.5); (b) 
Ni(II)(TMC) (pH 7–11.5) (FL = fraction of species at given pH). Acidity constants (pKa) of 
[M(L)(H2O)]2+ (L = TMC) are summarized in the table. Experimental conditions: Co(II)(TMC) = 6 mM; 
Ni(II)(TMC) = 4 mM; I = 0.10 M NaCl; room temperature. Charges are omitted for clarity. aThe error in 
the last digit is shown in the parentheses.  
 
(ii) Activation of a Water Molecule by M(II)(TMC) Complexes for Amide Hydrolysis  
The spectroscopic and DFT analyses show that, in aqueous solutions, water binds to the metal 
centers of Co(II)(TMC), Cu(II)(TMC), and Zn(II)(TMC) complexes, not as a hydroxide but as a 
water molecule. Thus, the energies required to deprotonate these ground-state complexes were 
calculated (Table 4.3a). The pKa value of the ground-state [Co(TMC)(H2O)]2+ complex is 
calculated to be 8.7 which is consistent with the experimental value of 8.5 obtained through UV-
vis variable-pH titration experiments (Figure 4.16).68 Given the range of typical pKa values of 
amino acids (4–12.5) and their possible variations depending on microenvironment, the pKa value 
of ca. 8.5 suggests that the [Co(TMC)(H2O)]2+ complex would have a chance to be deprotonated 
by nearby amino acids thus generating a hydroxide ion (Table 4.4). In contrast, this deprotonation 
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of a water ligand appears to be less plausible for the other complexes. The complexes of 
[Cu(TMC)(H2O)]2+ and [Zn(TMC)(H2O)]2+ are calculated to have pKa values of 18.2 and 12.4, 
respectively. The pKa for [Zn(TMC)(H2O)]2+ could not be experimentally determined due to the 
absence of observable optical bands. The UV-vis titration experiment with Cu(II)(TMC) did not 
produce any spectral change in a pH titration range of 2–11 (data not shown). These results 
suggest that [Cu(TMC)(OH)]+ is already protonated to generate the aqua complex 
([Cu(TMC)(H2O)]2+) at pH 11 which supports a pKa value much greater than 11. Despite the fact 
that the ground-state Ni(II) complex is calculated to be four-coordinated, the Ni(II) center can be 
converted to a high-spin state with an axial ligand; the pKa for the reaction of [Ni(TMC)]2+ (S = 0) 
+ 2H2O → [Ni(TMC)(OH)]+ (S = 1) + H3O+ is known to be 10.1 (Figure 4.16).34 The calculated 
pKa is deviated because this process should involve the dissociation of a hydrogen bond as 
forming the Ni–O bond, while in computations, this loss of a hydrogen bond could not be 
considered. The discrepancy between the experimental and DFT-calculated pKa, however, 
corresponds to a Gibbs free energy difference of ca. 3.6 kcal/mol which lies in the range of 
reported energies for a hydrogen bond, as expected.69,70 
 
Table 4.4. pKas of amino acids. 
 
Amino Acids pKa 
Asp 3.71 
Glu 4.24 
His 6.04 
Tyr 10.10 
Lys 10.79 
Arg 12.5 
cf. [Co(TMC)(H2O)]2+ 8.5 
 
(iii) Activation of an Amide Bond by M(II)(TMC) Complexes 
One other way of promoting amide hydrolysis is to activate the amide bond by having the 
carbonyl oxygen of the amide bond bound to the metal center and thus generate a more 
electrophilic character (Figure 4.17b, ii). To assess this possibility, the energies required to 
replace the water ligand of the ground-state M(II)(TMC) complexes with the amide carbonyl 
oxygen was calculated (Table 4.3b). Except for the case of Ni(II)(TMC) which does not bind to 
the amide in the singlet ground state, the water ligand could be replaced with a less than 6 
kcal/mol free energy. Considering that peptide hydrolysis is down-hill by 2–4 kcal/mol,71 amide 
activation via its carbonyl ligation to the metal center seems to be thermodynamically feasible 
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driven by the exergonic peptide hydrolysis (although this does not necessarily suggest fast 
kinetics). The possibility of having both water and amide ligands on the same metal center was 
discarded based on its excessive high energy calculated relative to the ground state (Figure 4.17b, 
iii). Then, combined the two plausible activation pathways discussed above, the binuclear 
mechanism in Figure 4.17b (iv) can be conclusively suggested for the [Co(TMC)(H2O)]2+ 
complex. Particularly, in the ground state, while other complexes have square pyramidal (or 
square planar) structures, only the cobalt complex has a TBP structure (Figure 4.15b) which 
would allow the TMC ligand to be distorted and the open coordination site to be less sterically 
hindered and thus more easily accommodate substrate entry and possible binuclear interactions, as 
shown in the structural overlay in Figure 4.15e and f. 
 
4.2.5. Proposed Mechanisms for the Hydrolysis of Aβ  by Co(II)(TMC) 
Based on the seminal work with platinum complexes in AD, and the biochemical, 
spectroscopic, mass spectrometric, and computational studies reported herein, we were able to 
conceive of two main pathways that may explain the anti-amyloidogenic activity of Co(II)(TMC) 
which was not observed for the other M(II)(TMC) complexes. The first possible pathway, as 
shown in Figure 4.17a, is the binding of Co(II)(TMC) to Aβ that in turn would facilitate 
conformational changes in Aβ and thus prohibit the formation of toxic aggregates. This is the 
mode of action that has been proposed for most metal complexes, including Pt(II/IV) and Co(III) 
Schiff base complexes.13-15 Such a transformation in peptide conformation could be envisioned to 
occur via multiple mechanisms [e.g., through monodentate coordination of Aβ to the metal center 
(Figure 4.17a, i), intermolecular binding of Aβ to two equivalents of M(II)(TMC) (Figure 4.17a, 
ii), or isomerization to a trans-III complex and subsequent formation of an intramolecular 
octahedral protein–M(II)(TMC) complex (Figure 4.17a, iii)]. The generation of intramolecular 
protein–M(II)(TMC) complexes (Figure 4.17a, iii) can be reasonably eliminated as a possible 
mechanism due to the absence of optical changes in the spectra of Co(II)(TMC), Ni(II)(TMC), 
and Cu(II)(TMC) that would be consistent with the formation of trans-III octahedral complexes. 
Furthermore, while MS studies did detect peaks consistent with the formation of Aβ–
Co(II)(TMC) complexes and IM studies showed a slight increase in the drift time of samples 
treated with Co(II)(TMC), identical results were also detected for Ni(II)(TMC), Cu(II)(TMC), and 
Zn(II)(TMC), thus failing to explain the discrepancy in their inhibitory reactivity. In fact, the 
increase in IM drift time upon administration of M(II)(TMC) suggests that the peptide may be 
directed toward a slightly expanded conformation relative to the complex-untreated peptide. 
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Actually, previously reported potent amyloid inhibitors were found to induce structural 
compaction of Aβ rather than elongation.58,72 Combined, these studies suggest that while the slight 
change in Aβ conformation may contribute to the overall reactivity of Co(II)(TMC) toward 
modulating Aβ aggregation, it does not alone provide a mechanistic explanation for why only 
Co(II)(TMC) alters Aβ aggregation. 
 
 
Figure 4.17. Schemes of the potential modes of action of M(II)(TMC) to modulate Aβ aggregation. (a) 
The conformation of Aβ is altered leading to the generation of off-pathway aggregates through (i) 
coordination to the metal center of M(II)(TMC) [e.g., Aβ–M(II)(TMC)]; (ii) intermolecular coordination 
of Aβ to two equivalents of M(II)(TMC); (iii) isomerization to the trans-III stereoisomer and subsequent 
formation of an octahedral complex. (b) Metal complexes facilitate the hydrolysis of amide bonds to 
generate Aβ fragments. Amide bond hydrolysis can be catalyzed by: (i) the activation of water by 
M(II)(TMC) to generate metal hydroxo nucleophiles; (ii) Lewis acid activation of the amide bonds; (iii) a 
mononuclear combined mechanisms where both substrates (i.e., water and amide) are coordinated to the 
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metal complex; (iv) a binuclear combined mechanism where two equivalents of M(II)(TMC) are used to 
produce the hydroxide source and activate the amide bond.  
 
Hydrolytic cleavage of Aβ’s amide bonds by Co(II)(TMC) may be an alternate route through which it 
is able to inhibit the formation of fibrils and disassemble mature aggregates into smaller and amorphous 
species. As shown in Figure 4.17b, the hydrolysis of amide bonds may proceed through three main 
pathways. First, hydroxide nucleophiles could be produced by the activation and deprotonation of water 
molecules by M(II)(TMC) to generate metal–hydroxo species (i.e., [M(TMC)(OH)]+) that are capable of 
attacking the carbonyl and subsequently hydrolyzing the amide bonds (Figure 4.17b, i). Such a 
mechanism would require the relatively facile deprotonation of the ground-state [M(TMC)(H2O)]2+ 
complexes. Based on our pH-dependent spectroscopic titration experiments and TDDFT calculations, 
Co(II)(TMC) would be expected to be the most reactive of the M(II)(TMC) complexes through this 
mechanistic pathway, thus explaining our observations from the gel/Western blot and TEM studies. The 
energies required to deprotonate the ground-state M(II)(TMC) complexes were found to be much lower 
for Co(II)(TMC) (11.9 kcal/mol for Co(II)(TMC) versus 16.9–43.3 kcal/mol for the other M(II)(TMC) 
complexes). It was also determined to have the most acidic pKa value (ca. 8.5) which implies that 
deprotonation of water bound to Co(II)(TMC) by nearby amino acids may be possible. In fact, EPR 
studies validated the existence of a distorted five- coordinate Co(II)(TMC) with exchangeable protons on 
the water molecule occupying the open coordination site. Ni(II)(TMC), Cu(II)(TMC), and Zn(II)(TMC), 
which were determined to have pKa values greater than 10, would be expected to have negligible amounts 
of metal–hydroxo species generated under physiological conditions thus explaining their lower 
proteolytic activity. Furthermore, a mechanism for water activation would also explain the enhanced Aβ40 
monomer signal suppression and fragmentation detected in the Co(II)(TMC)-treated MALDI–MS 
samples incubated at a slightly basic pH (e.g., pH 8.5). 
A second mechanism through which amide bonds could be hydrolyzed involves the ligand exchange 
of the water molecule of the ground-state complexes with an amide from the backbone of Aβ. Binding of 
the carbonyl oxygen atom to the metal center can prime the amide for nucleophilic attack by generating a 
more electrophilic substrate (Figure 4.17b, ii). Computationally, ligand exchange was found to be 
energetically feasible for M(II)(TMC) complexes (ca. 6 kcal/mol up-hill) especially when one considers 
the overall exergonic process of peptide hydrolysis (2–4 kcal/mol down-hill); however, this mechanism 
alone does not seem to explain the enhanced reactivity of Co(II)(TMC). For instance, Co(II)(TMC) was 
predicted to have the highest energy barrier for ligand exchange (5.74 kcal/mol) while Zn(II)(TMC) 
would be expected to have the lowest (3.95 kcal/mol; Table 4.3) and thus should be the more reactive 
cleavage agent if this was the sole mode of action. 
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Given the respective feasibility of both activation pathways, it also seems plausible that a combined 
mechanism could occur where the metal complexes could simultaneously generate the metal-hydroxo 
nucleophiles as well as activate Aβ’s amide bonds (Figure 4.17b, iii and iv). Theoretically, a combined 
mechanism may occur through a mononuclear (Figure 4.17b, iii) or binuclear (Figure 4.17b, iv) pathway. 
The intramolecular mechanism with both water and amide ligands bound to the metal center was 
excluded due to its relatively high calculated energy. An intermolecular system where one M(II)(TMC) 
complex generated a hydroxide source while another equivalent complex activates the amide does not 
seem unreasonable especially considering that our experiments were preformed with two equivalents of 
M(II)(TMC). Overall, our studies suggest the activation of water by M(II)(TMC) to be the likely 
mechanism of hydrolysis; however, the extent or degree to which they may also activate the amide or 
participate in an binuclear mode of action is still not completely clear. Moving forward, these mechanistic 
insights also suggest that hydrolytic cleavage may be further improved by redirecting the mechanism 
toward the concerted process. Studies are currently underway to test this hypothesis. 
 
Table 4.5. Potential blood-brain barrier (BBB) permiability of Co(II)(TMC). 
 
PAMPA-BBB assay 
–logPea 
5.0 ± 0.2 
(CNS+) 
–logPe < 5.40 (CNS+) 
–logPe > 5.70 (CNS–) 
 
aPrediction of the ability of the complex to penetrate the central nervous system (CNS) on the basis of 
literature values. Compounds characterized as CNS+ potentially possess the ability to penetrate the BBB 
and are available in the CNS. Compounds designated as CNS– are expected to have poor permiability 
through the BBB; therefore, their bioavailability into the CNS is considered to be minimal.  
 
4.2.6. Biological Applicability of M(II)(TMC) Complexes  
In order to gauge the practicality of Co(II)(TMC) as an anti-amyloidogenic agent, we first 
assessed its ability to penetrate the blood-brain barrier (BBB) with the parallel artificial membrane 
permeability assay adapted for the blood-brain barrier (PAMPA-BBB; Table 4.5). Co(II)(TMC) 
was predicted to passively diffuse across the BBB based on its –logPe value compared to those of 
other previously reported BBB-permeable molecules (–logPe = 5.0 ± 0.2 where –logPe < 5.40 is 
CNS+ and –logPe > 5.70 is CNS–; CNS = central nervous system). Next, the MTT assay [MTT = 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] was employed to evaluate the 
cytotoxicity of Co(II)(TMC) using the human neuroblastoma SH-SY5Y (5Y) cells (Figure 4.18). 
The cell viability of ca. 98% was measured for 5Y cells treated with up to 20 μM Co(II)(TMC) 
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(Figure 4.18). Even with elevated amounts of compound treatment [i.e., 50 and 100 μM 
Co(II)(TMC)], the cell viability was still ca. 80%. These results were particularly interesting 
given the absence of any Aβ-targeting moieties augmented onto the ligand framework that could 
impart substrate specificity to Co(II)(TMC). We hypothesized that this cellular tolerance for 
Co(II)(TMC) may be due to its preferential cleavage of Aβ which lacks a well-defined tertiary (or 
quaternary) structure over essential biological proteins that are highly folded. Therefore, due to 
the disordered structure, the amide bonds in Aβ may be more accessible to Co(II)(TMC) for 
hydrolysis with respect to the amide bonds in highly folded proteins which should be more 
protected from undesired cleavage.  
 
 
Figure 4.18. Cell viability measurements of Co(II)(TMC) using human neuroblastoma SH-SY5Y cells. 
Cell viability (%) was determined by the MTT assay compared to cells treated with ddH2O [MTT = 3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide].  
 
In order to test this hypothesis, we analyzed the MALDI–MS spectrum of Co(II)(TMC)-treated 
ubiquitin samples spiked with internal standards of melittin for monomer suppression and peptide 
fragmentation (Figure 4.19). Ubiquitin was chosen for its similarity in size to Aβ (i.e., 8.5 kDa) and its 
well-defined and tightly folded structure.30 Unlike the Aβ40 samples incubated with Co(II)(TMC), the 
ubiquitin samples did not produce any detectable fragments and compared to the internal standard, there 
was no noticeable reduction in the singly-charged monomer peak. Together, these studies show that 
Co(II)(TMC) is BBB permeable and relatively non-cytotoxic with preferential cleavage activity toward 
amyloidogenic peptides over highly structured proteins, which suggests its potential to be used for further 
biological applications. 
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Figure 4.19. MALDI–MS analysis of ubiquitin incubated with Co(II)(TMC). The peak intensities are 
normalized to ubiquitin in the absence of Co(II)(TMC). All measurements were conducted with the 
addition of an internal standard, melittin (5 μM), and calibrated based on the linear correlation between 
the concentration and the signal intensity. 
 
4.3. Conclusions  
Since the initial report of Co(III)(cyclen) complexes, very little has been reported to 
understand and develop anti-amyloidogenic cleavage agents for AD. In order to further explore 
the applicability of this approach, we developed a series of divalent metal tetra-N-methylated 
cyclam complexes with the purpose of achieving a degree of tunability and control through their 
unique stereochemistry and coordination spheres which do not exist in the previously reported 
octahedral Co(III)(cyclen) complexes.20 To our surprise, we found that Co(II)(TMC) was able to 
modulate the aggregation pathways of Aβ40 and Aβ42 as observed by gel/Western blot and TEM, 
while the other divalent metal complexes [i.e., Ni(II)(TMC), Cu(II)(TMC), and Zn(II)(TMC)] did 
not. MS and IM–MS studies attributed the anti-amyloidogenic activity of M(II)(TMC) complexes 
to their ability to promote amide bond hydrolysis rather than induce peptide compaction as has 
been previously observed for small molecules and Co(III) complexes.13,58,72  
Spectroscopic and computational studies into the mechanism of hydrolysis were further 
performed in order to elucidate the reason for the superior proteolytic activity of Co(II)(TMC) and 
to find additional strategies to tune the cleavage activity of such compounds. Mechanistically, the 
activation of water by M(II)(TMC) would explain the enhanced activity of Co(II)(TMC) with 
respect to the other complexes due to its relatively acidic pKa of the water-bound ground-state 
complex, but the activation of amide bonds by M(II)(TMC) could not be completely ruled out due 
to the overall exergonic process of peptide hydrolysis. Although, by itself M(II)(TMC)-facilitated 
activation of amides could not explain the metal center dependence observed in the gel/Western 
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blot and TEM studies. Finally, a concerted mechanism through which a single metal complex 
binds both a water molecule and an amide was discarded due to the high energy associated with 
both ligands bound to the sterically confined metal center. Given the feasibility of activating water 
and amides individually, a combined binuclear mechanism may be plausible.  
Overall, our mechanistic studies suggest that in addition to tuning the cleavage reactivity of 
the metal complexes through the choice of metal ions, we could also further improve the 
hydrolytic cleavage by promoting a concerted reaction mechanism by providing two or more open 
cis coordination cites on the metal center to facilitate the activation of the amide bond and the 
production and attack by a hydroxo ligand simultaneously via an intramolecular fashion. 
Furthermore, the biological applicability of Co(II)(TMC) was established by showing its ability to 
diffuse across the BBB and its relatively low cytotoxicity which appears to be partially a result of 
its preferential interaction with amyloidogenic proteins over highly structured substrates. Taken 
together, our findings on the metal center dependence for amyloidogenic peptide cleavage, along 
with the mechanistic insights, not only bestow a new strategy through which the cleavage activity 
and selectivity of proteolytic metal complexes can be tuned, but it also shows that high potency, 
which often leads to poor substrate selectivity, is not required to achieve the desired anti-
amyloidogenic reactivity.  
 
4.4. Experimental Section  
 
4.4.1. Materials and Methods 
All reagents were purchased from commercial suppliers and used as received unless otherwise 
noted. Aβ40 and Aβ42 were purchased from Anaspec (Aβ42 = DAEFRHDSGYEVHHQKLVFFA-
EDVGSNKGAIIGLMVGGVVIA; Fremont, CA, USA). Trace metal contamination was removed 
from buffers and solutions used for Aβ experiments (vide infra) by treating with Chelex overnight 
(Sigma-Aldrich, St. Louis, MO, USA). Optical Spectra were recorded on an Agilent 8453 UV-vis 
spectrophotometer. TEM images were taken using a JEOL JEM-2100 transmission electron 
microscope (UNIST Central Research Facilities, Ulsan National Institute of Science and 
Technology, Ulsan, Republic of Korea). Absorbance values for the PAMPA-BBB assay were 
measured on a Molecular Devices SpectraMax 190 microplate reader (Sunnyvale, CA, USA). 
Mass Spectra for investigating the interaction of M(II)(TMC) with Aβ were taken on a MALDI–
TOF/TOF mass spectrometer (UNIST Central Research Facilities, Ulsan National Institute of 
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Science and Technology, Ulsan, Republic of Korea) and a Synapt G2 ESI–IM mass spectrometer 
(Waters, Milford, MA, USA). 
 
4.4.2. Preparation of M(II)(TMC) Complexes  
 
4.4.3. [Ni(TMC)](NO3)2 
TMC (0.13 g, 0.5 mmol) was added to an acetonitrile solution (5 mL) of Ni(NO3)26H2O (0.15 g, 0.5 
mmol). The resulting solution was refluxed for 12 h. After cooling, the solvent was removed under 
vacuum to give a bluish green solid. The solid was filtered and the filtrate was then washed with diethyl 
ether and dried in vacuum. Yield: 0.20 g (90%). UV-vis (H2O): λmax (ε) = 393 nm (110 M-1cm-1). ESI–MS 
(in CH3CN): 157.2 m/z for [Ni(TMC)]2+ and 376.3 m/z for [Ni(TMC)(NO3)]+. Anal. Calcd for 
C14H32N6NiO6: C, 38.29; H, 7.34; N, 19.14. Found: C, 38.28; H, 7.34; N, 19.26. 
 
4.4.4. [Co(TMC)(NO3)](NO3) 
TMC (0.13 g, 0.5 mmol) was added to an acetonitrile solution (5 mL) of Co(NO3)26H2O 
(0.15 g, 0.5 mmol). The resulting solution was refluxed for 12 h. After cooling, the solvent was 
removed under vacuum to give a pink solid. The solid was filtered and the filtrate was then 
washed with diethyl ether and dried in vacuum. Yield: 0.19 g (86%). UV-vis (H2O): λmax (ε) = 
466 nm (50 M-1cm-1). ESI–MS (in CH3CN): 178.2 m/z for [Co(TMC)(CH3CN)]2+ and 377.1 m/z 
for [Co(TMC)(NO3)]+. Anal. Calcd for C14H32CoN6O6: C, 38.27; H, 7.34; N, 19.13. Found: C, 
37.83; H, 7.30; N, 18.88. 
 
4.4.5. [Cu(TMC)(CH3CN)](ClO4)2 
TMC (0.13 g, 0.5 mmol) was added to an acetonitrile solution (5 mL) of Cu(ClO4)26H2O 
(0.19 g, 0.5 mmol). The resulting solution was refluxed for 12 h. After cooling, the solvent was 
removed under vacuum to give a blue solid. The solid was filtered and the filtrate was then 
washed with diethyl ether and dried in vacuum. Yield: 0.25 g (96%). UV-vis (H2O): λmax (ε) = 
615 nm (190 M-1cm-1). ESI–MS (in CH3CN): 159.5 m/z for [Cu(TMC)]2+, 180.2 m/z 
[Cu(TMC)(CH3CN)]2+, and 418.2 m/z for [Cu(TMC)(ClO4)]+. Anal. Calcd for C16H35Cl2CuN5O8: 
C, 34.32; H, 6.30; N, 12.51. Found: C, 34.05; H, 6.24; N, 12.47. 
 
4.4.6. [Zn(TMC)(CH3CN)](ClO4)2 
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TMC (0.13 g, 0.5 mmol) was added to an acetonitrile solution (5 mL) of Zn(ClO4)26H2O (0.19 g, 0.5 
mmol). The resulting solution was refluxed for 12 h. After cooling, the solvent was removed under 
vacuum to give a white solid. The solid was filtered and the filtrate was then washed with diethyl ether 
and dried in vacuum. Yield: 0.26 g (99%). ESI–MS (in CH3CN): 180.6 m/z for [Zn(TMC)(CH3CN)]2+ and 
419.2 m/z for [Zn(TMC)(ClO4)]+. Anal. Calcd for C16H35Cl2N5O8Zn: C, 34.21; H, 6.28; N, 12.47. Found: 
C, 34.11; H, 6.28; N, 12.32. 
 
4.4.7. Aβ  Aggregation Experiments 
All experiments were preformed according to previously published methods.58-61 Prior to experiments, 
Aβ40 or Aβ42 was dissolved in ammonium hydroxide (NH4OH, 1% v/v aq), aliquoted, lyophilized 
overnight, and stored at –80 °C. A stock solution of Aβ was prepared by dissolving lyophilized peptide in 
1% NH4OH (10 μL) and diluting with ddH2O. The concentration of the solution was determined by 
measuring the absorbance of the solution at 280 nm (ε = 1450 M-1cm-1 for Aβ40 and ε = 1490 M-1cm-1 for 
Aβ42). The peptide stock solution was diluted to a final concentration of 25 μM in Chelex-treated buffered 
solution containing HEPES (20 μM), pH 7.4, NaCl (150 μM). For the inhibition studies,58-61 M(II)(TMC) 
(50 μM) was added to a solution containing Aβ (25 μM) and incubated at 37 °C with constant agitation 
for 4, 8, or 24 h. For the disaggregation studies,1-4 Aβ was incubated at 4, 8, and 24 h at 37 °C with 
constant agitation prior to treatment with M(II)(TMC) (50 μM). The resulting samples containing Aβ 
(preincubated for 4, 8, or 24 h) and M(II)(TMC) were incubated at 37 °C with constant agitation for 24 h. 
 
4.4.8. Gel Electrophoresis with Western Blotting 
Samples from the inhibition and disaggregation experiments were analyzed by gel 
electrophoresis with Western blotting utilizing an anti-Aβ antibody (6E10) following previously 
reported procedures.58-61 Samples (10 μL) were separated on a 10-20% Tris-tricine gel 
(Invitrogen, Grand Island, NY, USA). Following separation, the proteins were transferred onto 
nitrocellulose, which was blocked with bovine serum albumin (BSA, 3% w/v, RMBIO, Missoula, 
MT, USA) in Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) for 4 h at room 
temperature. The membranes were incubated with antibody (6E10, 1:2000, Covance, Princeton, 
NJ, USA) in a solution of 2% BSA (w/v in TBS-T) overnight at 4 °C. After washing, the 
horseradish peroxidase-conjugated goat antimouse secondary antibody (1:5000) in 2% BSA was 
added for 1 h at room temperature. A homemade ECL kit5 was then used to visualize the results 
on a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA). 
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4.4.9. Transmission Electron Microscopy (TEM) 
Samples for TEM were prepared according to previously reported methods.58-61 Glow-
discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) 
were treated with Aβ samples from the inhibition and disaggregation experiments (5 μL) for 2 
min at room temperature. Excess sample was removed by blotting with filter paper followed by 
washing three times with ddH2O. Each grid was incubated with uranyl acetate (1% w/v ddH2O, 5 
μL, 1 min). Upon removal of excess uranyl acetate with filter paper, the grids were dried for at 
least 30 min at room temperature before measurement. Images from each sample were taken on a 
JEOL JEM-2100 transmission electron microscope (UNIST Central Research Facilities, Ulsan 
National Institute of Science and Technology, Ulsan, Republic of Korea) at 120 kV and 25,000x 
magnification. 
 
4.4.10. Electron Paramagnetic Resonance Spectroscopy (EPR) 
All EPR measurements were performed at Western Seoul Center, Korea Basic Science Institute. X-
band CW-EPR spectra were collected on a Bruker EMX plus 6/1 spectrometer equipped with an Oxford 
Instrument ESR900 liquid He cryostat using an Oxford ITC 503 temperature controller. X-band CW-EPR 
spectra were collected with the following experimental parameters: microwave frequency, 9.6 GHz; 
microwave power, 1 mW; modulation amplitude, 10 G; time constant, 40.96 ms; 5 scans; temperature, 4 
K.  
All pulsed EPR measurements were performed at 4 K. Q-band pulsed EPR data were obtained on a 
Bruker ELEXSYS E580 spectrometer using an EN5107D2 resonator. Cryogenic temperatures were 
achieved with an Oxford CF-935 cryostat and an Oxford ITC temperature controller. Electron spin echo 
detected field sweep experiments were carried out using the two pulse sequence, π/2-τ-π-echo, with pulse 
lengths of tπ/2 = 32 ns and tπ = 64 ns and inter-pulse time of τ = 200 ns. ESEEM experiments were 
performed utilizing the three pulse sequence, π/2-τ-π/2-T-π/2-echo, with a pulse length of tπ/2 = 32 ns and 
inter-pulse times of τ =160–168 ns and Tinitial = 80 ns. Davies ENDOR experiments were conducted 
utilizing the pulse sequence, π-T-π/2-τ-π-echo, with microwave pulse lengths of tπ/2 = 32 ns and an inter-
pulse time τ of 200 ns. A radio frequency (RF) π pulse with a length of 20 μs was applied during the time 
T. Mims ENDOR measurements were carried out using the pulse sequence, π/2-τ-π/2-T-π/2-echo, with a 
microwave pulse length of tπ/2 = 32 ns and an inter-pulse time of τ = 400 ns. In this sequence, the RF 
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power is applied during the time T (20 μs) to drive nuclear spin transitions. All pulsed ENDOR spectra 
were obtained using stochastic sampling for a better baseline of the spectra.  
W-band EPR data were obtained on a Bruker ELEXSYS E680 spectrometer operating at ~94 GHz 
with a cylindrical high Q-resonator (EN680). Electron spin echo detected field sweep experiments were 
performed using the two pulse sequence, π/2-τ-π-echo, with pulse lengths of tπ/2 = 20 ns and tπ = 40 ns 
and an inter-pulse time of τ = 200 ns. 
 
4.4.11. Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (MALDI–MS). 
Aβ40 (100 μM) samples incubated with M(II)(TMC) (200 μM) in a Chelex-treated buffered 
solution containing HEPES (20 mM, pH 7.4) and NaCl (150 μM) were incubated at 37 °C for 24 
h with constant agitation. Incubated Aβ40, matrix [α-cyano-4-hydroxycinnamic acid (5 mg/mL) 
dissolved in 40% CH3CN and 2% CF3COOH], and 50 μM of the internal standard were mixed in 
a ratio of 5:4:1 and loaded on the MALDI-MS target plate. After thoroughly drying the samples, 
MALDI–MS spectra were obtained using an Ultraflex III time-of-flight mass spectrometer 
(Bruker Daltonics, Bremen, Germany). 
 
4.4.12. Computational Details 
All DFT calculations were performed by using the B3LYP functional,75-79 the 6-311G* basis set,79-81 
and polarizable continuum model (water) with the Gaussian 09 package.82-86 Initial geometries for 
geometry optimizations were derived from the X-ray crystal structures of trans-I-[Co(TMC)(N3)]+ 
(KAVSIJ01)87, trans-I-[Ni(TMC)(N3)]+ (TMCAZN01)45, trans-I-[Cu(TMC)(H2O)]2+ (DUKPOO)46, trans-
III-[Cu(TMC)(Br)]+(XISVEA)88, and trans-I-[Zn(TMC)(H2O)]2+ (XACMOD)47 by replacing the axial 
ligand with H2O or OH–. The optimized structures were then used to perform frequency calculations to 
evaluate the Gibbs free energy corrections and TDDFT calculations to predict electronic absorption 
spectra. For the calculation of pKa, ΔGsolv(H+) = –265.9 kcal/mol was used to consider a solvated proton.73  
Given the known variations in DFT-predicted properties depending on the choice of functionals,89,90 
we tested the effect of Hartree-Fock exchange in the calculation of UV-vis spectra to select a 
computational method that can reproduce the electronic structures of the metal complexes correctly. 
When the trans-I-Cu(II)(TMC) and trans-III-Cu(II)(TMC) complexes are dissolved in water, they display 
ligand-field (LF) transitions at ca. 617 nm (16200 cm-1) and 549 nm (18200 cm-1), respectively (Figure 
B.16a,d). The axial ligands of these complexes are supposed to be occupied by water. Thus, the models 
for the trans-I- and trans-III-Cu(II)(TMC) complexes having either the water or hydroxo ligand were 
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calculated using the BP and B3LYP functionals. The TDDFT-predicted UV-vis spectra of these models 
suggest that, regardless of which functional is used, the complexes in neutral aqueous solution should 
have a water ligand rather than a hydroxo ligand, because the latter case should cause less split in the 
ligand field than the water molecule and thus display LF transitions at much lower energies than the 
experimental observations. The LF transitions of the [trans-I-Cu(TMC)(H2O)]2+ and [trans-III-
Cu(TMC)(H2O)]2+ complexes are then better reproduced by using the B3LYP functional than the BP 
functional, in terms of their energies relative to the intense charge transfer band growing in high energy at 
> 400 nm (25,000 cm-1). Therefore, the B3LYP functional was employed for all computations. 
 
4.4.13. Competition Experiments 
An Aβ40 stock solution was prepared by dissolving lyophilized peptide in 1% NH4OH (10 μL) 
and diluting with ddH2O. The concentration of the solution was determined by measuring the 
absorbance of the solution at 280 nm (ε = 1450 M-1cm-1). The peptide stock solution was diluted 
to a final concentration of 25 μM in Chelex-treated buffered solution containing HEPES (20 μM, 
pH 7.4) and NaCl (150 μM). Increasing concentrations of sodium azide (NaN3) or sodium cyanate 
(NaOCN) (0–5 mM) were added to the sample of Aβ (25 μM) and incubated for 2 min at room 
temperature. Co(II)(TMC) (50 μM) was then added to the reaction mixture and incubated at 37 °C 
with constant agitation for 24 h. The resultant samples were then analyzed by gel electrophoresis 
with Western blotting utilizing an anti-Aβ antibody (6E10). Samples (10 μL) were then separated 
on a 10-20% Tris-tricine gel (Invitrogen, Grand Island, NY, USA). Following separation, the 
proteins were transferred onto nitrocellulose, which was blocked with bovine serum albumin 
(BSA, 3% w/v, RMBIO, Missoula, MT, USA) in Tris-buffered saline (TBS) containing 0.1% 
Tween-20 (TBS-T) for 4 h at room temperature. The membranes were incubated with Antibody 
(6E10, 1:2000, Covance, Princeton, NJ, USA) in a solution of 2% BSA (w/v in TBS-T) overnight 
at 4 °C. After washing, the horseradish peroxidase-conjugated goat antimouse secondary antibody 
(1:5000) in 2% BSA was added for 1 h at room temperature. A homemade ECL kit91 was then 
used to visualize the results on a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA). 
 
4.4.14. Internal Standard Calibration 
Melittin, a component in honey bee venom, was purchased from Sigma Aldrich and used 
without further purification. The concentration of melittin was determined by measuring the 
absorbance of the solution at 280 nm (ε = 5570 M-1cm-1).92 Different concentrations (1–200 μM) 
of melittin were prepared and diluted by 10-fold in order to construct the calibration plot. Melittin, 
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matrix, and HPLC grade water were mixed at a ratio of 1:4:5 and loaded on the MALDI–MS 
plate. For MALDI-MS, the matrix solution was prepared with 5 mg/mL of α-cyano-4-
hydroxycinnamic acid dissolved in 40% CH3CN and 2% trifluoroacetic acid (CF3COOH). The 
signal intensity ratio was calculated by dividing the signal intensity for melittin by the sum of 
intensities for the 30 most dominant peaks. The calibration equation was derived from the linear 
regression of the signal intensity ratio values. The remaining quantity of the singly-charged Aβ40 
was estimated by utilizing the linear correlation between concentration and signal intensity. The 
concentration was determined from the experimental intensities of melittin and Aβ40. 
 
4.4.15. Electrospray Ionization–Mass Spectrometry (ESI–MS) 
Aβ40 (100 μM) was incubated with M(II)(TMC) (500 μM) in 100 mM ammonium acetate (pH 
7.5) at 37 °C for 1 h without agitation. The incubated Aβ40 samples were diluted by 10-fold before 
injection into the mass spectrometer. The capillary voltage, sampling cone voltage, and source 
temperature were set to 2.8 kV, 70 V, and 60 °C, respectively. The backing pressure was adjusted 
to 3.2 mbar. To obtain the ion mobility spectra, ion mobility wave height and wave velocity were 
adjusted to 10 V and 450 m/s, respectively. More than 200 spectra were obtained for each sample 
at a range of 300–3000 m/z and averaged for analysis. 
 
4.4.16. Isomerization Experiments 
The potential isomerization of M(II)(TMC) (M = Co, Ni, and Cu) was followed by UV-vis. 
M(II)(TMC) was dissolved in Chelex-treated buffered solution containing HEPES (20 mM, pH 
7.4) and NaCl (150 μM) to a final concentration of 20 mM for Co(II)(TMC), 10 mM for 
Ni(II)(TMC), and 2.5 mM for Cu(II)(TMC). Their optical spectra were monitored over a 24 h 
period at 37 °C without agitation. 
 
4.4.17. Parallel Artificial Membrane Permeability Adapted for the Blood-Brain Barrier 
(PAMPA-BBB) Assay. 
PAMPA-BBB experiments were carried out using the PAMPA Explorer kit (pION Inc., 
Billerica, MA, USA) with modifications to a previously reported protocol.58,59,61,93-96 Each stock 
solution was diluted with Prisma HT buffer (pH 7.4, pION) to a final concentration of 25 μM (1% 
v/v final DMSO concentration). The resulting solution was added to wells of the donor plate (200 
μL, 12 replicates). BBB-1 lipid formulation (5 μL, pION) was used to coat the polyvinylidene 
fluoride (PVDF, 0.45 mM) filter membrane on the acceptor plate. The acceptor plate was placed 
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on top of the donor plate forming a sandwich. Brain sink buffer (BSB, 200 μL, pION) was added 
to each well of the acceptor plate. The sandwich was incubated for 4 h at ambient temperature 
without stirring. UV-vis spectra of the solutions in the blank, reference, acceptor, and donor plates 
were measured using a microplate reader. The PAMPA Explorer software v. 3.5 (pION) was used 
to calculate –logPe for each compound. CNS+/– designations were assigned by comparison to 
compounds that were identified in previous reports.94-96 
 
4.4.18. Cell Viability Measurements 
Human neuroblastoma SH-SY5Y (5Y) cells were maintained in media containing 45% 
minimum essential medium (MEM), 45% F12, and 10% fetal bovine serum (FBS, GIBCO, Grand 
Island, NY, USA), 100 U/mL penicillin (GIBCO), and 100 mg/mL streptomycin (GIBCO). The 
cells were grown in a humidified atmosphere with 5% CO2 at 37 °C. Cell viability upon treatment 
of Co(II)(TMC) was determined by the MTT assay [MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide, Sigma-Aldrich]. The cells were seeded in a 96 well plate 
(15000 cells/100 mL). The cells were then treated with various concentrations of Co(II)(TMC). 
After 24 h incubation, MTT [25 mM; 5 mg/mL in PBS (pH 7.4, GIBCO)] was added to each well 
and the plate was incubated for 3 h at 37 °C. Formazan produced by the cells was solubilized by 
the addition of an acidic solution of N,N-dimethylformamide (DMF, 50% v/v, aq, pH 4.5) and 
sodium dodecyl sulfate (SDS, 20% w/v) overnight at room temperature in the dark. The 
absorbance was measured at 600 nm using a microplate reader. Cell viability was calculated 
relative to cells containing an equivalent amount of ddH2O. Error bars were calculated as standard 
errors from three independent experiments. 
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Appendix A. 
Stereochemistry of Tetramethylcyclam Metal Complexes 
Directed by Unexpected Anion Effects 
 
 
 
 
 
 
 
I thank Professor Jaeheung Cho and Hyeonwoo Tak for their assistance with the synthesis and X-ray 
crystallography measurements. I was involved with identifying the anion effect from preliminary data, 
growing the crystals for X-ray analysis, and the writing of the manuscript with the assistance of Professor 
Lim.  
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A.1. Introduction  
N-substituted cyclams have become one of the most widely studied and utilized group of macrocyclic 
ligands since Barefield and Wagner initially reported the preparation of TMC (1,4,8,11-tetramethyl-
1,4,8,11-tetraazacyclotetradecane) and its respective metal complexes in 1973.1,2 The rise in popularity of 
TMC and other similar N-substituted cyclams most definitely arose from the unique properties of the 
ligands (e.g., distinctive stereochemistry, coordination spheres, and accommodation of unusual oxidation 
and spin states)2-6, which have directed their use for a broad range of applications spanning many different 
fields some of which include: medicine,7-10 catalysis,11-13 and biomimetic chemistry.14-15 In particular, 
TMC has been critically important in stabilizing high-valent non-heme metal oxo cores to investigate 
mechanisms and reactive intermediates in biological reactions that are relevant to sustainable energy 
formation.14-21 
 
 
Figure A.1. Chemical structures of [M(TMC)]2+ (TMC = 1,4,8,11-tetramethyl-1,4,8,11-
tetraazacyclotetradecane). The two most common diastereomers are presented (trans-I and trans-III). The 
trans-I conformation forms pentacoordinate complexes by binding one ligand on the syn face. The trans-
III isomer generates octahedral complexes by binding two ligands in the open axial sites. 
 
Perhaps the most interesting property of TMC is the distinctive stereochemistry of its metal 
complexes that can be theoretically found in five possible diastereoisomeric forms with the two most 
thermodynamically stable being the trans-I and trans-III isomers (Figure A.1).2 The two isomers have 
very different fundamental properties (e.g., catalytic activity, kinetic stability, redox chemistry) the most 
obvious of which are their coordination environments.2,13,22-25 The trans-I metal complexes that have all 
four methyl moieties positioned on the same side of the macrocyclic plane almost always generate 
tetracoordinate square planar complexes or pentacoordinate square pyramidal or trigonal bipyramidal 
(TBP) structures while the trans-III metal complexes tend to exclusively produce hexacoordinate 
octahedral complexes.2 Almost all metal TMC complexes, especially those with 3d metal centers, are 
found in the trans-I structures where isomerization of the trans-I complexes to the trans-III conformation 
has been shown to be difficult and highly dependent on solution conditions.2,26 As a result, very little is 
known about the properties and fundamental chemistries of the trans-III metal TMC complexes.2 
Therefore, due to the importance and broad application of TMC and other N-methylated cyclam ligands, a 
facile and fundamental comprehensive approach to selectively and systematically prepare the trans-III 
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metal TMC complexes would be significantly valuable. Herein, we report an unexpected anion effect that 
directs the stereochemistry of [Cu(TMC)]2+ whereby those prepared with Cu(NO3)26H2O yield the 
unanticipated trans-III isomer and those synthesized with Cu(ClO4)26H2O gave the expected trans-I 
metal complex. We therefore propose this previously undiscovered anion dependence as a potentially 
new, simplistic method for the preparation and exploration of additional novel trans-III metal TMC 
complexes.  
 
A.2. Results and Discussion 
 
 
Figure A.2. UV-vis spectra of [Cu(TMC)](NO3)2 and [Cu(TMC)](ClO4)2. The optical spectrum of 
[Cu(TMC)](NO3)2 (red line) is blue shifted in comparison to [Cu(TMC)](ClO4)2 (blue line) which is 
consistent with an octahedral trans-III-[Cu(TMC)](NO3)2 complex.  
 
A.2.1. Preparation and Optical Properties of [Cu(TMC)]2+ 
[Cu(TMC)](NO3)2 and [Cu(TMC)](ClO4)2 were prepared in high yields (ca. 90%) following identical 
synthetic procedures adapted from previously reported methods.2 TMC was added to an acetonitrile 
solution containing either an equivalent of Cu(NO3)26H2O or Cu(ClO4)26H2O and the resulting reaction 
mixtures were refluxed for 12 h to give purple and blue solids, respectively. Initial evidence to support 
their difference in stereochemistry was presented in their optical spectra (Figure A.2). The UV-visible 
(UV-vis) spectrum of [Cu(TMC)](ClO4)2 presented a single broad band at ca. 630 nm that was consistent 
with previous literature reports of pentacoordinate trans-I-[Cu(TMC)]2+ complexes which would be 
expected by following this synthetic procedure (i.e., the direct metalation of TMC; Figure A.2, solid 
line).3 Surprisingly, the peak in the optical spectrum of [Cu(TMC)](NO3)2 was more intense and 
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significantly blue-shifted (ca. 554 nm) with respect to [Cu(TMC)](ClO4)2 (Figure A.2, dashed line). This 
spectrum is consistent with previous reports of an octahedral trans-III-[Cu(TMC)]2+ complex that was 
generated by an electrochemically driven comproportionation reaction;27 however, unlike the 
electrochemically generated complex, this trans-III-[Cu(TMC)](NO3)2 complex appeared to be stable 
irrespective of the solution conditions.2,26 Similar blue-shifts in the optical spectra of [Ni(TMC)]2+ 
complexes have also been reported; thus, further supporting an octahedral trans-III structure for the 
nitrate complex and a pentacoordinate square pyramidal or TBP perchlorate complex.4 
 
 
Figure A.3. Chemical structures of [Cu(TMC)](NO3)2 and [Cu(TMC)(H2O)](ClO4)2. Hydrogen atoms are 
omitted for clarity. a) ORTEP diagram of the cationic part of [Cu(TMC)](NO3)2 with thermal ellipsoids 
drawn at the 30% probability level. b) Ball-and-stick representation of the cationic part of 
[Cu(TMC)(H2O)](ClO4)2 (gray C, blue N, red O, brown Cu). Selected bond distances (Å) and angles (°) 
are summarized in Table B.1. The crystal structure of [Cu(TMC)(H2O)](ClO4)2 is adapted from reference 
29 for comparison. 
 
A.2.2. X-ray Crystallographic Analysis of [Cu(TMC)]2+ 
To further probe the stereochemistry of the [Cu(TMC)]2+ complexes, crystals suitable for X-ray 
analysis for [Cu(TMC)](NO3)2 were obtained by slow diffusion of diethyl ether into a methanol solution 
of [Cu(TMC)](NO3)2 and the resulting structural data was compared to previously reported structures for 
[Cu(TMC)](ClO4)2.27,29,30 As shown in Figure A.3, in agreement with our UV–vis data, [Cu(TMC)](NO3)2 
was found to be in the hexacoordinate trans-III conformation with two nitrate anions occupying the open 
axial sites while the perchlorate complex, was observed to possess a trans-I distorted square pyramidal 
structure consistent with the steric constrains of having all four methyl moieties located on the same side 
of the macrocyclic plane.2,3 The bond angles (i.e., almost all right angles) and lengths of 
[Cu(TMC)](NO3)2, particularly the elongated Cu–O bonds (2.612 Å), are consistent with the expected 
tetragonally elongated octahedral structure characteristic of Cu(II) complexes with strong Jahn-Teller 
effects (Table A.1) and are comparable to similar structures found in the literature.27,31 Additional 
differences in the two structures that are worth mentioning are the degree of distortion in the macrocyclic 
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ligand and the distance that the copper center sits above the macrocyclic plane. In [Cu(TMC)](ClO4)2 the 
copper atom is found to be sitting 0.242 Å above macrocyclic plane which is also severely distorted, as 
can be observed by its averaged dihedral angle of 23.43° (dihedral angles were calculated by measuring 
the distance between the two intersecting planes defined by the four N donor atoms; Table A.1). This 
extent of distortion was not observed in the trans-III-[Cu(TMC)](NO3)2 complex which has its metal 
center sitting coplanar with the four N donor atoms of the macrocycle. 
 
Table A.1. Selected crystallographic metrics for [Cu(TMC)](NO3)2 and [Cu(TMC)](ClO4)2. 
 
[Cu(TMC)](NO3)2 [Cu(TMC)](ClO4)2a 
Cu–N1 2.074 Å Cu–N1 2.086 Å 
Cu–N2 2.083 Å Cu–N2 2.040 Å 
Cu–O1 2.612 Å Cu–N3 2.079 Å 
Distance above the 
macrocyclic plane 0.0 Å Cu–N4 2.094 Å 
N1a–Cu–N2a 87.28° Cu–O1 2.398 Å 
N1a–Cu–N2b 92.72° Distance above the macrocyclic plane 0.242 Å 
N1a–Cu–O1a 87.58° N1–Cu–N2 94.04° 
N1b–Cu–O1a 92.42° N2–Cu–N3 84.93° 
N2a–Cu–O1a 89.13° N3–Cu–N4 94.06° 
N2b–Cu–O1a 90.87° N4–Cu–N1 86.22° 
N1a–N2a–N1b–N2bb 0.0° N1–N2–N3–N4b 23.43° 
 
aThe structure and metrics presented for [Cu(TMC)](ClO4)2 were taken from a previous report.29 bThe 
reported dihedral angle (i.e., N1–N2–N3–N4) for [Cu(TMC)](ClO4)2 is the average of the two 
measurements obtained by defining the angle by the N1–N3 or N2–N4 axis.  
 
A.3. Conclusions  
In conclusion, an unexpected anion effect that directs the stereochemistry of [Cu(TMC)]2+ was 
reported and fully characterized by X-ray crystallography and UV–vis spectroscopy. We proposed that 
this anion dependence could be utilized as a new and facile approach to the preparation of trans-III metal 
TMC complexes (or similar N-methylated cyclams), which have been largely unexplored due to the initial 
challenges associated with their synthesis.2 Moreover, not only does this method represent a more rapid 
and easier approach to generate trans-III complexes than previous methods (i.e., electrochemical and 
cyclam methylation) which, to date, have only yielded trans-III-[Ni(TMC)]2+ and trans-III-
[Cu(TMC)]2+,23,27,28,34 but it also suggests that the first report for direct preparation of trans-III-
[Cu(TMC)]2+ may not be solely due to the synthetic conditions employed (i.e., refluxing with NaOH) and 
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instead may be partially attributed to the use of copper bis(tetrafluoroborate).31 In fact, very few reports of 
metal TMC complexes with anions other than perchlorate metal salts are available most likely due to the 
ease with which the perchlorates generate crystals suitable for X-ray analysis. Overall, our initial 
spectroscopic findings with [Cu(TMC)]2+ support the fact that facile perpetration of trans-III metal TMC 
complexes may be prepared by the careful selection of the metal salt. Additional studies are underway to 
evaluate the extent to which this anion effect may be generalized to other transition metal complexes and 
even additional tetra-N-alkylated cyclams.  
 
A.4. Experimental Section  
 
A.4.1. Materials and Methods  
All reagents were purchased from commercial suppliers and used as received unless otherwise noted. 
Optical Spectra were recorded on an Agilent 8453 UV–vis spectrophotometer. Electrospray ionization 
mass spectra (ESI-MS) were collected on a Waters (Milford, MA, USA) Acquity SQD quadrupole mass 
instrument, by infusing samples directly into the source using a manual method. The spray voltage was 
set at 2.5 kV and the capillary temperature at 80 °C. 
 
A.4.2. X-ray Crystallography.  
Single crystal of [Cu(TMC)](NO3)2(H2O)0.5 was picked from solutions by using a nylon loop 
(Hampton Research Co.) on a handmade copper plate mounted inside a liquid N2 Dewar vessel at ca. -40 
°C and mounted on a goniometer head in a N2 cryostream. Data collections were carried out on a Bruker 
SMART APEX II CCD diffractometer equipped with a monochromator in the Mo Kα (λ = 0.71073 Å) 
incident beam. The CCD data were integrated and scaled using the Bruker-SAINT software package, and 
the structure was solved and refined using SHELXTL V 6.12.38 Hydrogen atoms were located in the 
calculated positions. All non-hydrogen atoms were refined with anisotropic thermal parameters. Crystal 
data for [Cu(TMC)](NO3)2: C14H32CuN6O6, mono- clinic, P21/n, Z = 2, a = 7.9917(4), b = 15.0923(8), c = 
8.3426(5) Å, β = 106.381(2)°, V = 965.38(9) Å3, μ = 1.175 mm–1, ρcalcd = 1.527 g cm–3, R1 = 0.0264, 
wR2 = 0.0883 for 2395 unique reflections, 126 variables. The crystallographic data are listed in Table S1, 
and Table 1 lists the selected bond distances and angles.  
 
A.4.3. Preparation of [Cu(TMC)](NO3)2(H2O)0.5.  
TMC (0.13 g, 0.5 mmol) (TMC = 1,4,8,11-tetramethyl-1,4,8,11-tetraazacyclotetradecane) was added 
to an acetonitrile solution (5 mL) of Cu(NO3)2xH2O (0.09 g, 0.5 mmol). The resulting solution was 
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refluxed for 12 h. After cooling, to room temperature, the solvent was removed under reduced pressure to 
give a blue powder. The solid was filtered and the filtrate was then washed with diethyl ether and dried in 
a vacuum. Yield: 0.25 g (95%). UV–vis (H2O): λmax (ε) = 554 nm (216 M-1cm-1) ESI–MS (in CH3CN): 
157.6 m/z for [Cu(TMC)]2+, 180.1 m/z for [Cu(TMC)(CH3CN)]2+, and 381.2 m/z for [Cu(TMC)(NO3)]+ 
Anal. Calcd for C14H33CuN6O6.5: C, 37.12; H, 7.34; N, 18.55. Found: C, 36.68; H, 7.02; N, 18.86. 
Crystals suitable for X-ray diffraction were obtained by slow diffusion of diethyl ether into a MeOH 
solution of [Cu(TMC)](NO3)2(H2O)0.5. 
 
A.4.4. Preparation of [Cu(TMC)](ClO4)2 
[Cu(TMC)](ClO4)2 was prepared following an identical procedure as the one reported for 
[Cu(TMC)](NO3)2 except Cu(ClO4)26H2O (0.19 g, 0.5 mmol) was used to give a blue solid. 
Crystallographic data was obtained from previously reported perchlorate complexes.35-37 Yield: 0.25 g 
(96%). UV–vis (H2O): λmax (ε) = 615 nm (190 M-1cm-1). ESI–MS (in CH3CN): 159.5 m/z for 
[Cu(TMC)]2+, 180.2 m/z for [Cu(TMC)(CH3CN)]2+, and 418.2 m/z for [Cu(TMC)(ClO4)]+. Anal. Calcd 
for C16H35Cl2CuN5O8: C, 34.32; H, 6.30; N, 12.51. Found: C, 34.05; H, 6.24; N, 12.47. 
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Appendix B. 
Additional Supplementary Data 
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B.1. 1H / 13C NMR Charcterization of the Multifunctional Derivatives (AQP2-4 and AQDA1-3) 
 
 
 
Figure B1.1. 1H NMR spectrum of AQP2 [400 MHz, (CD3)2SO]. 
 
 
 
Figure B.2. 13C NMR spectrum of AQP2 [100 MHz, (CD3)2SO]. 
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Figure B.3. 1H NMR spectrum of AQP3 [400 MHz, (CD3)2SO]. 
 
 
 
Figure B.4. 13C NMR spectrum of AQP3 [100 MHz, (CD3)2SO]. 
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Figure B.5. 1H NMR spectrum of AQP4 [400 MHz, (CD3)2SO]. 
 
 
 
Figure B.6. 13C NMR spectrum of AQP4 [100 MHz, (CD3)2SO]. 
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Figure B.7. 1H NMR spectrum of AQDA1 [400 MHz, (CD3)2SO]. 
 
 
 
Figure B.8. 13C NMR spectrum of AQDA1 [100 MHz, (CD3)2SO]. 
  
9.0 8.0 7.0 6.0 5.0 4.0 
ppm 
3.0 
N
HN
HO
N
90 80 70 50 40 60 100 110 120 130 150 
ppm 
140 
N
HN
HO
N
 166 
 
 
Figure B.9. 1H NMR spectrum of AQDA2 [400 MHz, (CD3)2SO]. 
 
 
 
Figure B.10. 13C NMR spectrum of AQDA2 [100 MHz, (CD3)2SO]. 
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Figure B.11. 1H NMR spectrum of AQDA3 [400 MHz, (CD3)2SO]. 
 
 
 
Figure B.12. 13C NMR spectrum of AQDA3 [100 MHz, (CD3)2SO]. 
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B.2. Supplemental EPR Data for Co(II)(TMC) 
 
 
 
Figure B.13. Q-band ESE-EPR spectra of Co(II)(TMC) complex in H2O (black), D2O (blue) and H217O 
(red). *indicates the background from the resonator. 
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Figure B.14. 1H-ENDOR spectra of Co(II)(TMC) complex at different magnetic fields. 
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Figure B.15. Q-band ESE-EPR spectrum of CoCl26H2O in aqueous solution. 
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B.3. Supplemental Computational Data for M(II)(TMC) 
 
 
Figure B.16. Electronic absorption spectra of (a) trans-I-Cu(II)(TMC) experimentally obtained in 
aqueous solution; (b) TDDFT-predicted trans-I-[Cu(TMC)(OH)]+ (dotted gray) and trans-I-
[Cu(TMC)(H2O)]2+ (solid gray) models obtained using the BP functional; (c) TDDFT-predicted trans-I-
[Cu(TMC)(OH)]+ (dotted black) and trans-I-[Cu(TMC)(H2O)]2+ (solid black) models obtained using the 
B3LYP functional; (d) trans-III-Cu(II)(TMC) experimentally obtained in aqueous solution; (e) TDDFT-
predicted trans-III-[Cu(TMC)(OH)]+ (dotted gray) and trans-III-[Cu(TMC)(H2O)]2+ (solid gray) models 
obtained using the BP functional; and (f) TDDFT-predicted trans-III-[Cu(TMC)(OH)]+ (dotted black) and 
trans-III-[Cu(TMC)(H2O)]2+ (solid black) models obtained using the B3LYP functional. 
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B.4. Supplemental Mass Spectrometry Fragmentation Data for M(II)(TMC) 
Table B.1. The monoisotopic mass (m/z), the charge state (z), and sequence for each fragment ion 
observed in the ESI–MS spectra (Figure 4.9). Detected peaks are denoted as D. Newly generated Aβ40 
fragments formed upon M(II)(TMC) treatment are labeled in blue. Ions only detected in the samples 
treated with Co(II)(TMC) or Cu(II)(TMC) are labeled in red and green, respectively.  
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B.5. Supplemental X-ray Crystallographic Data  
 
Table B.2. Crystal data and structure refinement for [Co(TMC)(NO3)](NO3). 
 
Identification code [Co(TMC)(NO3)](NO3) 
Empirical Formula C14H32CoN6O6 
Formula weight 439.38 
Temperature  113(2) K 
Wavelength  0.71073 Å 
Crystal System  Orthorhombic  
Space group  Pna21 
Unit cell dimensions 
a = 17.0670(8) Å   α = 90° 
b = 12.9148(6) Å   β = 90° 
c = 8.7358(5)   Å   γ = 90° 
Volume  1925.52(17) Å3 
Z 4 
Density (calculated) 1.516 g/cm-3 
Absorption coefficient  0.936 mm-1 
F(000) 932 
Reflections collected 54666 
Independent reflections  3780 
Absorption correction  Multi-scan 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 3780/1/248 
Goodness-of-fit on F2 0.796 
Final R indices [I>2sigma(I)] R1 = 0.0573, wR2 = 0.1424 
R indices (all data) R1 = 0.0918, wR2 = 0.1729 
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Table B.3. Crystal data and structure refinement for [Ni(TMC)(CH3CN)](NO3)2. 
 
Identification code [Ni(TMC)(CH3CN)](NO3)2 
Empirical Formula C16H35N7NiO6 
Formula weight 480.22 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal System  Tetragonal  
Space group  P43 
Unit cell dimensions 
a = 13.407(2)   Å   α = 90° 
b = 13.407(2)   Å   β = 90° 
c = 24.102(4)   Å   γ = 90° 
Volume  4332.3(16) Å3 
Z 8 
Density (calculated) 1.472 g/cm-3 
Absorption coefficient  0.943 mm-1 
F(000) 2048 
Reflections collected 60414 
Independent reflections  10902 
Absorption correction  Multi-scan 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 10902/1/551 
Goodness-of-fit on F2 0.974 
Final R indices [I>2sigma(I)] R1 = 0.0587, wR2 = 0.1377 
R indices (all data) R1 = 0.1107, wR2 = 0.1650 
 
  
 175 
Table B.4. Crystal data and structure refinement for [Cu(TMC)](NO3)2. 
 
Identification code [Cu(TMC)(NO3)2] 
Empirical Formula C14H32CuN6O6 
Formula weight 443.99 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal System  Monoclinic   
Space group  P121/n1 
Unit cell dimensions 
a = 7.9917(4)   Å   α = 90° 
b = 15.0923(8) Å   β = 90° 
c = 8.3426(5)   Å   γ = 90° 
Volume  965.38(9) Å3 
Z 2 
Density (calculated) 1.527 g/cm-3 
Absorption coefficient  1.175 mm-1 
F(000) 470 
Reflections collected 39083 
Independent reflections  2395 
Absorption correction  Multi-scan 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 2395/0/126 
Goodness-of-fit on F2 0.801 
Final R indices [I>2sigma(I)] R1 = 0.0264, wR2 = 0.0883 
R indices (all data) R1 = 0.0343, wR2 = 0.0977 
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